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"Primary" platelet aggregation is usually reversible and is 
mediated solely by an exogenous agonist. "Secondary" platelet
aggregation is irreversible and is initiated by an exogenous
mediator but propagated by endogenous mediators synthesised 
(eg. TXA^, PGG^, PGH^) and/or secreted (eg. ADP,
5HT) by activated platelets. Activated platelets also synthesis 
two phospholipids
l-0-alkyl-2-acetyl-glycerol-3-phosphorylcholine (PAF; PAF 
acether) and lysophosphatidic acid (LPA) which are potent 
inducers of platelet activation and hence may also serve as
endogenous mediators of human platelet activation. These
various agonists interact with specific recognition sites or 
receptors in/on the platelet. Agonist-receptor interaction 
influences the intracellular concentrations of biochemical 
intermediaries. These so-called "second messenger" molecules 
(eg. Ca-H-, cAMP, 1 ,2-diacylglycerol) influence the rates of 
those very biochemical reactions that govern the cellular 
response. At the commenCEMEWT of this study no systematic 
examination of the effects and/or mechanism(s) of action on 
platelets of putative lipids mediators of platelet adivation 
(PAF, LPA and TXA^) had been conducted. Consequently my 
initial studies were concerned with assessing:-
1. The effects of PAF, LPA, TXA^ (using U44069, a TXA2  
mimetic) on platelet aggregation, degranulation and TXB2  
biosynthesis.
2. The role of endogenous arachidonate metabolites and ADP in 
the above responses.
Thereafter, using the fluorescent Ca++ indicator dye quin2, I
IP-
examined the role, the sources and the pharmacology of elevated 
cytosolic free calcium concentration ( |^Ca+H^ i) in
agonist-induced platelet activation.
In platelet rich plasma PAF (10 - 100nM), U44069 (10 - lOOnM) 
and LPA (1 - 30 |jM) induced "primary" aggregation whereas
higher concentrations elicited "secondary" aggregation, 
degranulation and (except for IJ44069) TXB^ biosynthesis.
Agents : ( aspirin, dazoxiben, trimethoquinol and
13-azaprostanoic acid) that inhibit the formation or action of 
PGG^, PGH^ and TXA^ impaired PAF- and LPA-induced 
aggregation and degranulation. In this respect the thromboxane 
synthetase inhibitor dazoxiben was much less effective than 
inhibitors of cyclooxygenase or endoperoxide/TXA^ receptor 
antagonists. It was concluded that PAF and LPA-induced 
secondary aggregation and degranulation depend upon an intact 
cyclooxygenase but not thromboxane synthetase. The ADP receptor 
antagonist (beta-gamma methylene ATP) suppressed "secondary" 
aggregation but not degranulatio.n or TXB^ formation 
elicited by PAF or LPA. Consequently, endogenous ADP is 
important in mediating phospholipid-induced secondary 
aggregation.
Resting ^Ca-M-J i in quin2 loaded platelets was estimated to be 
90 + 3 nM The platelet stimulatory agonists PAF, LPA, U44Ü69,
thrombin, ADP, 5HT and vasopressin but not adrenaline induced a 
concentration-dependent elevation of |^a-H^ i to around 500nM. 
Chelation of extracellular Ca-H- using EGTA markedly attenuated 
the elevation of a^-i-f-J i induced by all agonists, indicating 
that the major source of elevated j^ a-f-^  i derives via influx of
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external Ca-H-. Moreover the effects of PAF and ADP on 5HT 
release were markedly attenuated by removal of external Ca++ 
whereas the effects of thrombin were only slightly reduced. 
This suggests that for PAF and ADP elevated |^ Ca-f-^  i is an 
important mediator/determinant of 5HT release, but is less 
important for the effect of thrombin.
Depolarization of the platelet trans-membrane potential using 
high o = 112nM failed to elevatej^ Ca-f-i^  i or alter the extent
of the elevation of j^ a-f--^  i induced by agonists. In addition,
the dihydropyridine Ca++ channel agonist BAY K8644 failed to 
elevate |^ Ca-f-Q i or alter responses to agonists. It is concluded 
that Ca-H- influx across the plasma membrane occurs via channels 
that open as a consequence of agonist-receptor interaction - 
receptor operated channels (ROCs) rather than as a consequence 
of changes in membrane potential - voltage operated channels 
(VOCs).
Calcium channel blockers (CCBs) are agents that prevent the
influx of extracellular C a n  and recently, based on
pi^nimodipine binding studies, have been separated into 
three distinct classes . To determine whether the ROC 
associated with particular platelet agonists was sensitive to a 
particular class of CCB the inhibitory effects of nicardipine 
(class I), verapamil (class II) and diltiazem (class III) were 
examined against submaximal primary aggregation induced by PAF, 
LPA, Ü44Ü69, ADP and vasopressin. Aggregation induced by all 
agonists was inhibited in a concentration-dependent manner by 
the CCBs. However, with the exception of diltiazem which
upotently inhibited the response induced by PAF and U44069 
(l^g = 9 uM and 15 yiM respectively), and verapamil which 
potently inhibited the response induced by PAF = 22
±  4 jjM), inhibition was only observed with high
concentrations of CCBs ( > lOOjjM). Hence it would appear that 
the ROC associated with the PAF receptor is sensitive to class 
II and class III, whereas the ROC associated with the U44069 
receptor is only sensitive to class III CCB.
When the inhibitory effect of verapamil and diltiazem was 
monitored against submaximal elevations of|ca+^ i induced by 
PAF and U44069 an identical inhibitory profile was observed. 
However both diltiazem and verapamil abolished the elevation of 
|ca4-^ i completely. Hence verapamil and diltiazem are capable of 
inhibiting both Ca++ influx and Ca++ mobilization. Indeed,
when monitored under conditions ofj^a+-^o = ImM andj^a+H^o = 
OmM (ie. in the presence of 3mM EGTA), the concentration 
response curve for inhibition, by verapamil, of the elevation 
ofI^ Ca-f-^  i induced by PAF were identical.
The nature of the selective inhibition of PAF-induced platelet 
responses by verapamil was further examined. Verapamil
inhibited , apparently competitively, PAF-induced platelet 
aggregation, elevation of j^Ca+4-J i and phosphoinositide 
hydrolysis - believed to be the molecular mechanism underlying 
agonist-induced elevation in |^Ca++J i . These effects on
aggregation, and |^Ca++J i were shared by the quaternary 
derivative of verapamil (D575) which is normally inactive as a
CCB unless injected into the cell. It is concluded that the 
effects of verapamil are due to an action at the outer surface
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of the platelet plasma membrane and could he attributed ,to a 
competitive interaction at the putative PAF receptor.
It is known that agents which stimulate adenylate or guanylate 
cyclase inhibit platelet functional response to all agonists. 
Several studies have shown that cAMP can enhance Ca++ uptake by 
platelet membrane fractions and in smooth muscle the inhibitory 
response of cGMP is thought to be due to redistribution of Ca++
i. Hence the inhibitory effect of PGI^, PGD^ (adenylate 
cyclase stimulants), Na nitroprusside ( a guanylate cyclase 
stimulant) and 8-bromo-cAMP and 8-Bromo-cGMP was compared on 
platelet aggregation, and on elevations of j^Ca+^ i induced by 
PAF. The rank order of potency for inhibition of aggregation 
was identical to that for inhibition of j^Ca-f^ i (ie. PGI^ >
PGD^ > NaNP >8Br cCMP > BBr cAMP) suggesting that 
supression of j^Ca++~j i availability may be the mechanism 
underlying the action of cAMP and cGMP.t
suggesting that there exists homeostatic mechanisms for Ca++
Agonist-induced elevations ofFca-t-^ i in platelets is transient.
sequestration and/or extrusion. Addition of PGI^, PGC^, 
or NaNP at the peak of the elevation of|ca-i-^i induced by PAF
resulted in an enhanced rate of Ca++ restoration. It has been
reported that cGMP may be produced by platelets following
exposure to stimulatory agonists and this could act as an
ionendogenous regulatory of elevated|^a4-^ i. However no elevati 
of platelet cGMP or cAMP was observed for up to 5 min. 
following the addition of PAF, thrombin or U44069 to platelets. 
It is concluded that cGMP may serve as a negative feedback 
regulator of elevated |^a-H^ i in platelets, and that other
16
endogenous molecules eg. 1,2-diacylglycerol may also subserve 
such a role.
It is clear that changes inj^ Ca-i-^  i alone are unlikely to be the 
sole determinant of platelet reactivity. Nevertheless a 
knowledge, firstly of the processes that govern jjCa-H^ i in 
platelets and secondly, of how these may be interfered with 
pharmacologically, should facilitate the choice or design of 
therapwtic agents to limit platelet reactivity.
1. PLATELET STRUCTURE, FORMATION AND LIFE CYCLE.
Equatorial cross section Longitudinal cross section
Figure la. Diagramatic representation of 
platelet ultrastructure viewed in equatorial and 
longitudinal cross-section. MT - microtubules; MC
— mitochondria; PM — plasma membrane; DG — dense 
granules; AG - alpha granule; LYS - lysosomes; OCS
- open canalicular system; GLY - glycogen 
granules.
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1.1. MORPHOLOGY
The resting platelet is discoid in shape, 2-3jjm in diameter and
0.7jjm in thickness and is the smallest of the formed elements 
of the blood.
The main structural features of this cell are illustrated in 
figure la. The plasma membrane is composed of a lipid bilayer 
with protein inclusions , similar in structure to other blood 
cells and rich in glycoproteins. A band of microtubules forms a 
peripheral ring around the eguatorial plane and is thought to 
serve as a cytoskeleton responsible for maintaining the shape 
of the quiescent cell. Phillips et. al. (1983) have also 
described 'the existence of an extensive microfilament system 
which may also contribute to the platelet architecture.
The dense tubular system is derived from endoplasmic reticulum 
and consists of internal membranes subjacent to the plasma 
membrane. This system may function in calcium metabolism 
(Stationed et. al., 1969).
The open canalicular system is a series of invaginations of the 
plasma membrane and is responsible for the sponge like 
appearance of the platelet in electron micrographs. These 
invaginations increase the surface area of the platelet and 
maintain a close connection between the internal and external 
environment. The function of this system is unclear but may 
facilitate exocytosis.
Platelets contain three populations of storage granules: 
electron dense granules (dense bodies ), alpha-granules and 
lysosomes. In addition platelets also contain glycogen granules 
and a few mitochondria.
Pscudo p o d l a
M l c r o f i b r l Is/ 
MlcrotubulI
Open Canal leular 
System
Dense Granule—
Lysosome
Dense Tubular 
System oc Granule
Glycogen Granules CentralIsed 
Mlcrotubul1
Mitochondrion -
Activated Platelet
Figure lb. Diagramatic 
activated platelet
representation of
1 8
Once activated platelets rapidly lose their disc shape and 
become spherical with protruding pseudopodia (figure lb.,). Such
gross alterations in the platelet profile are thought to be due
to structural changes in the underlying cytoskeleton. In
platelets the cytoskeleton has two functions, structural and
contractile. The structure of the quiescent platelet is
apparently maintained by the microtubules and also perhaps the 
microfilament system. Platelet activation is associated with
clustering of internal granules in the centre of the platelet
surrounded by a ring of microtubules and microfilaments. In
addition both filamentous systems are present in the
pseudopodia. Clearly a reorganization of the cytoskeleton
occurs upon platelet activation. The actual sequence of events 
has not yet been established, however centralization of the
cytoskeleton is though to be due to contraction of the existing 
cytoskeleton and responsible for granule clustering. 
Depolymerization of the cytoskeleton is also thought to occur 
followed by formation of a restructured cytoskeleton, this
event may be responsible for the formation of pseudopodia, (see 
section 2.2. 2ou.
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1.2. ORIGIN AND LIFE CYCLE
The blood platelet is an anucleate cell with only a vestigil 
protein synthesizing ability. Consequently most of the 
structual and functional components must be derived from the 
progenitor cell, the megakaryocyte.
Megakaryocytes were first recognised as the platelet progenitor 
by Jrfright (1906) based purely on morphological similarities 
between the two cell types. Since then much evidence has 
accumulated supporting a platelet mégacaryocyte "axis". For 
example thrombocytopenia is accompanied by an increase in the 
size and number of megakaryocytes (Marker & Finch, 1969), 
conversely thrombocytosis suppresses megakaryocytopoiesis. 
Megakaryocytes and platelets share common antigens (Humphrey, 
1955; Vazques & Lewis, I960; de Levai, 1967), display 
similarities in chemical composition (Jackson, 1973;
Darzynkiewiez etal, 1967; Rabellino et al, 1979) and isotopic 
labelling of the megakaryocyte leads to subsequent labelling of 
the circulating platelets (Odell & McDonald, 1964;
Pennington, 1969; Najean & Ardaillou, 1969).
Platelets are formed by the division of the cytoplasm of 
megakaryocytes, large polyploid cells (20-50jjm) found 
predominantly in the bone marrow but also in lung, liver and 
heart (Smith & Butcher, 1952). Formation of individual 
platelets in the megakaryocyte occurs in an orderly process. 
Synthesis of platelet components, assembly and accumulation are 
reflected in the different stages of megakaryocyte maturation. 
Three distinct steps are recognized. The megakaryoblast is
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marked by intense endomitosis accompanied by internalization 
and proliferation of the plasma membrane which ultimatly 
divides the megakaryocyte cytoplasm into individual platelets, 
the so-called demarcation membranes. This process begins in the 
earliest identifiable megakaryocyte (MacPherson, 1971; 
Levine, 1980). Also characteristic of this stage is intense 
protein synthesis (Behnke, 1970). The golgi apparatus is 
highly active and thought to be involved in mucopolysaccharide 
synthesis (lavassoli, 1979) an essential component of the 
plasma membrane. Granule formation is less evident at this 
stage. As the megakaryocyte matures increasing RNA synthesis is 
characteristic of the second stage. This is observed 
histologically by increased basic staining. In the basophil 
megakaryocyte cell organelles are now prominent, granule 
formation is also evident and concentrated in the vicinity of 
the golgi apparatus (MacPerson, 1972; Geyer & Schaaf, 
1972). These granules exhibit histological similarities with 
alpha-granules of circulating platelets (Breton-Gorius & 
Guichard, 1975). Since alpha-granules appear to be formed in 
the megakaryocyte it is also likely that the granule proteins, 
such as B-thromboglobulin and platelet derived growth factor, 
are synthesised by the megakaryocyte. Indeed some platelet 
specific proteins have been identified in the megakaryocyte 
(Castro-Malaspina et. al., 1981). Smooth endoplasmic 
reticulum is present and is histochemically identical to the 
dense tubular system of the platelet (Breton- Gorius & Reyes, 
1976). Also, so-called platelet specific glycoproteins have 
been isolated from megakaryocytes (Rabellino et al, 1981). 
Towards the end of this stage basophilic staining diminishes
21
and endomitosis ceases.
The megakaryocyte is the fully differentiated member of the 
series, although microtubules and dense tubule fragments are
still randomly distributed and do not exhibit the orderly
structures associated with platelets, probably indicating that 
platelets are not yet fully formed. The precise process whereby 
platelets are liberated by the mature megakaryocyte is unclear. 
Evidence suggests that megakaryocytes form pseudopodia which 
penetrate the blood sinusoids releasing segments of cytoplasm 
into the blood (Becker & de Bruyn, 1976; lavassoli, 1979). 
These segments or proplatelets are elongated structures of 
about 2.5 X 120jjm and it has been estimated that the mature 
megakaryocyte may produce up to six proplatelets each 
proplatelet giving rise to as many as one thousand platelets 
(Becker, 1976). The process of fragmentation probably takes 
place in tbe circulation. The precise location is unknown 
although the microcirculation of the lung has been suggested as 
a likely area (Trowbridge et. al., 1983). Apparently it is 
also possible for the entire^ megakaryocyte to pass the 
marrow-blood barrier and enter tbe circulation (Kinosita & 
Ohno, 1958). This seems to be the source of the pulmonary 
megakaryocytes where, because of their size, they are trapped 
in the microcirculation. Again this may be the location of 
fragmentation (Trowbridge et. al., 1983).
The control of megakaryocyte maturation is still poorly 
understood, but a humoral substance(s) in the blood termed
thrombopoietin has the ability to stimulate immature
megakaryocytes, increasing ploidy and size (Odell et. al., 
1976). The level of thrombopoietin varies inversely with the
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circulating platelet concentration (Odell & Murphy, 1974). 
Therefore in thrombocytopenia the level of this hormone 
probably increases and when the normal platelet count is 
attained the thrombopoietin level probably decreases leading to 
a parallel fall in the rate of megakaryocyte maturation and 
hence platelet production.
The circulating platelet concentration is normally around 2 x 
10^/ml. A number of technigues have been employed to assess 
the life-span of the circulating platelet. Of thesej^^^CrJ — 
labelling appears to be the most reliable and indicates a 
period of about 10 days (Marker & Finch, 1969). Senescent 
platelets are removed from the circulation by the 
reticuloendothelial system. The mechanism by which this system 
recognises that platelets are ready for removal is unclear 
although Greenberg et. al. (1975) have found that lowering 
the platelet sialic acid content results in immediate clearence 
from the circulation. Incorporation into a haemostatic plug is 
also responsible for removing platelets from the circulation 
and conseguently the activity of the haemostatic process would 
obviously influence the platelet life-span.
2. BLOOD PLATELETS: CELLULAR REACTIONS AND BIOLOGICAL 
FUNCTION.
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2.1. PLATELET REACTIONS.
Considering their size and anucleate nature it hardly seems
surprising that blood platelets, for so long, were viewed
merely as preparation artifacts. Yet for the same reasons it
seems remarkable that these cells are capable of such a wide
variety of cellular reactions. Such reactivity makes the
platelet unique among the blood cells.
V
2.1.1. ACTIVE TRANSPORT
In their quiescent state platelets actively transport 
5-hydroxytryptamine (5HT), adenine, adenosine and taurine from 
the plasma (Gordon & Milner, 1967). Indeed virtually all 
the plasma 5HT is sequestered in the dense bodies of these 
cells. 5HT uptake is energy dependent and occurs against a 
considerable concentration gradient (Lingjaerde, 1969; 
Sneddon, 1969; Shaskan & Snyder, 1970). Two separate uptake
mechanisms are involved in this process; one, located in the
plasma membrane, is responsible for transport from the plasma 
to the cytosol; the second, located in the granule membrane, 
transports the amine from the cytosol into the dense bodies 
(Pletscher et. al., 1978; Rudnick et. al., 1980). Adenine 
and adenosine are accumulated by different specific uptake 
processes (Sixma et. al., 1976) and incorporated into the 
cytoplasmic nucleotide pool. Platelets have two nucleotide 
compartments (Ugurbil & Holmsen, 1981) that are virtually 
non-exchangable. The cytoplasmic pool which provides the energy
2U
requirements for the cell, and a pool sequestered in the dense 
bodies. The latter is secreted during the release reaction. The 
function of taurine uptake is at present unknown.
2.1.2. PHAGOCYTOSIS
Like white cells circulating platelets may be capable of 
phagocytosis and could therefore contribute to the removal of 
particulate material from the blood (Aken & Vreeken, 1969).
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2.2. RESPONSES TO STIMULI.
The unique role of platelets DEfgAfJK. in the morphological and 
biochemical changes that occur during stimulation. In response 
to physiological stimuli platelets develop the following 
properties and hence participate in the associated cellular 
reactions.
1. They adhere to foreign surfaces (adhesion).
2. They lose their discoid shape and become spherical with
protruding pseudopodia (shape change).
3. They unmask membrane phospholipids (exposure of
pro-coagulants).
4. They cohere with other platelets (aggregation).
5. They secrete biologically active constituents from storage
granules (release reaction).
6. They generate and release active metabolites of
arachidonic acid (icosanoid biosynthesis).
7. Display various manifestations of active contraction (clot
retraction).
Platelets reactivity can be stimulated by a number of
physiological agonists and can be inhibited by agents such as
PGI^, PGE^, & PGD^. Specific membrane receptors are 
responsible for recognising the external stimulus and for
initiating the processes that translate the extracellular
stimulus into the appropriate cellular response. Furthermore 
the cohesive properties of the activated cell stems from the
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exposure of specific receptors for fibrinogen or lectins on the 
plasma membrane. The principle component of these receptors are 
membrane glycoproteins. Thirty or more glycoproteins are
associated with the plasma membrane of platelets and the role 
of some of these glycoproteins, in receptor expression, is 
discussed in sections 2.2.6.
The above reactions bestow upon the platelet considerable 
biological versatility and collectively dictate the principle 
function of the blood platelet. Platelets are involved in 
inflammation, wound healing and certain pathological 
conditions, however haemostasis is the one physiological 
process that depends exclusively on the platelet. In the event 
of vascular injury platelets adhere to the subendothelium. 
Platelet aggregates form on the carpet of adherent cells 
resulting in the formation of a primary haemostatic plug.
Activated platelets accelerate several reactions in the 
coagulation pathway thus promoting fibrin deposition in the 
primary plug. Finally the loose: meshwork of platelets and
fibrin condenses to form a clot culminating in the cessation of 
bleeding. Activation of this system in the absence of any 
apparent physiological motive is responsible for the
pathological condition of thrombosis.
The role of platelets in inflammation has not been fully
assessed. An increase in vascular permeability and the 
accumulation of leukocytes, at the site of tissue damage, is 
characteristic of the inflammatory response. Platelets release 
various factors which have the potential to mediate both 
phenomena. Moreover since platelets accumulate at the site of
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tissue damage they may play a significant role in mediating 
this process. Platelet mitogens may also contribute to the 
genesis of atherosclerosis.
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2.2.1.ADHESION.
One of the unique reactions the of platelet is their ability to 
adhere to a variety of "foreign" or more correctly thrombogenic 
surfaces. In vivo the endothelial lining of the vasculature 
constitutes a nonthrombogenic surface. Consequently platelets 
circulate as quiescent cells. In the event of endothelial 
discontinuity, for example from vascular trauma, platelets 
adhere to the subendothelial connective tissue (Hugues, 1960; 
Zucker & Borelli, 1962). Connective tissue consists of 
microfibrils of elastic, basement membrane, and collagen 
fibrils. Of these, platelets have the highest affinity for 
fibrillar collagen (Mayer 4 Weisman, 1978; Cazenave et. al., 
1973). However it is not absolutely clear whether or not 
adhesion involves a classical receptor-ligand interaction. 
Observations that collagen, extracted from activated platelets, 
was associated with fibronectin (Bensusan et. al., 1978) 
prompted the hypothesis that this glycoprotein may be the 
collagen receptor on platelets. Fibronectin is found in the 
plasma and on the surface of cells including platelets and is 
also secreted by platelets (Bensusan et. al., 1978; Plow et.
al., 1978). Subsequent studies using anti-fibronectin
antibodies have shown that inhibition of this glycoprotein has 
little effect on adhesion (Santoro & Cunningham, 1979).
Adhesion also requires a plasma cofactor Von Willebrand factor 
(VWf) (part of the Factor VIII complex). Platelets from blood 
lacking this factor (patients with Von Willebrand's disease)
display poor adhesion (Tschopp et. al., 1974). Kao et.
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al. (1979) have shown that quiescent platelets have a low 
affinity for VWf. In contrast VWf binding to the subendothelium 
correlates with platelet adhesion (Sakariassen et. al.,
1979). It has been proposed therefore, that a subendothelial 
component binds VWf causing a subsequent allosteric alteration 
enabling this protein to recognise a specific receptor on the 
platelet (Kirby, 1977; Kao et. al., 1979).
Ristocetin is an antibiotic which induces platelet 
agglutination only in the presence of VWf (Howard 4 Firkin, 
1971). A number of studies indicate that the 
ristocetin-dependent VWf receptor on platelets is glycoprotein 
lb on the plasma membrane (Berndt 4 Phillips, 1981). 
Ristocetin could therefore mimic the endothelial component by 
causing the same allosteric alteration in VWf allowing it to
bind to platelets.
Platelet adhesion is the first stage in the formation of a
haemostatic plug. Collagen not only acts as a binding matrix
but is also a potent secretago.gue (see platelet secretion 
2.2.4).
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2.2.2. PLATELET SHAPE CHANGE.
Shape change is one of the early manifestations of the platelet 
response. In cell suspensions this reaction is characterised by 
a rapid change from discs, in the quiescent state, to spheres 
with protrusions of pseudopodia in the activated state. The 
function of shape change is not completely clear although 
pseudopodia are thought to facilitate aggregation and are 
probably involved in clot retraction. A shape change also 
occurs in adherent cells where they spread over the 
thrombogenic surface, however this is a much slower response 
than that observed in the cell suspension.
While such changes involve gross alterations in the membrane 
contour, the underlying mechanism appears to be a 
reorganization of the fibrillar cytoskeleton with the plasma 
membrane responding passively.
Platelets contain two of tbe three fibrillar systems of 
eukaryotic cells: microtubules and microfilaments. These
systems have two apparent roles in platelets - structural and 
contractile.
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2.2.2a. ULTRA-STRUCTURAL EVENTS ASSOCIATED WITH PLATELET 
ACTIVATION: ROLE OF MICROTUBULES AND MICROFILAMENTS
Microtubules are present as an equatorial band in the resting
platelet (White, 1971) and appear to function in
maintaining the discoid shape of the cell. The link between
microtubules and cell shape was first suggested by Fawcett
(1959) in an article on bullfrog erythrocytes. Subsequent 
V
observations that certain mammalian erythrocytes (Camel & 
Llama) which have an ovoid structure contained a marginal 
bundle of microtubuli while other mamalian erythrocytes, devoid 
of structure, had no such system support this view (Barclay, 
1966).
In platelets direct evidence for a structural role for this 
organelle became apparent using techniques which selectively 
destroy microtubules. Microtubules may be classified into two 
major groups : "stable" & "labile" (Wilson 4 Bryan, 1974). 
Stable microtubules, typified by those seen in cilia and 
flagella, are temperature insensitive - that is they do not 
depolymerize on cooling. In contrast labile microtubules, seen 
in the spinacle lattice of dividing cells and in the dendrites 
of nervous tissue, are extremely temperature sensitive and 
unlike stable microtubules are also sensitive to anti-mitotic 
agents such as colchicine. Platelet microtubules fall into the 
latter group. Consequently the function of this organelle may 
be simply resolved by its selective destruction either by 
cooling or treatment with an anti-mitotic. Under such 
conditions quiescent platelets lose their disc shape and become
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irregular or spherical (Behnke, 1970).
What happens to microtubules upon platelet stimulation?
Electron micrographs have revealed a great deal of information
on this topic. Unlike cooled platelets, where the origional
coil can reform on warming (Behnke, 1970), physiological
stimulation results in a reorganisation of the microtubules.
The initial event appears to be contraction of the equatorial
band, since following stimulation a centralized band is observed 
V
surrounding the intracellular organelles. Later parallel 
bundles of microtubules are observed in the pseudopodia 
indicating a depolymerization and reorganisation of the 
original structure. Biochemical evidence, measuring colchicine 
binding also supports the conclusion that microtubules break 
down and later reform (Steiner & Ikeda, 1979).
The available evidence supports a structural role for 
microtubules in the resting platelet. Although bundles of 
microtubules are observed in the pseudopodia they are unlikely 
to be involved in pseudopod formation since pseudopod formation 
is unaffected by colchicine treatment (Boyle-Kay & Fudenberg, 
1973).
Microfilaments or actin containing filaments are present in the 
platelet in two forms - polymerized as filaments (F-actin) or 
in the monomeric form (G-actin). The cytoplasm within the 
microtubule ring is dense and granular and therefore prohibits 
the observation of filamentous material. Consequently it is 
difficult to establish whether this system contributes to the 
shape of the resting cell. Nachmias (1983) believes that in
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the resting cell actin exists predominantly in the monomeric
form which polymerizes on activation. Phillips et. al.
(1983) have also shown that polymerization occurs on
stimulation. In contrast however, the latter group believe that
an extensive fibrillar network, consisting of 40 - 50 %
F-actin, exists in the resting cell which increases to 60 - 80
%  upon activation. Indeed these workers have extracted, from
resting cells, such a network which retains retains a discoid 
V
shape. Although fibrillar material cannot be observed in the 
resting cell electron micrographs of activated cells show the 
microfilaments, like microtubules, as a bond surrounding the 
centralized organelles and extensivly in the pseudopodia.
The work of Phillips et. al. (1983) presents a possible 
structural role for the microfilament system in the resting 
cell. Microfilaments are present in the pseudopodia, again no 
firm evidence links microfilaments to pseudopod formation, 
however, some of the studies by Nachmias tentatively indicates 
a positive role in pseudopod formation.
Shortly after the initial shape change there is a 
reorganisation of the cytoplasmic contents. Platelet granules 
are centralised within the cytoplasm. Because the centniised 
granules are surrounded by a band of microtubules and 
microfilaments it has been proposed that microtubules and/or 
microfilaments are responsibe for this event. It has been 
suggested that such a movement brings the granules into 
intimate contact with the open canalicular system into which 
they are thought to secrete their contents (Sixma, 1974).
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The kinetics of this movement preceeds or co-incides with 
degranulation (Skaer, 1981).
Microtubules play an important role in insulin secretion from 
the pancreatic B-cells and in the secretory activity of the 
thyroid, parathyroid, anterior pituitary, polymorphonuclear 
leukocytes and macrophages (Dustin, 1978). Although it has 
not been established whether granule centralization is causally 
related to exocytosis or whether this event is indeed mediated
'V
by microfilaments or microtubules it is though'tthat activation 
of the contractile elements of these systems sweeps the 
cytoplasmic organelles in a centripetal motion.
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2.2.3. UNMASKING MEMBRANE PHOSPHOLIPIDS.
The involvement of membrane phospholipids in the coagulation 
process has been reviewed recently (Zwaal, 1978). Platelet 
activation is associated with profound changes in membrane
lipids. Among these changes a phospholipid procoagulant 
complex, termed platelet factor 3 (PF3), is unmasked on the
outer plasma membrane. PF3 accelerates the formation of
thrombin from prothrombin and the convertion of factor X to Xa. 
These reactions require the formation of an activated
intermediate complex comprising the various
enzyme/substrates. PF3 is thought to provide a matrix which 
allows factors X, V and prothrombin to bind with the correct 
conformation forming the so-called prothrombinase complex, and 
similarly factors IX and VII to form the factor X activating 
complex.
PF3 is thought to be a negatively charged phospholipid. 
Platelet phospholipids may be classified according to the 
charge on their polar head groups. At neutral pH
phosphatidylcholine (PC) phosphatidylethanolamine (PE) and 
sphingomylin (5PM) have no net charge while phosphatidylserine 
(PS) and phosphatidylinositol (Pl) are negatively charged. In 
the resting platelet the negatively charged PS and PI are 
almost exclusively located in the inner leaflet of the plasma 
membrane whereas the outer leaflet is composed of neutral 
phospholipids (Zwaal 4 Bevers, 1983).
Platelet stimulation is associated with a transbilayer movement 
of PS. Consequently the outer membrane surface becomes
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negatively charged. The mechanism(s) underlying this movement 
is unclear but probably occurs as a consequence of shape
change. PF3 activity has also been extracted from the 
alpha-granule membrane. Hence part of the PF3 activity may be 
derived from fusion of the alpha-granule with the plasma 
membrane.
In exposing PF3 the platelet can:-
;a) promote and confine coagulation to the imediate vicinity
of the injury.
b) consolidate the haemostatic plug through fibrin 
deposition.
c) propagate the haemostatic response by promoting thrombin 
formation.
Dense bodies:- ATP (adenosine triphosphate) 
ADP (adenosine diphosphate ) 
pyrophosphate 
ionic calcium
5HT (5'hydroxytryptamine )
Alpha granules:- f ibrinogen 
factor V 
thrombospondin 
fibronectin
platelet factor 4 (PF4)
low affinity platelet factor 4 (LAPF4) 
B-thromboglobulin (BTG)
platelet derived growth factor (PDGF) 
platelet basic protein (PBP)
vascular permeability factor
albumin
Lysosomes:- B-N-acetyl glucosaminidase
B-g^actosidase
B-glucuronidase
B-glycerophosphatase
elastase
Table 1. Constituents secreted from platelet dense bodies, alpha 
granules and lysosomes.
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2.2.4. PLATELET SECRETION.
Platelets disPlay two types of secretion. They can selectively
release the contents of intracellular storage granules (release
reaction) and generate and release metabolites of arachidonic
acid. Secretion is an important event in the haemostatic
process but also accounts for much of the biological 
V
versatility of these cells, allowing them to participate in 
such events as inflammation, wound healing and atherogenesis.
Release reaction : the constituents released from platelet
granules are indicated in table 1.
The mechanisms involved in platelet degranulation are complex 
and have been the subject of several studies (Holmsen,
1980).
In vitro it is clear that some physiological stimuli such as 
thrombin and collagen can directly induce the release of 
constituents from all three granule types whereas release 
induced by ADP is restricted to dense bodies and alpha-granule 
constituents and is dependent on cell-cell contact 
(aggregation) and on the formation of thromboxane A^ or the 
cyclic endoperoxides (PGG2 ,PGH2 )*
Exocytosis by platelets is similar to that in other cells in 
that the granule membrane fuses with the plasma membrane 
thereby releasing its contents into the external environment.
The invaginations of the open canalicular system may facilitate
exocytosis by effectively bringing the extracellular 
environment (surface membrane) into close contact with the 
centre of the platelet and the storage organelles located 
there.
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2.2.5. METABOLITES OF ARACHIDONIC ACID.
This topic is discussed in more detail in section 3.1. dealing 
with arachidonic acid metabolism. Platelet stimulation 
results in the mobilization and metabolism of arachidonic acid. 
The free acid may be metabolised by two enzymes. Cyclooxygenase 
catalyses the formation of the labile intermediates the 
endoperoxides PGG^ &■ PGH^ which are the substrates for 
thromboxane synthetase, producing the even more labile 
thromboxane (TXA^), and isomerases, resulting in the 
formation of the stable prostaglandins PGD^ and PGE^* 
Alternatively the free acid may be converted by a lipoxygenase 
enzyme to 12-hydroxy-eicosatetraenoic acid (HETE). Arachidonic 
acid metabolites are not actively secreted but, by virtue of 
their lipophilicity, diffuse down their concentration gradient 
out of the cell.
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2.2.6. AGGREGATION
In addition to adhesion to collagen the development of adhesive 
properties on the plasma membrane also leads to 
platelet-platelet cohesion, provided that the cells are brought 
into close contact, resulting in a multicellular aggregate. In 
vivcr aggregated platelets form the primary haemostatic plug at 
the site of vascular injury. In the absence of an apparent 
physiological SflMOWS platelet aggregates are responsible for 
various thrombotic conditions.
The mechanisms involved in platelet-platelet cohesion are 
distinct from those involved in adhesion to collagen. This 
reaction is usually but not always preceded by shape change; 
pseudopodia greatly enhance the chance of cell-cell contact. 
Since aggregation does not occur in normal quiescent cells it 
is probable that platelet activation results in the exposure or 
at least full expression of an,"aggregation receptor" on the 
plasma membrane. A polyvalent extracellular ligand is thoughtto 
form a bridge between the "aggregation receptors" of adjacent 
platelets.
Considerable evidence indicates that the plasma membrane 
glycoproteins lib and III are particularly important in 
platelet-platelet cohesion (Nurden 4 Caen, 1975; Phillips 4 
Agin, 1977). Thrombasthenia is an inherited bleeding 
disorder. Platelets from patients with this condition respond 
normally to physiological stimuli but fail to aggregate and do
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not exhibit clot retraction. Nurden & Caen (1974) first
reported that thrombasthénie platelets were deficient in
certain membrane glycoproteins and subsequent studies by
Phillips and Agin (1977) revealed the identity of these
glycoproteins as being lib and III. Phillips et. al. (1981)
have isolated an "aggregation complex" consisting of the
cytoskeletons from individual platelets linked together in
aggregates.
>•
What is the aggregation receptor ? These workers found that 
glycoproteins lib and III were the only membrane glycoproteins 
selectively retained with the aggregated cytoskeletons. In 
addition antiserum with antigenic activity towards glycoprotein 
lib inhibits platelet aggregation (Degos et. al., 1975).
What is the nature of the intraplatelet bridge ?
The structure of the intraplatelet bridge has yet to be 
conclusively established. However fibrinogen, which is present 
in plasma, is bound to the platelet membrane, is stored at high
concentrations in the platelet alpha granules and has the
potential to act as a polyvalent ligand, appears to be an 
essential component of the bridge.
The importance of fibrinogen is emphasised by the following 
observations (Berndt & Phillips, 1981):-
1) Thrombin stimulated platelets enhances the agglutination 
of fixed bovine erythrocytes; the enhanced agglutination
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was due to additional "agglutinin" secreted from
activated platelets.
2) Various inhibitors of agglutination also inhibit
aggregation.
3) Human platelet fibrinogen, treated with alpha-thrombin, 
induces agglutination of fixed bovine erythrocytes.
4) Platelets obtained from an afibrinogénémie donor do not
secrete "agglutinin".
V
5) Antifibrinogen antibodies inhibit aggregation.
6) Quiescent platelets have a low affinity for fibrinogen
whereas activated platelets have a high
affinity and the binding requires extracellular calcium;
this high affinity binding is not observed when
thrombasthénie platelets are used.
It has also been demonstrated that fibrinogen itself acts as a 
receptor for an endogenous lectin secreted by activated
platelets (Gartner et. al., 1981). In a recent study a
number of alpha granule proteins were examined for potential 
lectin activity (Jaffe et. al. 1981) by measuring their 
ability to induce agglutination of either fixed erythrocytes or 
platelets similar to the method described above. One particular 
glycoprotein thrombospondin, which is also present, in plasma 
was identified as having specific lectin activity. Purified 
thrombospondin displayed Ca++-dependent binding to platelets
and induced agglutination of erythrocytes and platelets.
Moreover agents that block thrombin-induced platelet 
agglutination also block agglutination induced by
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thrombospondin. In addition excess fibrinogen inhibits 
thrombospondin-induced agglutination; presumably, by binding to 
thrombospondin, fibrinogen prevented thrombospondin binding to 
platelet receptor (ie.platelet bound fibrinogen).
Hence the development of platelet-platelet cohesion requires an 
"aggregation receptor" on the plasma membrane. This may be the 
glycoprotein Ilb/lII complex, together with a polyvalent 
bridging ligand in which fibrinogen, ionic calcium and a 
lectin, which may be thrombospondin, are essential components. 
Gartner (1979) has suggest&b that several different 
platelet-platelet bridges may occur. In support of this view it 
is known that thrombasthénie platelets, which lack glycoprotein 
Ilb/III, do not display mutual cohesion but cohere with normal 
platelets, indicating that, at least in this situation, an 
asymetrical bridge can exist; ie. different bonds are important 
on opposite platelets (Gerrard et. al., 1979).
2.2.6a. PLATELET AGGREGATION: ."PRIMARY" AND "SECONDARY"
AGGREGATION.
Platelet activation can be monitored in vitro. The most common 
technique is the photometric measurement of platelet 
aggregation by the method developed by Born (1962). When 
aggregation is monitored in this way two distinct responses are 
observed, "primary" aggregation and "secondary" aggregation 
(figure 2).
"Primary" aggregation is a monophase reversible response not 
associated with secretion of platelet granule constituents nor
accompanied by arachidonic acid metabolism. (Mustard & 
Packham 1970)
"Secondary" aggregation can be monophasic or biphasic and is 
associated with secretion of granule constituents, arachidonic 
acid mobilization and the biosynthesis of prostaglandin 
endoperoxides (PGG^ & PGH^) and thromboxane 
(TXA2 ). That is, the observed response is initiated by the 
exogenous agonist but is propagated by endogenous agents: 
PGG^V PGH^, TXA^, secreted ADP and 5HT, by inducing 
further platelet aggregation, provide a mechanism for positive 
feedback (Holmsen et. al., 1969; Hamberg et. al., 1975)
In addition to TXA^, PGG^ and PGH^ platelets have 
the potential to synthesise other proaggregatory lipids: 
platelet activating factor (PAF) and lysophosphatidic acid 
(LPA) which may also be potentially important mediators of 
platelet activation. The involvement of lipids in mediating 
platelet reactivity is discussed in section 4.
Presumably both exogenous and endogenous agonists act on 
specific receptors on the plasma membrane or perhaps in the 
case of lipophilic agents at the cell interior. In platelets, 
as in other cells, the concentration of free calcium is thought 
to be the principle intermediary that links receptor occupancy 
to functional response (Gerrard, 1981). The role of calcium 
and the ability of the cell to modulate its functional response 
by regulating the concentration of cytosolic free calcium is 
discussed in section 3.
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2.3. PATHO-PHYSIOLOGICAL ROLES OF PLATELET ACTIVATION.
2.3.1. ROLE OF SECRETION IN HAEMOSTASIS.
In vivo many of the platelet responses involved in the 
haemostatic process occur simultaneously therefore it is
difficult to demonstrate the inter-relationship of secretion 
with other platelet responses. Histologically the initial step 
in the haemostatic process is the adhesion of circulating 
platelets to subendothelial collagen. Collagen, a powerful 
secretagogue, induces secretion by these adherent cells; a 
process thought to be responsible for propagating the 
haemostatic response. Specifically stimulation of platelets in
the immediate vicinity of the adherent cells results in 
aggregation of platelets and the formation of a platelet 
aggregate. The secreted agents responsible for propagation are 
the arachidonate metabolites TXA^, the endoperoxides 
PGG^ & PGH^, ADP and 5HT.
TXA^ is also a potent vasoconstrictor, constriction of the 
damaged blood vessel may be an important mechanism in the 
cessation of bleeding.
Thrombin formation is also important in propagating the 
haemostatic response. Activated platelets, by exposing PF3, not 
only promote thrombin formation but secrete agents which 
prevent it's inactivation. Several alpha-granule proteins PF4, 
LAPF4, BTG, PDGF and fibronectin display heparin neutralising
activity, of these PF4 has the highest activity (Niewiarowski
& Paul, I98I).
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2.3.2. CLOT RETRACTION.
This is the process whereby the loose meshwork of platelets and 
fibrin, which make up the haemostatic plug, condenses to form a 
clot. This response is unaffected by colchicine treatment and 
it is generally accepted that the contractile force underlying
V
the event is provided by actomyosin. One model, proposed by 
Cohens & de Vries (1973) suggests that the extensive 
bundles of actin filaments, present in the pseudopodia, in
association with myosin act against the inelastic fibrin
strands of the plug.
The discovery that the glycoprotein complex Ilb/lII is retained 
on the actin filaments of aggregated platelets (Phillips et. 
al., 1983) support this model since these glycoproteins are 
probably the binding site for fibrinogen (Berndt &. Phillips,
I98I) and may serve to connect fibrin strands on the outer 
surface of the platelet to the actin filaments.
2.3.3. INFLAMMATION.
Platelets that accumulate at the site of vascular injury
produce an increase in vascular permeability (Mustard et. 
al., 1965). Nachman et. al. (1972) reported that a 
cationic protein (Mwt. 30,000 ; permeability factor) caused an 
increase in vascular permeability by inducing histamine release 
from mast cells. This same protein also acts on the fifth
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component of complement (C5) to liberate a fragment with 
chemotactic activity for polymorphonuclear (PMN) leukocytes 
(Packham, 1968); leukocytes secrete potent permeabilizing 
agents. Certain arachidonate metabolites also share these 
activities. Silver et. al. (1974) reported that PGE2 
directly increased vascular permeability, while Turner et. 
al. (1975) demonstrated that HETE is also chemotactic for PMN 
leukocytes. In addition released 5HT has a profound influence
y
on vascular permeability (Gordon & Milner, 1976).
2.3.4. WOUND HEALING.
Some of the most potent serum mitogens are proteins secreted 
from platelet alpha-granules and, in vitro, stimulate the 
proliferation of several cell types including fibroblasts and 
smooth muscle j_(Ross, 1974; Rutherford & Ross, 1976; Kohler & 
Lipton, 1974). The platelet proteins which show mitogenic 
activity are PBP, PDGF and LAPF4. PBP and PDGF appear to 
possess similar mitogenic activity (Heldin et. al., 1979). 
LAPF4 is immunologically identical with PBP but is a weaker 
mitogen (Paul et. al., 1980).
2.3.5. ATHEROGENESIS.
Migration of smooth muscle cells from the media to the intima 
and subsequent proliferation causing intimai thickening may be 
due to factors released from adherent platelets that are both 
chemotactic and mitogenic (eg. PDGF), In addition it is known
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that persistent mural thrombi are eventually covered by 
endothelium and incorporated into the arterial wall leading to 
further vessel occlusion (Mustard & Packham, 1975).
3. MECHANISMS THAT REGULATE PLATELET REACTIVITY.
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3.1. CALCIUM AND CELL REGULATION
Inorganic ions, especially divalent metal cations, are 
essential cofactors in many biological reactions. By regulating 
the intracellular concentration of these ions, through 
selective permeability changes in the plasma membrane, cells 
can control the intracellular reactions responsible for energy 
metabolism, exocytosis, muscle contraction and other cellular 
responses.
A central role for calcium, as the principle divalent metal ion 
for regulation of cell function, was advocated and pioneered by 
L.V. Heilbrumn in the earler half of this century. Such a role 
was initially regarded with scepticism and only in recent 
years, with the development of techniques for manipulating 
calcium concentrations, has this role gained wide acceptance.
The cytosolic concentration of free calcium ( |ca+-^ i ) in the 
cell is maintained at very low levels relative to the 
extracellular concentration, typically 10 ^M. To achieve 
this large concentration gradient cells actively transport 
calcium out across the plasma membrane by means of am.
ATP-dependent Ca++-pump or Ca++/Na+ exchange. Alternatively
certain intracellular organelles, such as mitochondria and 
reticulum, are able to sequester calcium.
In maintaining a low Ca-H- the cell has the ability to regulate 
all Ca-f-4— dependent events simply by increasing |^a4-^ i. 
Consequently, in response to a physiological stimulus, a
transient increase in Ca++ permeability of the plasma membrane 
or in some cases translocation of intracellular calcium is
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evoked resulting in an elevation of|j;:a-f-^ i and stimulation of 
calcium-dependent reactions. Calcium therefore, may be 
considered as a biochemical intermediary or "second messenger" 
in stimulus-response coupling.
In order to act as an intermediary or second messenger calcium 
itself must act on a receptor. There appears to exist specific 
calcium receptor proteins, notably calmodulin and troponin,
which confer calcium sensitivity to many of the biochemical
reactions underlying cellular responsiveness.
3.2. THE ROLE OF CALCIUM IN PLATELET ACTIVATION.
The first indication that an elevation in jca-t^ i may regulate
platelet functional response came from observations using 
ionophores for divalent cations; A23187 induces shape change, 
aggregation and secretion in platelet suspensions (Feinman & 
Detwiler, 1974; Massini & Luscher, 1974; White et. al., 1974; 
Feinstein & Eraser, 1975). These antibiotics effectively
increase membrane permeability for divalent ions. Consequently 
A23187 would allow extracellular calcium to pass, down its
concentration gradient, into the cytoplasm hence increasing
I^Ca-H^ i. Indeed A23187 can induce a net uptake of ^^Ca++ 
(Massini & Luscher, 1974). In addition TMB-8 an
intracellular calcium antagonist in muscle (Malagodi & Chiou,
1975) inhibits platelet secretion induced by A23187 which can 
be overcome by increasing extracellular calcium (Charo et al,
1976).
In the absence of extracellular calcium aggregation is
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abolished. Thus extracellular calcium is essential for 
aggregation and is thoughtto act by stabilizing intra-platelet 
bridges (Gerrard, 1981). However in human platelets shape 
change and secretion are relatively unaffected under these 
conditions. It is suggested that these responses are mediated 
by translocation of calcium from intracellular storage pools 
to the cytosol.
Intracellular calcium in platelets is distributed in several 
storage sites. The major site is the dense granules, containing 
approximately 60% of all platelet calcium. The mechanism by 
which calcium is transported into this organelle is unknown and 
although dense granules constitute the largest calcium pool in 
platelets, this pool does not appear to contribute to [ca+^ i. 
(Gerrard, 1981) The dense tubular system (DTS) ( a form of 
reticulum ) has been compared to sarcoplasmic reticulum, a well 
defined calcium-accumulating organelle in skeletal and cardic 
muscle, and may well perform a similar function in platelets 
(Statland et. al., 1969). Indeed a membrane fraction 
containing Ca++-dependent ATPase activity, and thoughtto be 
DTS, has been isolated from platelets (Kaser-Glanzman et. 
al., 1977) In addition to the DTS platelets also contain 
mitochondria and, while the calcium accumulating 
characteristics are not well known, by analogy with other 
cells, platelet mitochondria may also function as a calcium 
storage organelle (Scharf & Luscher, 1979).
That platelets can utilize i is supported by the
observation that platelet activation induced by ADP is 
inhibited by deuterium oxide (D^O) (Le Breton et. al..
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1976). D^O inhibits the release of calcium from
sarcoplasmic reticulum in muscle (Kaminer et. al., 1972). 
Since the DTS is thoughtto function in a manner analogous to 
sarcoplasmic reticulum it seems likely that the inhibition of 
platelet function by D^O is mediated by blocking calcium 
release from the DTS.
The origiw of j^Ca++J i has been the subject of many 
investigations. lonophore studies indicate that platelets can
y
utilise both extracellular calcium and calcium translocated 
from intracellular storage pools. The relevent importance of 
each of these sources, in a physiological context, is the
subject of much debate and may in fact depend on the stimulus
(Le Breton, 1982).
While studies with ionophores indicates the importance of
calcium in platelet activation the evidence for a central role 
is circumstantial. Direct evidence that an elevation in|ca+-^i 
mediates platelet activation has been reported by Le Breton 
et. al. (1982). Using the fluorescent calcium probe,
chlortetracycline (CTC) they demonstrated that A23187 and more 
importantly the physiological stimulus ADP and U44069 (a
TXA2  mimetic) induce an elevation in|ca+-^i, further, a 
rise in ^Ca++^ i could also be evoked in conditions of low 
extracellular calcium, presumably due to calcium translocation. 
Also using this technique Feinstein (1980) has shown that 
the elevation in [^a++J i, induced by thrombin, precedes dense 
body secretion.
These results apparently demonstrate the central role ofj^ Ca-»-^  i
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in platelet activation. However changes in CTC-fluoreacence are 
not conclusive since its precise location within the platelet 
is unknown and could partition into calcium containing 
organelles. In addition it is not absolutely clear that the 
changes are specific for calcium since magnesium ions also have 
a high affinity for CTC (Caswell, 1972).
In the "shocked cell" technique small pores are produced in the 
plasma membrane by means of a localized electrical discharge. 
This allows passage of small ions between the extracellular 
medium and the cytosol. Manipulation of extracellular calcium 
allows |l]a-M^  i to be varied in a controlled and quantifiable 
manner. Using this techique Knight et. al. (1982) have 
titrated ||ca++J i required to evoke lysosomal enzyme release and 
secretion of dense body constituents. They found that half 
maximum release, for both granule types, occurred when |ca+-^ i = 
|jCa4-^ o = 1.9 juM.
The most compelling evidence for the role of calcium has been 
demonstrated using the fluorescent calcium indicator dye Quin2  
(Tsien, 1982). This dye has a high affinity for ionic 
calcium, is located predominatly in the cell cytoplasm and 
unlike CTC, which measures relative changes in |pa+-»^  i, 
quantifiable changes in|l]a+-^ i may be made (see results). Using 
the calcium ionophore ionomycin Rink et. al. (1982) have 
also titrated the ^Ca+^4 threshold required to evoke various 
functional responses. They found that shape change was induced 
at |^Ca++J i = 400 - 600 nM, release of dense body constituents
occured at jj^ a-t-^  i = 0.7 - 1 jjM and aggregation required |^ Ca-t-^
i = 2 jjM.
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From the results obtained in this study it is clear that the 
concentrations of physiological stimuli that evoke platelet 
functional responses do not elevate ^Ca++J i to the values 
titrated by Rink or Knight. This being the case Ca-H- alone may 
not be the only second messenger in platelets. Such a view is 
supported by the observation that collagen, a potent 
aggregating agent and secretagogue, does not appear to elevate 
rCa-nl i (Rink et. al. 1983).
r 1In addition to elevating Can- i most platelet agonists, 
including collagen, induce inositol phospholipid hydrolysis. 
Diacylglycerol (DAG), a transient intermediary of this 
hydrolysis, may represent a Ca-H-independent second messenger 
(Nishizuka, 1984).
DAG activates a protein kinase, protein kinase C, (see section
3.3.4.) an event that occurs normally during stimulation and is 
mimicked by phorbol esters (l2 - 0 -tetradecanoyl
phorbol-13-acetate) (TPA). In platelets exogenous
diacylglycerol (l-oleoyl-2-acetyl-glycerol) (OAG) or TPA do not 
elevate j^Ca-H^i, yet evoke secretion and aggregation in a manner 
resembling that produced by collagen (Rink, 1983). Indeed 
Rink et. al. (1983) have demonstrated that a small 
sub-threshold elevation in |^Ca-H^ i, induced by ionomycin, 
synergises with OAG or TPA to produce secretion similar to that 
induced by physiological stimuli.
It is known that several platelet agonists, including ADP and 
adrenaline, can inhibit adenylate cyclase and since an 
elevation in cAMP is associated with platelet inhibition.
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Salzman (1974) has proposed that the converse, inhibition 
of adenylate cyclase, may be a possible mechanism for
activation. However Haslam et. al. (1978) has reported that 
inhibition of adenylate cyclase does not induce or potentiate 
aggregation.
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3.3. INTER-RELATIONSHIP BETWEEN CALCIUM AND CYCLIC 
NUCLEOTIDES.
While calcium appears to be one of the second messengers that 
links receptor occupancy to functional response cAMP represents 
the most important inhibitory second messenger. cGMP also
exerts inhibitory effects on platelet function. As the effects 
C a -H  and cAMP/cGMP are antagonistic in platelets, it might be
expected that they exhibit an inverse relationship: that is an 
elevation in one inhibits the availability of the other.
Much of the experimental evidence on this topic indicates that 
cAMP can inhibit the availability of Ca++. For example
Kaser-Glanzmann et. al. (1977) have demonstrated that the
Ca-H-accumulating activity of isolated membrane fractions is 
markedly enhanced in the presence of cAMP. In intact platelets 
Owen and Le Breton (1981) have shown that Ca++ binding is 
inversely related to intracellular levels of cAMP. In addition 
phosphodiesterase inhibition augments Ca-H binding (Owen and 
Le Breton, 1981)
On the other hand Roden and Feinstein (1976) have 
demonstrated that Ca-H is a potent inhibitor of adenylate 
cyclase. It has also been shown that TMB- 8  diminishes the 
ability of TXA^ to inhibit adenylate cyclase (Gorman et. 
al., 1979) and that platelet inhibition, due to cAMP, may be 
overcome by high concentrations of the Ca++ ionophore A23187 
(Le Breton et. al., 1982). Presumably the ionophore 
maintains a rate of influx/release which is greater than the 
rate of extrusion and/or resequestration promoted by cAMP, 
resulting in a net elevation inj^a-*-^ i. Hence it would appear
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that a bidirectional relationship exists between Ca++ and cAMP. 
The effects of cGMP on Ca++ availability in platelets have 
apparently not been examined. However evidence in other systems 
(Schultz, 1977) would suggest that cGMP may act to regulate 
Ca++ availability (discussed in section 9). Similarly the 
effect of C a -H  on platelet guanylate cyclase has not been 
investigated.
4. PUTATIVE LIPID MEDIATORS OF PLATELET ACTIVATION
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Various classes of lipids can induce platelet activation w^icu 
range from fatty acids (icosanoids), to ether lipids (PAF), to 
phospholipids (PA, LPA) and to neutral lipids (DAG).
4.1. PLATELET ARACHIDONIC ACID.
Arachidonic acid (AA) (5,8,11,14,-eicosatetraenoic acid) is one 
of the most abundant fatty acid in platelets. It is derived 
either from modification of the essential fatty acid linoleic 
acid (obtained from a vegetable diet) or directly from a diet 
containing animal products. The free acid is present only in
trace quantities in the cytosol, being incorporated into
lyso-phosphatides by an acetyl CoA synthetase and 
acyltransferase(s) - the activities of which are probably
reflected by the low background level of AA. Virtually all
arachidonic acid is esterified in the sn 2  position of
phospholipids. Phosphatidylethanolamine (PE) contains most of 
the arachidonic acid 49 - 55 % with 26 - 31 % contained in
phosphatidylcholine (PC) and the remaining 14 - 25 %
distributed between phosphatidylserine (PS) and
phosphatidylinositol (Pl) (Marcus et. al., 1969; Cohen & 
Derksen, 1969).
4.1.1. MOBILIZATION OF ESTERIFIED ARACHIDONIC ACID
Icosanoids, the metabolic products of arachidonic acid, are not 
stored in platelets but are synthesised during platelet
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activation. Only the free acid may serve as a substrate for
metabolizing enzymes. Hence the first step in arachidonic acid
metabolism is its . release from membrane phospholipids. The
phospholipid substrate and mechanism by which AA is liberated
is the subject of much contention. The reason for such
contention becomes apparent from the following observations.
The total content of AA in platelets is around 100 nmol/10
cells (Neufeld & Majerus, 1983). Activated platelets have
been reported to be capable of releasing 15 - 25 % of the total
AA in less than 30 sec. (Majerus, et. al., 1983; Smith, et.
al., 1985). The free acid is rapidly metabolised by
cyclooxygenase and lipoxygenase; over 60% in 2 min. (Hamberg
& Samuelsson, 1974), and to a much smaller extent by
isomerases. In addition acyltransferase activity is likely to
reincorporate free acid and is probably the mechanism
underlying the observation that AA is transfered to plasmalogen
PE following activation (Rittenhouse-Simmons et al., 1981).
It is these factors that make an estimation of the amount of
free acid liberated, its phospholipid origin and mechanism(s)
by which it is liberated particularly difficult to determine.
Bills et. al. (1977) first demonstrated that radiolabelled
AA was released from the sn-2 position of phospholipids in much
greater proportions than other fatty acids and proposed that
the selectivity was due to the action of a phospholipase A^ 
^PLA^) enzyme. PLA^ enzymes have been extracted and
purified from platelets in several studies (Derksen & Cohen,
1975; Jesse & Cohen, 1976; Jesse & Franson, 1979; Apitz-Castro
et. al., 1979). Additional support for such a mechanism comes
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from observations by Broekman et. al. (1980) that, in
response to platelet agonists, l-acyl-sn2 -lyso phospholipids
are formed in parallel with the free acid.
In studies devised to determine the phospholipid origin of AA, 
in platelets prelabelled with radioactive AA, were reported to 
lose their label principally from PC and PI (Bills et. al.,
1976; Russel & Deykin, 1976; Schoene, 1978). For example, in
a study using rabbit platelets 41 % of the label came from PC
with 28 % from PI, 22 % from PE and 7 % from PS (Van Den
Bosch, 1980). However these initial studies did not take into 
account the size of the phospholipid pools, that is the
Ü
distrib^ion of AA within the various phospholipids species. 
When this factor (pool size) was considered the contribution
made by PC was estimated to be 14 %, PI = 24 % and PS = 3 %
whereas PE contributed the majority of free acid, approximately 
58 % (Van Den Bosch, 1980).
Indeed, in human platelets, when lyso-phospholipids were 
quantitatively monitored Broekman et. al. (1980) reported a 
rapid hydrolysis of PI, lyso PE consisting of both 1-alk-l enyl 
and 1 -acyl forms were observed as well as a small rise in
lyso-PC but only after 60 sec. No change in PS was observed.
Hence by acting as a substrate for PLA^ PE, PC and PI may
serve as a source of AA in platelets.
In experiments using disrupted platelets Bell, et. al. 
(1979) were unable to detect sufficient PLA2  activity to 
account for the amount of AA released by intact platelets 
following supramaximum stimulation. In addition, the PLA2  
activity found was not specific for 2 -arachidonyl- and acted
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equally on 2 -oleoyl- phospholipids.These workers have therefore 
proposed an alternative pathway to account for the selective 
release of AA. In this scheme 1,2-diacylglycerol (DAG) is
formed by the action of a PI specific PLC enzyme (see section
3.3.1. for details), AA is then cleaved from DAG by a
DAG-lipase. As PI hydrolysis is one of the earliest biochemical 
events initiated by platelet agonists and as DAG, formed
transiently, is rich in AA this scheme represents a plausible
mechanism for the liberation of AA. Moreover sufficient DAG 
lipase activity has been extracted from platelets to support
such a mechanism (Bell et. al., 1979).
These workers have estimated that the amount of AA released by 
platelets, in response to supramaximum concentrations of
9
agonists , to be approximately 10 nmol/10 cells/min. They
9
calculate that 5 - 1 0  nmol/10 cells of PI is hydrolysed 
within 10 - 60 sec. and hence could account for all the AA
released by the intact cell. Critics argue, however, that the 
bulk of PI hydrolysed is recycled back to PI via phosphatidic 
acid (pa) (Lapetina, 1982) hence the majority of DAG would 
be phosphorylated to PA. Indeed, in platelets, the level of PA 
rises following activation (Lapetina et al., 1979).
However, it has been pointed out that the fatty acids in 
resynthesised PI may differ from those in the origional PI 
(imai et. al., 1981; Prescott &. Majerus, 1981) suggesting 
at least some of the PA recycled to PI originates from
synthesis de novo.
In a more recent study Smith et. al. (1985) have shown that 
in the presence of both CO and LO inhibitors (LG inhibition was
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absent in the study by Bell and colleagues) that 32 nmol
AA/lO cells could be released following treatment witb 
high concentrations of thrombin, representing approximately 25 
%  of the total platelet AA. In this study Smith demonstrated 
that 40 % of the PI hydrolysed is recovered as
l-stearoyl-2-arachidonoyl PA. Hence only 60 % of the PI
hydrolysed could be utilised by the DAG lipase pathway which 
could only account for > 15 % of the AA released in this study. 
Further studies by Chau and Tai (1983) using platelet 
membranes have suggested that the release of AA via this
pathway requires the sequential action of a diglyceride lipase 
and a monoglyceride lipase. The DG lipase catalyses the 
déacylation of DG at the sn-1 position thereafter AA is cleaved 
by a monoglyceride lipase. In support of this pathway for 
liberation of AA this group have shown that there is a 
transient accumulation of arachidonyl monoglyceride as well as 
arachidonyl diglyceride in prelabelled human platelets 
following thrombin treatment. They also found that addition of 
a specific DG lipase inhibitor abolished the accumulation of 
monoglyceride but not of AA, suggesting that, while this 
pathway could contribute to the liberation of AA, its 
inhibition does not markedly alter agonist-induced AA release.
It is possible, as suggested by Lagarde (Guichardant & 
Lagarde, 1980), that the PLC/DG Lipase pathway may play a 
more significant role when submaximal stimuli are employed.
A further mechanism by which AA may be liberated again 
necessitates the hydrolysis of PI. Lapetina (1982) has
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described a PLA2  enzyme which favours the specific 
degradation of PA. Lapetina (1982) argues that the 
agonist-induced accumulation of PA, in platelets, preceeds the 
accumulation of AA and therefore could act as a source for the 
latter. However other workers have shown that the accumulation 
of PA parallels that of AA in platelets (Majerus et. al., 
1983) and in some tissues lags behind the physiological 
response (Cockcroft et. al., 1980; Farese et. al., 1981) 
(discussed in section 4.3.3.). One would expect that with such 
a mechanism lyso PA would be formed in amounts equivalent to 
the free acid, however the amount of lyso PA recovered after 
platelet stimulation represents about 1 0  % of the accumulated 
PA (Lapetina et. al., 1981) which would suggest that only a 
fraction of PA formed is hydrolysed to sn-2 lyso PA. However 
Lapetina argues that rapid reacylation of lyso-PA occurs by a 
unique transferase which transfers AA from PE and PC (discussed 
in section 3.3.5.). Such an enzyme has been demonstrated in rat 
liver microsomes (Irvin & Dawson 1979), and a third type of 
PLA^ enzyme would presumably be an integral component of
this system. The origi lal experiments by Lapetina and 
colleagues were conducted on horse platelets, since then 
attempts to demonstrate the existence of a PA specific PLA^ 
enzyme in human platelets have failed. It has also been argued
that the lyso PA formed upon thrombin stimulation is
l-lyso-2-acyl glycerol -3-phosphate which indicates a PLA^ 
activity rather than PLA2  (Mauco et. al. 1978).
The relative importance of the various pathways leading to 
liberation of AA remains to be assessed fully. However at
64
present degradation of phospholipids by PLA2  appears 
quantitatively to be the most important mechanism.
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4.1.2. METABOLISM : THE CYCLOOXYGENASE PATHWAY. (Fig. 3)
Cyclooxygenase rapidly catalyses the formation of cyclic 
endoperoxides PGG^ and PGH^ from free arachidonic acid 
(Hamberg & Samuelsson, 1973, 1974). This enzyme consists of 
two components, the initial oxygenation of arachidonic acid , 
giving rise to the so called " oxygen burst " or " respiratory 
burst " is catalysed by prostaglandin endoperoxide synthetase 
resulting in the formation of PGG^. Subsequent reduction of 
PGG2 , yeilding PGH2 , is catalysed by cyclooxygenase 
peroxidase. Both PGG^ and PGH2  are short lived (I 1/2 =
5 min. at 37°C) intermediates and are converted principally 
into thromboxane (TXA2 ) by the enzyme thromboxane
synthetase (Smith et. al., 1976; Hamberg et. al., 1975).
TXA2  is extremely labile with a half life of 30 sec. in
aqueous medium and approximately 5 min. in plasma,: the
increased stability being due to binding to plasma albumin. Its 
formation is normally detected by the appearance of its stable 
breakdown product thromboxane 8 2  (1 X8 2 )'
In addition to thromboxane formation platelet isomerase 
enzymes also catalyse the formation of small amounts of stable 
icosanoids ( PGE2 , PGF^and PGD2 ) from the cyclic 
endoperoxides . The total production of these stable
prostaglandins amount to less than 1  % of the amount of
TX8 2  synthesised (Smith et. al., 1973). Two other
stable products are formed in equimolar amounts with TX8 2  
these are:- 12-hydroxy-5,8 ,10 heptadecatrienoic acid (HHT) and 
malondialdehyde (MDA).
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4.1.3. EFFECTS OF CYCLOGXYGENASE METABOLITES ON PLATELET 
REACTIVITY.
4.1.3a. THROMBOXANE A^ AND THE ENDOPEROXIDES
The first action of the arachidonate metabolites on platelets 
was reported by Willis & Kuhn (1973) and Vargaftig & 
Zirinis (1973), and the active moiety was termed "Labile 
Aggregating Stimulating Substance" (LASS) by the former group, 
reflecting it's major action - platelet aggregation and
degranulation. A vasoconstrictor activity had been reported by 
Piper & Vane (1969) who called it "Rabbit Aorta Contracting 
Substance" (RCS). Although TXA^, the principle constituent 
of LASS and RCS, has been reported to possess calcium ionophore 
activity (Gerrard et. al., 1978). It's platelet aggregating 
and vasoconstrictor activity are almost certainly mediated by 
combination with specific receptors (MacIntyre, I98I).
Early observations indicated that the formation of TXA^ was 
a prerequisite for platelet aggregation (Hamberg et. al., 
1975). However it is now clear that the endoperoxides 
PGG^ & PGH2  can directly induce aggregation and are 
slightly less potent than TXA^ (in platelets) (Hamberg 
et. al., 1975; Moncada & Vane, 1977) and may in fact share 
the same receptor (Le Breton 1983; Jones, 1984). The 
importance of these agents in the haemostatic response has been 
discussed under platelet secretion.
In vitro platelet stimulation by certain agonists such as PAF,
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ADP, adrenaline and low, but not high, concentrations of 
thrombin and collagen have an absolute requirement for TXA2  
or PGG2 /PGH2  to evoke degranulation. The mechanism 
underlying this action of TXA2 /PGG2 /PGH2  is
unknown.
4.1.3b. OTHER PROSTANOIDS
The naturally^prostaglandins (TXA2 /PGG2 ,PGH2 , PGE,
PGP, PGI, PGD) exhibit a unique biological profile. In general,
studies using techniques such as rank order of agonist potency
(Coleman et. al., 1980; Jones, 1984) selective antagonists
(MacIntyre & Salzman 1978) and binding studies (Hung et.
al., 1982; Siegl et. al., 1979) indicate that a specific
receptor exists for each of the natural prostaglandin classes,
with a possible subclassification of the PGE2  receptor
(Jones, 1984). In platelets initial studies identified and
characterised stimulatory and inhibitory receptors (MacIntyre
& Salzman 1978). Since then most studies have concentrated on
characterising the TXA2 /PGH2  and PGI2  receptor.
Much less information is known about the PGD2 , PGp2 ^and
PGE2  receptors however it is likely that these
prostaglandins also act by combining with distinct receptors on
the platelet. Indeed the original experiments by MacIntyre
and Salzmann (1978) using selective antagonists identified a
distinct PGD2  receptor and more recently binding studies
have identified a single PGD2  receptor type with a Ka of 
—7
4.1 10~ M and approximately 600 binding sites per platelet
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(Siegl et. al., 1979). Exogenous PCD. inhibits platelet 
functional responses. The concentrations of PGD^ which 
produce inhibition are associated with an elevation in platelet 
cAMP (Smith et. al. 1974). Hence the inhibitory effect of 
this prostaglandin in platelets apparently is mediated by 
combination with a unique receptor coupled to adenylate 
cyclase.
Two effects have been reported for PGE^- Low concentrations OF 
this prostaglandin have been reported to enhance
agonist-induced aggregation, particularly "secondary 
aggregation" induced by ADP, while higher concentrations 
inhibit agonist-induced platelet functional responses (Kloeze 
1967; Shio & Ramwell 1972). The concentrations of PGE^ 
which produce inhibition are associated with an elevated level 
of platelet cAMP (Salzman et al., 1972; McDonald & Stuart 
1974). In theory a sub-population of the PGE^ receptors 
could explain the dual effects of exogenous PGE^* Such is 
the case in smooth muscle where one receptor type mediates a 
stimulatory response and the other an inhibitory response 
(Jones, 1984). However stimulation of an excitatory 
receptor would be expected to enhance both primary and 
secondary aggregation. Low concentrations of PGE2  have been 
reported to inhibit adenylate cyclase (Salzman 1976), again 
however, one would expect, as cAMP inhibits all functional 
responses, that inhibition of adenylate cyclase would enhance 
all platelet responses and not just secondary aggregation. It 
has been reported that the enhancement of aggregation by
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PGE2 is blocked by aspirin (Shio & Ramwell, 1972)
suggesting that its effect is mediated by a metabolite of 
cyclooxygenase. One proposal which might account for this 
effect is that low concentrations of exogenous PGE2 , which 
do not activate adenylate cyclase, antagonise the effect of 
agonist-induced PGD2  (Willis & Smith 1981). Presumably 
PGE2  binds to the PGD2  receptor without evoking a 
functional response thereby preventing the action of PGD2 *
It is known that the effects of exogenous PGD2  are blocked 
by PGE2  (Anderson et. al., 1980). Such a hypothesis, 
however, assumes that during the course of a normal 
agonist-induced response (secondary aggregation) PGD2  is 
formed in sufficient amounts to elicit a biological response. 
Indeed it has been suggested that PGD2  may in fact be 
produced in sufficient quantities to evoke a biological 
response, fuelling speculation that it may be inolved in a 
negative feedback system which limits the extent of platelet 
activation (Smith et. al. 1974). Though this view is not 
universal as some studies suggest that the amount of PGD2 , 
around lOpmol/ml and upwards, required to inhibit aggregation 
vastly exceeds that amount produced by activated platelets 
(Oelz et. al., 1977).
PGE_ has been reported to selectively inhibit platelet 
ZKr*
aggregation induced by arachidonic acid and the thromboxane 
mimetic U46619 (Hung et. al, 1982). In these studies the 
authors were unable to relate inhibition to changes in cAMP
content but demonstrated that specific ■PGE2 j^  binding
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could be displaced by both the U46619 and the TXA2 /PGH2 . 
receptor antagonist 13-azaprostanoic acid. It was concluded 
from these studies that PGF_. interacted with the
TXA2 /PGH2  receptor.
In contrast Armstrong and colleagues (1983) demonstrated
that PGF2 p^  inhibited primary aggregation induced by PAF,
thrombin and the TXA2  mimetic 1 1 , 9 -epoxymethano-PGH2
but not ADP. These workers found that PGF„ . could elevate
zC\
platelet levels of cAMP and cGMP. Inhibition of adenylate
cyclase but not guanylate cyclase inhibited the effect of
PGF„. It was concluded from these studies that the action
of PGF_ was mediated via stimulation of adenylate cyclase: 
zK
indeed the lack of effect on ADP would support this view as ADP 
can directly inhibit adenylate cyclase.
Further studies will be required to determine the exact the 
mode of action of PGp2 ^.
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4.1.4. LIPOXYGENASE PATHWAY. (Fig. 3)
The other route by which arachidonic acid may be metabolised is 
via a lipoxygenase enzyme to HPETE
(l2-L-Hydroxyperoxy-5,8,10,14-eicosatetraenoic acid) and 
subsequently reduced to HETE
(l2-L-Hydroxy-5,8,lG,14-eicosatetraenoic acid) (Hamberg & 
Samuelsson, 1974).
4.1.5.EFFECTS OF LIPOXYGENASES METABOLITES ON PLATELET 
REACTIVITY.
12-HPETE, like TXA^, is short lived in platelets and is 
rapidly reduced to 12-HETE. Both 12-HPETE and 12-HETE have been 
shown to inhibit platelet aggregation, the hydroperoxy 
intermediate being approximately three fold more potent than 
the corresponding hydroxy derivative (Aharony et al., 1982; 
Vericel & Lagarde, 1980,1981). The mechanism underlying this 
inhibition has not been clearly resolved. 12-HPETE has been 
reported to inhibit human platelet thromboxane synthetase 
(Hamnarstrom & Falardeau, 1977). However more recently 
Croset and Lagarde (1983) have shown that 12- and 15- 
HPETE/HETE specifically inhibit
PGG^-PGH^/TXA^-induced platelet aggregation without 
affecting their formation from exogenous arachidonic acid.
The biological role of the lipoxygenase metabolites, in 
platelets, is unknown, however Samuelsson et. al. (1976)
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have shown that the formation of lipoxygenase metabolites lags 
behind the formation of cyclooxygenase metabolites. As the 
former metabolites appear to be inhibitors while the latter are 
potent platelet activators, 12-HPETE and 12-HETE may act as 
part of a negative feedback system to limit the extent of 
activation.
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4.1.6. ARACHIDONATE METABOLITES AS REGULATORS OF PLATELET 
ACTIVITY IN VIVO: A POSSIBLE ROLE FOR TXA^ AND
PROSTACYCLIN.
The major metabolite of endothelial cell arachidonic acid is 
prostacyclin (PGI^), formed by the enzyme
PGI^-synthetase, and like TXA2  extremely labile.
PGI2  and TXA2  exert opposing effects: TXA2  promotes 
aggregation and vasoconstriction while PGI2  inhibits 
platelet aggregation and promotes vasodilatation. It has been
proposed that the activity of circulating platelets and
vascular homeostasis depends on the balance between TXA2
AND PGI2  (Moncada & Vane, 191^  . This balance may be
disturbed in certain pathological conditions. For example high 
concentrations of lipid peroxides, which inhibit 
PGl2 -synthetase (Moncada et. al., 1976) are associated 
with atherosclerotic lesions (Glavind et. al., 1952). Hence 
the lipid peroxides present in this pathological condition
could inhibit PGI2  in the vascular wall without impairing 
TXA2  generation by platelets. In contrast a characteristic 
of uremia is an increased "bleeding time apparently due to a 
platelet defect. It has been suggested that formation
in these platelets might be depressed.
o  H „ Ç -0 -(C H „ )  CH„
C H j-C + O -C H  Q
I II -
H „ C -0 -P -0 -C H 0 L IN E  
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Figure 4- Structure of platelet activating factor 
1-0-alkyl-sn2-acetyl glycerol phosphocholine (PAF) also known as 
PAF acether
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4.2. PLATELET ACTIVATING FACTOR.
Platelet-activating factor (also known as PAF, PAF-acether or 
AGEPC) is synthesised by a number of different cell types 
including rabbit basophils, human and rabbit polymorphonuclear 
leukocytes and monocytes, rabbit & human platelets, human 
endothelial cells, mast cells, murine peritoneal macrophages 
and rat renomedullary cells (Benveniste & Arnoux, 1983).
Recently the chemical structure of this molecule has been 
elucidated by two independent groups (Demopoulos et al, 1979; 
Benveniste et. al., 1979). PAF is an ether phospholipid of 
which l-G-hexadecyl/octadecyl-2-acetyl sn
glycerol-3 -phosphorylcholine are the current standards (fig 4 
). The 1-0-alkyl, sn-2 acetyl and the phosphorylcholine 
moieties are essential for optimum biological activity.
4.2.1. BIOSYNTHESIS.
PAF is not stored within the cell but is synthesized during 
activation. The most likely source of the PAF molecule is a 
membrane alkyl acyl glycerophosphocholine (alkyl acyl GPC). The 
enzymes involved in the generation of PAF from human platelets 
have not been fully assessed. However Snyder et al (1980) 
have examined other cell systems which release PAF and 
concluded that a cyclic activation/inactivation pathway exists. 
The reactions of this pathway are shown in fig ( 5 ).
Hydrolysis of the sn-2 -acyl moiety of alkyl acyl GPC by a
A c e t y l ‘ ran iTerate
Acetyl—CoA
LYSO-PAF
RCOOH
P h o jp h o lip a s e  A ^
r  OR
Acyl -
ACYL 
AF ANALOG
A c e ty lh y d ro la v e
A c e ta te
A cyl-C oA
A c y ltra n s fe ra s e
Figure 5. The reaction pathways Involved In the 
activation and inactivation of Platelet Activatin 
Factor from its membrane precursor alkyl acyl 
glycerol phosphocholine. (Taken from Platelet 
Activating Factor (Benveniste, J- & Arnoux, B. 
eds.) INSERM symposium 23).
A r v l - (  'oA
HOH
u<sc (i;c 2.f).].2G)
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T
A c v l - C o A
r\'. A c y l - C o . A : a l k y l g ly c c r o - P  a c y l t r a n s f o r a s r  (P C  2 .3 .1 .6 3 )
V. A l k y l a c y l g l y c c r o - P  pho.sphohydrolasc (E C  3 .1 .3 .4
C D P - c h o l i n c
] - A L K Y L - 2 - A C V L r s n - G L Y C E R 0 L
l - A L K Y L - 2 - L Y S O - s n - G L Y C E H O - 3 - P
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VI. C D P - c h o l i n c : a lk y la c y l g i y c c r o l
c ho l in c p M o s p h o tra n s fc ra s c  (E C  2 .7 .8 .2 )
l - A L K Y L - 2 - A C Y L - ^ - G L Y C E H O - 3 - P H O S P H O C H O L I N i :  
(a p re c u rs o r  o f  p l a l c l c l  a c t i v a t i n g  f a c t o r )
Figure 6. De-novo synthesis of alkyl acyl
glycerol phosphocholine the membraite precursor 
of Platelet Activating Factor. (Taken from Flatlet 
Activating Factor (Benvenise, J. & Arnoux, B. 
eds.) INSFRM symposium 23).
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phospholipase enzyme forms the biologically inactive
Lyso-PAF. Subsequent acétylation of the sn-2 position by an 
acetyl transferase results in the formation of the active 
molecule. PAF is rapidly inactivated to Lyso-PAF by acetyl 
hydrolases which are apparently present both within the cell 
and in the plasma. Reacylation of Lyso-PAF regenerates the 
parent substrate alkyl acyl GPC.
Alkyl acyl GPC, the cellular source of PAF, may be synthesised 
de-novo via the pathway illustrated in fig ( 6  ). Activity of 
alkyl-DHAP synthetase, the crucial enzyme of this pathway; 
which catalyses the unique reaction forming the essential ether 
bond from acyl-DHAP and long chain fatty alcohols, has only 
been measured in rabbit platelets and alveolar macrophages 
(Snyder et al, 1983). However human platelets as well as 
many other cell types that release PAF contain a large 
proportion of their choline phospholipids as alkyl acyl GPC and 
therefore probably also contain this enzyme.
An alternative pathway for the synthesis of PAF involves a 
specific choline-phosphotransferase with alkyl acetyl
sn-glycerol as the substrate. Much less information is known 
about this route.
Since activation of a phospholipase A^ enzyme is also the 
mechanism underlying the mobilization of arachidonic acid , it 
is tempting to speculate that activation of PLA^ releases 
both arachidonic acid and Lyso-PAF from the same membrane 
phospholipid. In PMN neutrophils Swendsen et al (1983) have 
shown that l-O-alkyl-2-acyl sn-glycero-3 -phosphorylcholine can 
act as a source of arachidonic acid. These cells form both PAF
76
and arachidonic acid from a single déacylation reaction. The 
evidence for such an event occuring in human platelets is less 
clear, Smith (1984) using labelled arachidonate has shown 
that l-O-alkyl-2-acyl GPC is rich in arachidonate but no 
significant hydrolysis of the sn-2 -acyl moiety occurs during 
stimulation. In contrast Chignard (1984) claims that a
substantial amount (15%) of arachidonic acid originates from 
alkyl acyl GPC. The full extent of this molecule's biological 
activity remains to^established. The range of cell types which 
synthesis this lipid implies an involvement in a wide variety 
of biological events.
4.2.2. BACKGROUND
Initial observations, almost 40 years ago , noted that
histamine was released from sensitized rabbit blood after
immunological challenge. Rabbit platelets contain large 
quantities of histamine and later studies (Barbare & 
Zvaifler, 1966) reported that the observed histamine release
was mediated by a leukocyte-dependent mechanism. The
involvement of a soluble factor was subsequently demonstrated 
by Siraganian & Osier (1971) and Henson, (1970). The
factor released from leukocytes caused platelet activation and
was therefore named "Platelet Activating Factor" (Benveniste, 
Henson & Cochrane, 1972). The specific leucocyte involved was 
identified as the basophil and the immune reaction was an 
IgE-dependent event. Much of the subsequent research 
concentrated on the role of PAF in immune/allergic and
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inflammatory reactions and as a mediator of platelet 
activation.
In completely unrelated studies Muirhead revealed a 
cardiovascular action of PAF. The antihypertensive activity of 
renomedullary cells was originally noted by Muirhead in 1958. 
The active principle was found to be lipid in nature and was 
named "Antihypertensive Polar Renomedullary Lipid" (APRL) 
(Muirhead at al, 1977). A number of 1-0-alkyl phospholipids 
were identified in subsequent studies, of which PAF was the 
most conspicuous (Muirhead et al, 1981).
4.2.3. BIOLOGICAL EFFECTS.
Exogenous PAF induces thrombocytopenia, bronchoconstriction and 
hypotension in the guinea pig, monkey and rabbit (Benveniste 
&. Vargaftig, 1983). The bronchopulmonary effects of PAF are 
platelet mediated in these species and can be separated from 
direct cardiovascular effects using platelet inhibitors. Rat 
platelets are refractory to PAF and hence only the 
platelet-independent effect of this agent, hypotension, is 
observed.
Although PAF can evoke inflammatory and allergic symptoms; is a 
potent vasodilator and platelet activator, its significance in 
pathophysiology is unclear. As an allergic mediator Pinkard 
(1979) has demonstrated that in vivo PAF is released into the 
plasma during the development of IgE-induced anaphylactic shock 
in rabbits, yet injection of PAF at the concentrations that 
produce vasodilation also produce thrombocytopenia.
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bronchopulmonary effects and may initiate leukotriene 
biosynthesis and stimulate heart rate (Vargaftig & 
Benveniste, 1983; Levi et al., 1984).
In platelets Chignard (1979) has suggested that the 
generation of PAF may represent a pathway of platelet 
activation that is independent of released ADP or arachidonic 
acid, the so called "Third Pathway". Intrapulmonary platelet 
sequ^tration is associated with the condition Adult Respiratory 
Distress Syndrom (ARDS). It has been postulated that PAF, 
secreted from alveolar macrophages activates platelets in the 
pulmonary circulation which in turn release vasoconstrictors 
producing ARDS. Therefore PAF may have an important role in 
asthma (Vargaftig & Benveniste, 1983; Levi et al., 1984).
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4.3. INOSITOL PHOSPHOLIPID METABOLISM.
Other lipid mediators of platelet activation are thought to 
include phosphatidic acid (PA), lysophosphatidic acid (LPA) and
1,2 diacylglycerol (DAG). Formation of these agents by 
stimulated platelets (and other cells) is thought to be 
intimately associated with inositol lipid metabolism which may 
also directly control platelet reactivity by regulating Ca++ 
"gating". Before discussing the effects of PA, LPA and DAG on 
platelets it is best to consider the current status (1984/5) of 
stimulated PI metabolism in cellular activation.
The inositol phospholipids constitute a minor component of the 
lipid membrane of most cell types comprising of about 1 0 % of 
the total phospholipid content. The first indication that these 
phospholipids may participate in stimulus-response coupling 
came in 1953 when Hokin & Hokin k observed an enhanced 
incorporation of P into phosphatidylinositol (Pl) of 
pancreatic cells following stimulation with acetylcholine. 
Since then this observation has been confirmed in numerous cell 
types and in response to a variety of agonists (Berridge,
1981). A common factor among all agonists that induce a "PI 
response" is that the cellular response is dependent upon i 
elevation of the intracellular free Ca++ concentrationjca+^ i.
4.3.1. PI RESPONSE OR PHOSPHOINOSITIDE CYCLE (Fig 7 )
P A - t r a n s p o r t  p r o t e i n PA GDI
PA
lns-1-4-5. P
Ptd Ins 4,5. P,
C D F  D A G
(d )
lns-l-2,cyclic P 
)''! i.)
inositOL
Pt d  I ns
P t d  Ins-TRANSPORT PROTEIN
Ret iculumCytop lasmPlasma Membrane
Figure 7. Inositol phospholipid hydrolysis.
The pathway description is given in text.
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The PI response consists of an early and rapid hydrolysis of 
the inositol phospholipids followed later by their resynthesis. 
The inositol phospholipids are present in three forms 
phosphatidylinositol (Ptd Ins) and its phosphorylated 
derivatives phosphatidylinositol 4, bisphosphate (Ptd Ins 4P) 
and phosphatidylinositol 4,5, trisphosphate (Ptd Ins 4,5, P2). 
The initial event following stimulation appears to be the 
activation of a phospholipase C enzyme (a). Since this 
enzyme is reportedly "Ca-independent", therefore active in the 
resting cell, the initial event may be the exposure of the 
appropriate inositol phospholipid substrate on the inner 
leaflet of the plasma membrane. Phospholipase C could act on 
all of the inositol phospholipids in each case resulting in the 
formation of diacylglycerol (DAG), which remains associated 
with the plasma membrane, and the hydrolytic inositol 
phosphates inositol 1-4-5 trisphosphate (Ins 1,4,5 P3) from
Ptd Ins 4,5 P2; inositol 1-4 bisphosphate (Ins 1,4 P2) from Ptd 
Ins 4 PI and inositol 1-2 cyclicphosphate (Ins 1-2 cyclic P) 
and inositol 1 phosphate (Ins 1 P) from Ptd Ins. However in 
liver cells the action of vasopressin results in a more rapid 
hydrolysis of Ptd Ins 4,5 P2 and Ptd Ins 4 P than Ptd Ins 
(Kirk et. al., 1981). MacPhee et. al. (1983) have 
shown similar findings in GH3 pituitary tumor cells in response 
to TRH. Therefore the predominant action of phospholipase C 
appears to be the hydrolysis of Ptd Ins 4 5 P resulting in DAG 
and Ins 1,4,5 P. This is probably followed by phosphorylation 
of Ptd Ins 4 P2 to Ptd Ins 4,5 P3 by specific kinases (g) 
in an attempt to maintain chemical eguilibrium. DAG is rapidly
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phosphorylated by diacylglycerol kinase (b) to phosphatidic 
acid (pa). pa and cytidine diphosphate (CDP) then form 
substrates for cytidine triphosphate-PA-cytidyl-transferase 
(c) forming CDP-diacylglycerol (CDP-DAG). Finally 
CDP-DAG-inositol-phosphatate transferase (d) reforms 
phosphatidyl-inositol. Inositol is rapidly reformed from the
inositol phosphates by the action of a phosphodiesterase
(e) and a phosphatase (f).
The cellular location of these reactions are unclear although 
some evidence suggests that the hydrolysis occurs at the plasma 
membrane and resyntheses at the reticulum membrane ( dense 
tubular system in platelets ). In such a system the movement of 
PA and Ptd Ins across the agueous phase (cytosol) would reguire 
a transport or carrier protein, the existence of such a protein 
has been reported (Laffont at. al., 1981).
4.3.2. POTENTIAL PHYSIOLOGICAL ROLE OF PHOSPHOINOSITIDE 
HYDROLYSIS.
Virtually all agonists that induce a PI response evoke a
calcium mediated cellular response. The correlation between the 
hydrolysis of PI and the generation of a calcium signal was 
first recognised by Michell (1975) who suggested that
agonist receptor interaction stimulated an enhanced PI 
hydrolysis which subsequently "gates" calcium. The sequence of 
events proposed by Michell are the subject of intense debate. 
In challenging this view the opposition argue that the PI 
response is a consequence, rather than a cause, of an increased
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availability of cytosolic free calcium. The credibility of 
Michell's proposal stems from the prediction that any cell 
which exhibits an early enhanced PI metabolism should always 
display a calcium mediated cellular response. This premise 
appears to hold true with one notable exception. In the adrenal 
medulla activation of nicotinic receptors can elevate 
intracellular calcium and evoke catecholamine secretion but do 
not cause a PI response whereas activation of muscarinic 
receptors elicit a PI response but do not elevate cytosolic 
calcium or cause release of catecholamines (Ficher et. al., 
1981).
Perhaps the most important factor in determining whether or not 
the change in calcium precedes or follows the hydrolysis of PI 
is the calcium sensitivity of the latter. If PI metabolism is 
responsible for calcium "gating" then the enzymes involved in 
this response should be active at calcium concentrations 
associated with the resting cell or in other words they should 
be independent of changes in cytosolic free calcium. The 
majority of studies on this topic conclude that PI metabolism 
is essentially a calcium "independent" event (Jones & 
Michell, 1978; Cockcroft & Comports, 1979; Kirk et. al., 1978; 
Fain & Berridge, 1979). However some exceptions exist, 
notably the neutrophil (Cockcroft et. al., 1980) and 
pancreas (Farese et. al., 1981), where the PI response is 
apparently calcium dependent.
Direct evidence for a causal relationship between PI hydrolysis 
and calcium "gating" comes from the work by Berridge and Fain 
(1979) who, using the blowfly salivary gland, successfully
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depleted the membrane PI content and in parallel were pble to 
show that calcium "gating" was severely diminished. Moreover 
when PI was restored calcium "gating" likewise recovered. 
Therefore, at least in this cell type, calcium "gating" would 
appear to be a consequence of PI metabolism .
4.3.3. RELATIONSHIP BETWEEN PHOSPHOINOSITIDE HYDROLYSIS AND 
CALCIUM GATING
HOW COULD THE PI RESPONSE "GATE" CALCIUM ?
Weiss & Putney (1981) have suggested that PI hydrolysis may 
be intimately associated with the opening of a receptor 
operated calcium channel thus allowing the influx of 
extracellular calcium. The immediate hydrolysis of Ptd Ins 4,5 
P2 presents a second possibility. This inositol phospholipid is 
a potent calcium chelator, much of the membrane bound calcium 
is probably associated with this .lipid (Buckley & Hawthorne, 
1972).
In human platelets Broekman (1984) has demonstrated that 
the decrease in membrane bound calcium correlates with Ptd Ins 
4, 5 P2 breakdown. Resynthesis of Ptd Ins 4, 5 P2, and
chelation of cytosolic free calcium, should therefore display a 
negative correlation with cell-response which may indeed be the 
case (Chap et. al., 1983). Accordingly, its hydrolysis may 
represent a mechanism for releasing membrane bound calcium. 
However these phospholipids also bind Mg++ with only slightly 
less affinity than Ca++ and since the Mg++ : Ca-H- concentration
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is 1 0  ^ : 1  it is more likely that the bulk of these lipids
will bind Mg-H-.(Fain 1982)
Phosphatidic acid (PA), formed during the PI response , 
exhibits calcium ionophore activity in artificial systems 
(Tyson et. al., 1976). It has been suggested that the 
formation of PA may act as a natural ionophore allowing both 
influx of extracellular calcium and mobilization of 
intracellular calcium. PA accumulates rapidly in platelets 
(Lapetina & Cuatrecasas, 1979), in smooth muscle (Salmon 
& Honeyman, 1980) and in mammalian salivary gland (Putney, 
1981). However in neutrophils (Cockcroft et. al., 1980) 
and pancreas (Farese et. al., 1981) PA formation lags 
behind the cellular response.
Finally Streb (1983) has demonstrated the ability of Ins 
1,4,5 P3 to release calcium from intracellular Ca+-f— storage 
sites in the pancreatic acinar cell and more recently from 
purified" platelet membrane fractions which were capable of 
Ca++-transport and thought to be DTS (O'Rourke et. al., 1985; 
Authi & Crawford 1985). The importance of Ins 1,4,5 P3 in 
regulating the availability of j^ a-»--^  i remains to be established 
conclusively. One important question that has yet to be 
answered is whether this metabolite can also evoke a calcium 
influx.
Agonist-induced inositol phospholipid hydrolysis may therefore 
directly control platelet reactivity by regulating the level of 
cytosolic free calcium. In addition several lipid metabolites 
of inositol phospholipid hydrolysis are considered to be
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mediators of platelet reactivity The importance of these,lipids 
in mediating platelet reactivity is discussed in the following 
sections.
4.3.4. 1, 2 DIACYLGLYCEROL .
1 , 2  diacylglycerol (DAq)is formed transiently during the course 
of inositol phospholipid hydrolysis and appears to represents a 
Ca++-independent second messenger. A ubiquitous kinase, protein 
kinase C, distinct from A and G kinases has been implicated in 
signal transduction in many cell types (Nishizuka 1984).
PKC is a phospholipid- (principally phosphatidylserine) and 
Ca-H—  dependent enzyme which posesses multifunctional catalytic 
activity (Nishizuka 1984). However small amounts of D#^c@n 
dramatically increase the affinity of the enzyme for C@f-+ 
conferring full activity in the absence of changes in the level 
of cytoplasmic Ca-H (Kaibuchi et. al-, 1981; Rink et- al-, 
1983). Various reports show that tumor promoting phorbol 
esters (PMA) or a synthetic diacylglycerol,
l-oleoyl-2-acetyl-3-glycerol (OAG) can mimic the effect of 
endogenous DG by directly activating PKC (Yananishi et- al-, 
1983; Nishizuka 1984). PMA can induce platelet aggregation 
and degranulation (Zucker et al-, 1974; White et al-, 1974; 
Mufson et al-, 1979). Activation of PKC, in platelets, 
results in the phosphorylation of a 40 Kd protein (Sano et 
al-, 1983) which has been reported by some workers as having 
a molecular weight of 47 Kd (Imaoka et- al-,1983; Haslan & 
Davidson 1984). Indeed initial studies demonstrated that 
OAG/PMA could induce secretion of dense body and lysosomal
86
constituents in the absence of changes in the level of 
cytosolic Ca+4- and that these responses correlated closely with 
phosphorylation of the 40 Kd protein (Yamanishi et al., 1983; 
Kaikawa et al., 1983).
4.3.5. PHOSPHOLIPIDS
Two phospholipids phosphatidic acid (PA) and lysophosphatidic
acid (LPA) are also reported to be platelet activators. PA
accumulates rapidly in platelets (Lapetina & Cuatrecasas
1979), and other cells following stimulation and has been
shown to possess Ca++ ionophore activity in artificial membrane
systems (Tyson et. al., 197^). Its rapid formation in
platelets could therefore elicit cellular responses by
elevating the cytosolic level of Ca-H-. Indeed early reports
demonstrated that exogenous PA could evoke platelet activation
(Gerrard et. al., 1978; Tokomura et. al., 1981; Gay et- al-,
1968). However in more recent experiments using very pure
preparations of PA Benton & Gerrard (1982) were unable to
a.
induce platelet aggregation, even at high concentrations. 
Gerrard has suggested that contamination of commercial P A  
preparations by LPA may account for some erroneous observations 
(Benton et. al., 1982). Whether or not exogenous PA
exhibits the same biological behaviour as endogenous PA remains 
to be determined.
LPA is also formed by activated platelets, exogenous L P A
induces platelet activation (Gerrard, 1977,1979; Tokomura 
1981) however, because the active concentration range of LPA
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in platelets is 5 - 300 jjM considerable doubt has been
expressed over the ability of this lipid to act as an
endogenous mediator as it seems unlikely that the cell could
generate these concentrations during stimulation. Lapetina
et. al. (1981) have estimated that the concentration of LPA
formed during stimulation amounts to 5  - 1 0  % of the
phosphatidic acid concentration. The amount of PA formed during 
supramaximal stimulation by thrombin is around 0.67 - 1.7 j jM  in 
a suspension of 3 x lO^cells/ml (Broekman, 1980).
Accordingly the concentration of LPA formed would he around
0.03 - 0.17 j jM .  Clearly this concentration would have little
effect on platelet reactivity. However it has been reported
(Michell 1968) that LPA generated during stimulation does
not leave the cell. Thus, if LPA was retained within the cell, 
an intracellular concentration of 14 - 77 j jM  could he achieved 
(Benton et al., 1982). This being the case LPA could have a 
considerable effect on platelet reactivity. Like PA it remains 
to he proven whether the addition of exogenous LPA to cells 
mimics the effect of intracellular LPA. In addition Lapetina's 
estimate of the amount of LPA formed may he an underestimate 
since rapid reacylation of LPA may occur (Lapetina et al., 
1981). Furthermore Benton et. al. (1982) have
demonstrated that in the presence of solubilizing agents LPA 
has a significant effect on platelet reactivity at 0.25 j j M .
4.3.6. ARACHIDONIC ACID.
Metabolites of inositol phospholipids are rich in arachidonate.
These include 1,2 diacylglycerol and PA. Arachidonic apid may 
be cleaved from 1,2,DC by either the direct action of a 1,2 
diacylglycerol lipase (Bell et al., 1979) or the seguential 
action of a 1 , 2  diacylglycerol lipase and a monoglycerol
lipase (Chau & Tai, 1983) or from PA by the action of a 
specific PLA^ (Billah et al., 1981). The liberation of 
arachidonic acid from inositol phospholipid metabolites has 
been discussed in section 4.1.1.
Many of the receptors associated with an elevation in the level 
of cytosolic calcium are also associated with an elevation of 
the intracellular level of cGMP (Michell, 1975; Berridge, 
1981). Hence a further conseguence of inositol phospholipid 
hydrolysis may be the activation of guanylate cyclase. The 
mechanism by which cGMP is elevated following receptor 
occupation is unknown. Although it has been suggested, because 
unsaturated fatty acid peroxides can activate platelet 
guanylate cyclase directly (Hidaka & Asano 1977), that the 
observed elevation of cGMP is mediated by an agonist-induced 
formation of arachidonic acid. Indeed in platelets it has been 
shown that blockade of cyclooxygenase can reduce 
collagen-induced formation of cGMP (Haslam & McClenaghan, 
1974). However more recently it has been demonstrated that 
protein kinase C can directly activate Guanylate cyclase in 
vitro (Zwiller et. al., 1985).
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4.4. AIMS OF STUDY
To characterise the effects and mechanisms of action of 
PUTATIVE LIPID MEDIATORS OF PLATELET ACTIVATION.
5. EXPERIMENTAL.
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5.1. PREPARATION OF PLATELET RICH PLASMA.
Human blood was obtained by anti-cubital venepuncture from 
willing donors who denied taking any medication for at least 1 2  
days. In certain specific instances blood was obtained from 
volunteers who had ingested aspirin (600mg) 24 hours
previously. Whole blood (9 Vol.) was collected in plastic 
tubes, mixed with 0.13 M trisodium citrate (1 Vol.) and 
platelet rich plasma prepared by centrifugation (1000 g: 22°C: 
5 min.). The platelet count was normally around 2 - 3 x 
1 0 ^/ml.
5.2. PLASMA FREE SUSPENSIONS OF PLATELETS.
Plasma free platelet suspensions (washed platelets) were 
prepared by gel exclusion chromatography using Sepharose 28. 
PRP (30 % of gel bed volume) was passed through a perspex
column containing sepharose 28 equilibrated with a modified 
Tyrodes buffer consisting of Natl (129 mM), Na^ Citrate (10 
mM), Na HCO^ (8.9 mM), Dextrose (0.56 mM), Trisma base (10 
mM), KCL (2.8 mM), K H^PO^ (0.81 mM), Mg CL^ (0.84 
mM) and Ca CL^ (2.4 mM); pH 7.4 at room temperature.
5.3. MEASUREMENT OF PLATELET AGGREGATION.
The technique used to monitor platelet aggregation was the 
method origi nally developed by Born (1962) and consists of 
monitoring the intensity of light passed through a stirred 
suspension of platelets (either PRP or washed platelets) before
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and after the addition of a drug. The formation of platelet 
aggregates produces a decrease in optical density. Hence the 
increase in light transmission, monitored by a photoelectric 
transducer coupled to a chart recorder for permanent record, 
gives an index of platelet aggregation.
5.4. PLATELET SECRETION.
Platelet secretion (dense body release, alpha-granule release, 
lysosomal enzyme release and thromboxane (1 x8 2
formation) was normally monitored in concert with platelet 
aggregation.
Using PRP which had been preincubated with |^^^5HT (1 jjM 
final concentration: 50 nCi/ml) for 40 mim. at 37°C. Normal
aggregation procedures were followed and at the appropriate 
time after agonist addition platelet reactions were terminated 
by the addition of 0.2 ml ice-cold EDTA (0.4 % (w/v)) in 
iso-osmotic saline containing imipramine (2 juM) to prevent 5HT 
reuptake. The contents were transfered to 1ml eppendorf tubes 
and the cells removed by centrifugation (8000 g; 4°C; 4 min.). 
Aliquotes of cell-free supernatant were used to measure 
secretion.
5.4.1. RELEASE OF DENSE BODY CONSTITUENTS.
Aliquots (100 ul) of cell-free supernatant were added to 
scintillation vials containing 1 0  ml triton:toluene:scintol 2  
(12.3: 6.7: 1 v/v) for measurement ofj^^^5HT release (R)
(a marker for dense body release). Identical aliquots
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containing platelet suspensions or cell-free supernatant from 
untreated platelets were also counted to obtain total (T) and 
background (B) radioactivity. Agonist-induced 
release was calculated as a percentage of total platelet 
content according to the equation:-
%  RELEASE OF
R - B
14
C 5HT = -------  X 100%
T - B
5.4.2. RELEASE OF ALPHA-GRANULE CONSTITUENTS.
Beta-thromboglobulin (BIG) (the marker used to monitor
alpha-granule release) was measured using a BIG 
radioimmunoassay kit obtained from Amersham International, 
Amersham, UK. Briefly 50 j j I  of cell-free supernatant or BIG 
standards (10 - 225 ng/ml) were incubated with 200 ul of 
anti-BTG anti-serum and 200 pi of 125 I-BTG (40 nCi). The 
incubation tubes were sealed, vortex-mixed and allowed to 
equilibrate at room temperature for one hour. The antibody 
bound BTG was separated from the free BTG by precipitation with 
an ammonium sulphate solution (500 pi). After centrifugation 
(10,000 g; 22°C: 15 min.) and removal of the supernatant the
radioactivity contained in the precipitate was counted using a 
New Egland Nuclear gamma counter. The ammount of BTG released 
was quantified by referring to a calibration curve comprising 
of BTG standards plotted against radioactivity bound.
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5.4.3. RELEASE OF LYSOSOMAL ENZYMES.
B-N-acetylglucosaminidase (B-NAG), a one of the major platelet 
lysosomal enzymes, was monitored as a marker for release of 
lysosomal constituents. Aliquotes ( 100 pi) of cell-free
supernatant or platelet pellet digested in 1 % triton X-100 
( 3 7 ° C :  30 min.) (enzyme source) were equilibrated at 37°C with
100 pi of 0.3 M sodium citrate buffer, pH 4.9, and the
reactions initiated by adding 1 0 0  pi of
4-methyl-umbelliferyl-2-acetamido- 2-deoxy-B-D-glucopyranoside 
(3 mM) (substrate). After 60 min., the reactions were 
terminated by heating at 100°C for 2 min., and 700 pi of
glass-distilled water was added to each sample. All samples 
were vortex-mixed, and 1 0 0  pi volumes of the diluted reaction 
mixture were added to 1.5 ml of 50 mM-glycine/NaOH buffer pH
10.4. The supernatant was clarified by centrifugation (14,000 
g: 20°C: 1 min.) and the fluorescence of this solution measured
in a Perkin-Elmer spectrophotofluorimeter with excitation and 
emission wavelengths of 370 nm and 450 nm respectively. 
Increases in supernatant fluorescence were expressed as a 
percentage of fluorescence in platelets of control,
unstimulated platelets.
5.4.4. MEASUREMENT OF THROMBOXANE B^ FORMATION.
Aliquotes (100 pi) of either cell-free supernatant or standard 
(10 pg - 1 ng TXB^/ml) were incubated with lOOpl of a 
1 / 2 0 . 0 0 0  dilution of anti-TXB^ anti-serum (the anti-serum 
was diluted in a potassium phosphate buffer (50 mM) containing
2500
^  2000
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O
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Figure 8. Thromboxane standard curve
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0.1 % (w/v) bovine gamma globulin, pH 7.3) and 200 ul of
3 1 •Hj-TXB^. The incubation tubes were sealed, vortexed,
and left to equilibrate for 18 hours at 4°C. Free TXB^ was
absorbed onto dextran-coated charcoal ( 1 0 0  jjl) (0.5 %  (w/v)
charcoal: 0.5 %  (w/v) dextran in a potassium phosphate buffer:
pH 7.3) and removed by centrifugation (8,000 g: 4°C: 4 min.).
3.Antibody bound Hj-TXB^ was estimated by liquid
scintillation counting. The amount of TXB^ generated by PRP 
samples was quantified by reference to a calibration curve 
comprising known TXB2  standards plotted against 
radioactivity bound. A typical curve is shown in fig. 8
5.5. MEASUREMENT OF CYTOSOLIC FREE CALCIUM (jca+^ i)
jca-f^i was measured using the calcium indicator dye Quin2
(Tsien, 1982). PRP was incubated with 10 jjM Quin2-acetoxy 
methyl ester (Quin2-AM) (37°C: 30 min.). In this form the dye 
readily permeates the plasma membrane, cytosolic esterases 
cleave the ester bond generating and trapping the active form 
(Quin2 free acid) of the dye in the cytoplasm. Loaded platelets 
were washed (to remove extracellular Quin2-AM) by gel
filtration using sepharose 2B equilibrated with a modified 
Hepes/Tyrodes buffer consisting of Na CL (129 mM), Na^ 
citrate (10.9 mM), Na HCO^ (8.9 mM), dextrose (0.56 mM) 
Hepes (5 mM), KCL (2.8 mM), K H^PO^ (0.81 mM), Mg
CL^ (0.84 mM), Ca CL^ (2.4 mM) and 0.35 %  (w/v) bovine 
serum albumin pH 7.4 at 20°C.
The normal intracellular Quin2 concentration was 0.8 - 1 mM and 
nominally the free extracellular Ca++ was restored to 1 mM free
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immediately before fluorescence measurement.
Platelet samples (1 ml) were contained in 1-cm square quartz 
cuvettes and maintained at 37°C. Fluorescence was recorded by 
an Amico-Bowman spectrophotofluorimeter coupled to a chart 
recorder, to secure a permanent record. Standard monochromator 
settings were;- excitation and emission 339 nm and 500 nm 
respectively.
The cytosolic calcium concentration^Ca+^i was calculated form 
the following formula
Ca-H-j= Kd (F - F min.)
(F max. - F)
where F is the fluorescence recorded, F min. and F max. are the
fluorescence recordings at very low and very high Ca++
respectively. Kd is the dissociation constant = 115 nM.
F max was determined by saturating Quin2 with Ca++. This was
achieved by lysing the cells which exposed the entrapped dye to
the high extracellular calcium concentration. Thereafter the
t
addition of EGTA, to chelated Ca++, allowed the detemination of 
F min. During initial studies . a number of techniques were 
employed to lyse the platelets. These included Triton X-100, 
ultra sonication and digitonin, of these digitonin (75 jjM final 
concentration) provided the most consistent and reliable 
results and was therefore used throughout the experiments 
described.
5.6. MEASUREMENT OF PLATELET cAMP AND cGMP BY 
RADIOIMMUNOASSAY.
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PRP or plasma free suspensions of platelets were treated with 
drug or vehicle for the appropriate time. Reactions were 
terminated and nucleotides extracted by the addition of ethanol 
(2 X vol.). Precipitated proteins were removed by 
centrifugation (15,000 g; 22°C; 30 mim.). The precipitate was 
washed with ethanol water (1 x vol.) (2 : 1 v/v) and the
combined supernatants evaporated to dryness at 60°C under a 
constant stream of air. Efficiency of extraction was normally 
95 %.
Radio-immunoassay methods were taken from Steiner et. el. 
(1969), Brooker et. al. (1983) and Lappin & Whaley 
(1983). Dried extracts or standards were dissolved in a 
sodium acetate buffer (50 mM: pH 6.2) and acetylated using a 
mixture of acetic anhydride:triethylamine (1 : 2 (v/v)) to
improve assay sensitivity. 100 jjl of either the unknown or 
standard (a) (0 - 500 pmoles cyclic AMP), (b) (0 - 500 fmoles
cyclic GMP) were incubated with (a) 100 yl of a 1: 2000
dilution of rabbit anti- cyclic AMP anti-serum (the anti-serum 
was diluted in 0.1 (w/v) bovine serum albumin) or (b) 100 jjl of 
anti-cyclic GMP anti-serum (1 : 300 dilution of anti-serum
obtained from Amersham International, Amersham, UK. diluted in 
0.1 % (w/v) bovine serum albumin) andj^^^^succinyl cyclic
AMP/GMP tyrosine methyl ester (2.66 nCi).
The incubation tubes were sealed vortexed and left to
equilibrate for 18 hours at 4°C.
A 500 jjl suspension of activated charcoal (0.25 % (w/v)) in a 
potassium phosphate buffer (100 mM:) bovine serum albumin: pH 
6.2) was added to each incubation tube to absorb free
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Figure 9b. Cyclic GMP standard curve.
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nucleotide which was then removed by centrifugation (8 , 0 0 0  g: 2  
min., 4°C) Aliguots (500 jjl) of the supernatant, containing the 
antibody bound tracer, was counted in a New England Nuclear 
gamma counter. Cyclic nucleotides content was quantified by 
referfing to calibration curves comprising of nucleotide 
standards plotted against radioactivity bound. Typical standard 
curves are depicted in fig. 9 a and 9 b
5.7. MEASUREMENT OF ^Hi-PAF BINDING TO RABBIT PLATELETS.
Rabbits were anaethetised by intravenous injection of 
Na-pentabarbitone and blood withdrawn, by polythene syringe (60 
ml containing 1/10 vol. Na-citrate) from the abdominal aorta. 
50 ml of whole blood was centrifu ed in 10 ml perspex tubes (50 
g, 20°C, 5 min.) to remove contaminating red cells. This
procedure was repeated until the PRP was essentially free of 
red cell contamination. Finally, in the presence of 
prostacyclin ( 1  jjg/ml ) platelets were pelleted by 
centrifugation (lOOO g, 209C, 12 min.), the supernatant
decanted, and the cells resuspended in the modified tyrodes 
buffer described in section 5.5. (jca-i-^  o = 1 mM)
Both labe\\6 . 0  PAF (l-0-alkyl-l'-2'
-PAF) (New-2-acetyl-sn-glycero-3-phosphorylcholine) (
England Nuclear) and u n l a b .1 3 ^ PAF
(1-0-hexadecy1-2-acety1-sn-glycero-3-phosphoryIcholine) were
dissolved in methylene chloride;ethanol:water ( 2 0  : 1 0  : 1
v/v).
^h|-PAF (100 nCi : 200 pM - 500 nM) was added to 1 ml
eppendorf tubes in the presence and absence of excess unlab
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PAF (10 |jM). The ligand vehicle was reduced to dryness under a 
constant stream of oxygen free nitrogen and stored at - 20°C 
until required.
The incubation was initiated by the addition of 1 ml of a 
plasma free suspension of rabbit platelets and carried out at 
either 4°C or 20°C for three min. Incubations were terminated 
by rapid centrifugation (10,000: 4°C: 4 min.). The supernatant 
was carefully aspirated and the pellet digested with hyamine 
hydroxide at 60°C for 6 hours. The remaining solution was then 
neutralized with (N) HCL and 300 jjl mixed with scintillation 
cocktail and counted for radioactivity.
Non-specific binding (counts recorded in the presence of excess 
ligand) were subtracted from total binding (counts recorded in 
the absence of excess ligand) to obtain specific binding.
5.8. MEA5UREÆNT OF PHOSPHATIDIC ACID FORMATION
A suspension of washed platelets was incubated, at 37 °C in the 
presence of carrier-free^^pJ-Phosphatidic acid (30 jjCi/ml) 
for 90 min. Thereafter the platelets were pelleted by 
centrifugation (800 g for 10 min at 15 - 20 °C) in the persence 
of PGI^ (0.3 jiM) and resuspended in 1.5 times the labelling 
volume of fresh buffer after which the platelets were ready for 
use.
Radiolabelled platelets (0.4 ml) (containing approximately 0.5 
1 mg of pnstein) were dispen ed into plastic tubes at 37°C. As 
a rough guide 10 ml of citrated whole blood yielded 3 aliquot s 
of labelled platelets. The maximum number of samples in any 
single experiment was 24 whilst within each experiment
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triplicate determinations for each drug treatment were 
performed. Reactions were initiate^ by the additions of various 
concentrations of agonists (4 jjl) in the presence of, or
subsequent to, the addition of verapamil (4 - 10 jjl) or the
appropriate vehicle as a control. Reactions were terminated by
transferring the entire platelet sample into a glass test-tube 
containing 2 ml of chloroform/methanol/lO M-HCl (25:50:4 v/v/v) 
at room temperature. Platelet lipids were extracted by 
partitioning of the aqueous and organic phases following the
addition of 0.625 ml of chloroform and 0.625 ml of water
according to the method of Lloyd et. al. (1972). After
vortexing the tubes and centrifugation (1000 g for 15 min.) the 
lower (chloroform) phase was removed into a glass vial using a 
pasteur pipette, dried at 40°C under nitrogen and stored at 
-20°C until use. The lipids were redissolved in 0.15 ml of
chloroform/methanol (9:1 v/v) and spotted on silica-gel t.l.c. 
plates (10 cm x 10 cm) for two-dimensional separation of 
phospholipids (Yavin & Zutra, 1977). This t.l.c. system 
employs a basic solvent in the first dimention 
chloroform/methanol/40% aqueous methylamine (15:6:1:5. 
v/v/v/v); neutralisation with HCl fumes; an acidic ether wash 
in the secnd dimention, diethyl-ether/glacial acetic acid 
(19:1, v/v) and an acidic solvent
chloroform/acetone/methanol/glacial acetic acid/water
(10:4:2:3:1, v/v/v/v/v), also in the second dimension, the
major phospholipids separated by this method are shown in 
figure |0. In some cases 5 jig carrier phosphatidate was to 
facilitate identification of this lipid. Jndividual spots were 
detected by exposure of the plates to iodine vapour and/or
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autoradiography on X-ray film (15 - 20 hr.). A typical
autoradiogram is shown in figure 10 phospholipids which
incorporated radioactivity are indicated by the hatched lines.
6. THE EFFECTS OF PUTATIVE LIPID MEDIATORS ON PLATELET 
ACTIVATION AND THE ROLE OF ENDOGENOUS PLATELET MEDIATORS 
(ARACHIDONATE METABOLITES AND RELEASED ADP) IN THESE 
RESPONSES.
PAF U44069 LPA
lOOnM30nM
lOOnM
SOOnM
Figure 11- Platelet aggregation induced by PAF, 
044069 and LPA. Agonists were added, at the 
concentrations indicated, to a stirred sample of 
PRP at 37*c to initiate aggregation.
Agonist Aggregation
Degranulation Markers 
5HT pXG BNAG 
( % of Total )
TXB;
( ng/ 1 0 8  Cells )
PAF 0-lpM 
PAF 0'5pM 
PAF 5 pM
LPA 10 p H  
LPA 50 p H  
LPA 200pM
U44069 0-2jiM 
UA4069 1 )iM 
U44069 5 y H
0
25±8
58±2
0
46±3
58±2
0
37110
6418
0
8316
8216
0
8216
84l6
0
7018
9015
0
1214
2418
0
912
2717
0
1*810-25 
3*010*26
0
2 * 06l0 * 3 
2.8610*2
R = reversible.
I = irreversible.
Table 2. Platelet activation induced by PAF, LPA and
U44069. Agonists were added at the concentrations indicated 
to stirred samples of PRP. After 2 minutes reactions were 
terminated by the addition of 1 vol. EGTA/imipramine as 
detailed in experimental. Thereafter cells were removed by 
centrifugation and aliquots of cell free supernatant assayed to 
determine the concentration of 5HT, TXBL, BNAG and BTG.
The results are the mean values from 4 - 8  experiments usually 
conducted in duplicate.
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6.1. EFFECTS OF PAF, LPA AND U44069 ON PLATELET ACTIVATION
PAF, LPA, PGG^, PGH2  and TXA^ are putative 
endogenous mediators of platelet activation. Due to their 
instability and/or bioconversion PGG^, PGH2  and 
TXA2  cannot be investigated directly consequently I 
utilized the stable analogue U44069 which mimics the effect of 
endoperoxides/TXA2  on platelets to assess the effect of 
these icosanoids. In this section I characterised the effects 
of these putative lipid mediators on the various aspects of the 
platelet activation process and assessed the importance of 
endogenous AA metabolites and released ADP.
PAF, U44069 and LPA induce a concentration dependent activation 
of human platelets. Low concentrations of PAF ( 10 - 100 nM ), 
U44069 ( 10 - 100 nM) and LPA ( 1 - 3 0  jjM) induced , monophasic
reversible platelet aggregation not associated with platelet 
secretion (primary aggregation). At higher concentrations all 
three agonists induced a monophasic or biphasic irreversible 
aggregation response (fig. 11 ) which was associated with the 
release of|^^^(^5HT (a marker for dense body secretion), BTG 
(a marker for alpha-granule secretion) (ie. secondary 
aggregation) and TXB2  formation induced by PAF and LPA. 
U44069, which is structurally simillar to TXB2 , cross 
reacted with anti-TXB2  antiserum and hence could not be 
measured. B-NAG (a marker for lysosomal secretion) release was 
also induced by PAF and LPA but not by U44069.
Table (2) summarises the effects of all three agonists on human 
platelet activation
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Figure 12. The effect of quinacrine on PAF-induced platelet 
aggregation Increasing concentrations of quinacrine 
AbSCi$5A were preincubated with stirred samples of PRP for 2 
minutes before the addition of PAF which induced sumaximal 
platelet aggregation. The ordinate shows the % inhibition of 
the control response. Results are the mean values S.E. from 
four experiments.
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6.2. THE ROLE OF ENDOGENOUS ARACHIDONICj METABOLITES AND ADP
In vitro platelet activation is normally initiated by exogenous 
agonists but propagated by endogenous platelet mediators, these 
include the cyclooxygenase metabolites of arachidonic acid 
(PGG^, PGH2  & TXA2 ) and ADP released from platelet 
dense bodies. Agents which interfere with the various stages of 
arachidonate metabolism or which compete for the receptors for 
these agents were employed to assess the contribution of the 
endogenous mediators to platelet functional response - 
aggregation and dense body release (monitored by measuring 
release) induced by PAF and LPA.
6.2.1. THE EFFECT OF A PLA2 INHIBITOR
Quinacrine has been reported to act ag a selective inhibitor of 
PLA2  (Lapetina et al. 1981). The effect of quinacrine 
on PAF-induced submaximal secondary aggregation is shown in 
figure (12). Quinacrine inhibited aggregation induced by PAF. 
The inhibition was concentration-dependent and at high 
concentrations the agonist response was abolished completely, 
implying that the effect was non-specific since inhibition of 
PLA2  alone should only suppress secondary aggregation 
without influencing "primary aggregation". A similar effect O P  
quinacrine was observed when LPA was the stimulating agonist 
(ie. non-specific inhibition) (data not shown).
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a s p i r i n  (200 uM)
LPA (35 nM)
♦
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5HT RELEASE 
( % OF TOTAL )
64 + 7 62 + 5
TXB^  ( ng/10®) 2.7 + 0.05 0.18 + 0.03 2.5 + 0.07 0.18 + 0.03
Figure 13. The effect of aspirin on PAF- and LPA-induced 
platelet activation. Supramaximum concentrations of agonists 
were added to stirred samples of PRP obtained from donors who 
had ingested aspirin (3 mg) at least 3 hours before donating. 
Reactions were terminated after 2 minutes of agonist 
stimulation by the addition of 1 vol. of EGTA/imipramine. Cells 
were removed by centrifugation and aliquotes of cell free 
supernatant assayed for 5HT and TXB^ content. The results 
are the mean values jf S.E. from 4 - 8  experiments.
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6.1.2. THE EFFECT OF CYCLGGXYGENASE INHIBITION.
In the presence of aspirin (200 jjM) TXB2  formation, 
monitored as an index of cyclooxygenase activity was abolished; 
remaining at basal levels (0.18 + 0.03 ng/10® cells; S.E. 
from 4 - 8  experiments conducted in duplicate). Under these 
conditions primary aggregation induced by PAF or LPA was 
unaffected. The extent of aggregation induced by supramaximal 
concentrations of PAF (5 jjM) or LPA (300 jjM) was unaffected by 
aspirin although the form had changed from an irreversible to a 
reversible response fig (13). 5HT release was completely 
abolished in the presence of aspirin.
6.2.3. THE EFFECTS GF THRGMBGXANE SYNTHETASE INHIBITIGN.
The effect of aspirin clearly indicates that the presence of 
cyclooxygenase metabolites of arachidonic acid (PGG2 ,
PGH2  & TXA^) are essential to achieve dense body 
secretion and irreversible aggregation induced by PAF and LPA. 
Under normal conditions the prostaglandin endoperoxides are 
rapidly converted to TXA2  by thromboxane synthetase. The 
importance of TXA2  alone in mediating dense body secretion 
and irreversible aggregation, induced by PAF and LPA, may be 
assessed by employing the thromboxane synthetase inhibitor 
dazoxiben (Randall et al., 1981). TXB2  formation was 
monitored as an index of TX-synthetase activity. When compared
to controls, in which PAF (5 jjM) and LPA ( 300 jjM) induced the
formation of 2.7 ±  0.05 and 2.5 ±  0.07 ng TXB2/10^
cells respectively, TXB2  levels in platelets treated with
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Figure 14. The effect of dazoxiben on PAF- and LPA-induced 
platelet activation. Dazoxiben (100 uM) was added to stirred 
samples of PRP. 2 minutes latter supramaximum concentrations of 
agonists were added. After 2 minutes of agonist stimulation the 
reactions were terminated as described for the previous figure. 
Results are the mean values + S.E. from 4 - 8  experiments 
conducted in duplicate.
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the TX-synthetase inhibitor dazoxiben remained at basal values 
(0.18 + 0.03 ng/10® cells (fig. 14*)» Thromboxane
synthetase inhibition had no effect on either "primary" or 
"secondary" aggregation induced by PAF or LPA.^^^C^SHT 
release was reduced from 60 % (controls) to 40 % in the
presence of dazoxiben (means + S.E. from 4 - 8  experiments 
conducted in duplicate).
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Figure 15- The effect of 13 azaprostanoic acid (13-APA) and 
trimethoquinol (TMQ) on PAF- and LPA-induced platelet 
activation- 13-APA/TMQ were preincubated for 2 minutes in 
stirred samples of PRP. Platelets were then stimulated with 
supramaximum concentrations of PAF or LPA and the reactions 
terminated 2 minutes later by the addition of EGTA/imipramine . 
Thereafter the 5HT and TXB_ content in aliquots cell free 
supernatant was assayed. Tne results are the mean values jf 
S.E. from 3 - 4  experiments conducted in duplicate.
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6.2.4. THE EFFECT OF PROSTAGLANDIN ENDOPEROXIDE/THROMBOXANE 
Ag RECEPTOR ANTAGONISM.
An intact cyclooxygenase is apparently essential to achieve 
14 I
C r5HT release and irreversible aggregation induced by PAF 
and LPA. Yet dazoxiben, which abolishes the formation of the 
principle metabolite of the cyclooxygenase pathway (TXA^) 
has no effect on aggregation and only inhibited|^^^cj-5HT 
release by 30 %  suggesting that the endoperoxides are capable 
of mediating secondary aggregation and dense body release. 
Hence agents which inhibit the binding of the endoperoxides and 
thromboxane to their common receptor in platelets would be 
expected to mimic the response recorded in the presence of 
aspirin.
The effect of two endoperoxide/TXA2  receptor antagonists 
trimetoquinol (TMQ) (MacIntyre & Wills 1978) and 13
azaprostanoic acid (Le Breton et al., 1981) (13-APA) on
PAF- and LPA-induced secondary aggregation are illustrated in 
fig (15). At concentrations which abolish aggregation induced 
by the TXA^ mimetic U44069, 13-APA (50yM) reversed the 
secondary response but had no effect on primary aggregation
induced by either PAF or LPA. Figure 15a shows a typical
aggregation trace induced by LPA in the presence and absence of 
13-APA.
TMQ displayed the same inhibitory pattern as 13-APA. In the 
presence of TMQ TXB2  formation induced by PAF (5 jjM) or LPA 
( 2 0 0  jjM) was inhibited by 70 %  from 2.3 + 0.2 (untreated 
control cells + PAF) and 2.2 + 0.3 (untreated cells + LPA)
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Figure 16. The effect of Beta-Gamma-Methylene-ATP (B-K- Me-ATP) 
on PAF-induced platelet activation. B-^- Me-ATP was preincubated 
in stirred samples of PRP for 2 minutes. Supramaximum
concentrations of PAF were added to initiate platelet activation 
and after 2 minutes the reactions were terminated by the addition
of EGTA/imipramine. Aliquots of cell free supernatant were then
assayed for 5HT and TXB. content. The results are the mean
values from 3 - 4  experiments conducted in duplicate.
1 0 6
ng/10^ cells to 730 ^  50 pg/lO^ cells in the 
presence of TMQ (20 jjM) (means hh S.E. from 3 - 4  (experiments 
conducted in duplicate). PAF- and LPA-induced 5HT
release was abolished by TMQ. Figure 15b shows the effect of 
TMQ on PAF-induced platelet aggregation, 5HT release and
TXB^ formation.
6.2.5 THE EFFECT OF BETA-GAMMA-METHYLENE-ATP ON PLATELET 
AGGREGATION AND DENSE BODY RELEASE INDUCED BY PAF AND LPA.
Beta-gamma-methylene-ATP (B- -Me-ATP), an ADP receptor 
antagonist (Cusack et al., 1985), was employed to examine
the contribution of released ADP to secondary aggregation
induced by PAF and LPA. B-^-Me-ATP, at concentrations which 
abolished aggregation induced by 1 jjM ADP, reversed the 
secondary aggregation response induced by 2 jjM PAF or 200 jjM 
LPA but had no effect on primary aggregation induced by either
PAF or LPA. PAF (5 jjM) and LPA (200 jjM) induced the formation
of 3.0 + 0.2 and 2.3 + 0.2 ng TXB^ /lO®
respectively. In the presence of B-^- Me-ATP no significant
reduction in TXB^ was observed (2.7 0.1 and 2.2 _+ 0.1
ng TXB^ /lO® for PAF and LPA respectively). However 5HT 
release induced by PAF and LPA was reduced from 60 jf 4 % to 
15 _+ 4 % and 52 ±_ 7 % to 13 +5 % respectively; mean
values + S.E. from 4 experiments conducted in duplicate. 
Figure 16 shows the effect of B-)( -Me-ATP on PAF-induced 
aggregation, 5HT release and TXB^ formation.
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6.3. CONCLUSION.
It is well established that human platelets can generate 
TXA2  and recently it has been shown that PAF (Chignard et 
al., 1980) and LPA (Schumacker et al., 1979) are also 
produced during physiological stimulation.
PAF, PLA and U44069 when added to human PRP induce primary
aggregation at low concentrations and induce secondary
aggregation at higher concentrations. Because they induce the 
selective release of constituents from the platelet dense 
bodies, alpha granules and lysosomes PAF and LPA may classified 
as powerful platelet agonists (Holmsen, 1972). In contrast 
U44069 does not induce lysosomal enzyme secretion and thus may 
be classified as a weak platelet agonist.
The release of dense body constituents and irreversible
aggregation by PAF or LPA requires the formation of TXA2  
though in the absence of TXA2  the endoperoxides are only 
slightly less effective in me dieting these responses. Released 
ADP is also necessary, in addition to TXA2  or the
endoperoxides, to achieve irreversible aggregation. Released 
ADP apparently also acts as a positive feedback mechanism for 
release of dense body constituents.
7. THE ROLE OF CYTOSOLIC FREE CALCIUM IN PLATELET 
ACTIVATION.
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Electrophysiological studies have established that the 
concentration of cytosolic free calcium is an important 
intermediary regulating stimulus _ -secretion coupling
(Silinsky, 1982) and stimulus-contraction coupling 
(Breeman et al., 1973). Because of their size conventional 
electrophysiological techniques cannot be applied to the study 
of platelet physiology. Until now a central role for calcium in 
modulating stimulus-response coupling in these cells has been 
largely circumstantial, being inferred from studies using the 
divalent ionophore A23187 (Feinstein, 19gO; Gerrard, 1981)
(see section 3) and by analogy with other cell systems;
platelet functional response also includes active contraction 
and secretion of granule constituents. Only recently with the 
development of the Quin2 technique, has direct evidence been 
available. In an attempt to elucidate the role of cytoplasmic 
calcium in stimulus response coupling in platelets first of 
all I examined, using Quin2, the effect of various agonists, 
including PAF, LPA and U44Ü69, on^Ca++ji in human platelets. 
Electrophysiological studies also have established that
agonist-induced changes in |^Ca++^ i may arise through
mobilization of Ca++ from intracellular storage sites and/or 
influx of extracellular Ca++ via channels, pores or carriers in 
the plasma membrane (Bolton, 1979; Breeman et al., 1973)
That similar mechanisms (ie. influx or mobilization) operate 
in/on platelets has again been inferred from studies using the 
calcium ionophore A23187 (Massini & Luscher, 1974) (see
section 3). By monitoring any change inj^a-H^ i in the presence 
and absence of EGTA, to chelate extracellular Ca++, I next
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sought to establish the possible source of i. The
assumption being that changes in [^Ca++J i monitored in the 
absence of external Ca++ cannot be due to influx and therefore 
must be attributed to mobilization of Ca++ from intracellular 
storage sites to the cytosol.
Various studies have shown that stimulated platelets take up
45
Ca++ implying that an influx of extracellular Ca++ occurs 
upon stimulation (Owen et al, 1980; Massini & Luscher, 
1974). Two types of calcium channel (or pore), which allow an 
influx of extracellular Ca++ down its electrochemical gradient 
have been identified. One which opens as the membrane is 
depolarized and the other which may admit Ca++ in the absence
of changes in the membrane potential. The latter type is thoughC 
to be closely associated with agonist receptors and therefore 
has been called receptor operated channels (ROC's), while the 
former is referred to as a voltage operated channel (VOC). 
(Bolton, 1979).
The types of Ca++-channel in the human platelet membrane have 
not been identified. MacIntyre and Rink (1982), using the 
fluorescent probe 3 ,3-dipropylthia-dicarbocyanine (DI 5-C3-5), 
reported that platelets stimulated by a number of agonists do 
not alter the membrane potential, suggesting that if an influx 
of Ca+4- occurs it does so through ROC's. This report, however
conflicts with that of Greenberg-Sepersky and Simmons 
(1984) who, using the same technique, reported a
depolarization of the membrane (5 - 10 mV) following
stimulation by thrombin and ADP.
Since VOC's are sensitive to changes in the membrane potential
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it should be possible to open these channels selectively by
depolarizing the trans-membrane potential. Platelets maintain 
large transmembrane gradients of potassium (K+) and sodium
(Na+) (Feinberg et el, 1977; Moake et al, 1970). Because
platelets maintain a low Na+ and high K+ permeability, at rest, 
the latter ion is the major contributor to the membrane
potential; indeed the potassium equilibrium potential (Ek) = 
the membrane potential (Vm) = 60 mV (MacIntyre & Rink,
1982) The membrane can therefore be readily depolarized by
suspending the cells in a medium containing a high
concentration of K+.
Hence in the fourth study of this section I used Quin2 loaded 
platelets suspended in a medium containing high extracellular
K+. In so doing, an elevation in|jl!a+-^i evoked by membrane
depolarization would establish the presence of VOC's. An
alternative strategy makes use of the recently developed
Ca-H— agonist BAY K8644, a dihydropyridine (DHP) analogue which 
selectively opens or maintains open VOCs (Yamamoto et al,
1984). In Quin2 loaded platelets this agent should also
elevate ^Ca+-^ i if VOCs are present. BAY K8644 has been shown to 
evoke a secretory response from electrically excitable cells
such as adrenomedulla (Montiel et al, 1984) and GH3
pituitary cells (Enyeart & Hinkle, 1984). Tsien (Hess et
al, 1984) has postulated that VOC's exist in three modes: 1)
inactive, 2) short opening and prolonged ^and 3) prolonged
opening and short closure. DHP agonists, which compete with DHP 
antagonists for a common binding site on the putative VOC
(Janis et al, 1984), alter the gating kinetics favouring
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mode 3 whereas the antagonist promotes modes 1 and 2. Moreover 
the effect of DHP agonists or antagonists is enhanced by 
membrane depolarization (so-called use-dependence) (Hess et 
al, 1984). Consequently incubating BAY K8644 with agonists 
which reputedly depolarize the membrane (thrombin and ADP) 
should potentiate any change in[ca+-^i recorded in the absence 
of this agent.
It is evident from section 6 that release of dense body
constituents induced by PAF and LPA requires the formation of
the endoperoxides or thromboxane A^. The mechanism by which 
these icosanoids induce the release of constituents of storage 
organelles is unknown. Rink et al. (1982) have shown that 
the various platelet functional responses can be triggered at
different jj2a++J i (see section 3.2.) suggesting that each 
functional response is triggered at a particular |^Ca-H^ i
threshold. Therefore one possible mechanism by which these
icosanoids might mediate PAF/LPA-induced dense body release 
would be to elevate|pa+-^ i to the threshold necessary to evoke 
this response.
In contrast to the cyclooxygenase metabolites it has been
suggested that lipoxygenase metabolites of arachidonic acid 
might function as feedback inhibitors effectively limiting the 
extent of the cellular response (see section 4.1.5.). Such a 
mechanism could involve reducing the availability of the second 
messenger ( ie.|ca+-^i). Inhibition of cyclooxygenase would be
expected to reduce the agonist-induced elevation by both
removing the effect of PGG2 ,PGH2  & TXA2  (ie that
part of the agonist-induced elevation evoked by
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PGG^jPGH^ & TXA2  receptor interaction) and by 
increasing the availability of arachidonic acid for metabolism 
by the lipoxygenase enzyme. Selective inhibitors of
lipoxygenase are not available at present. However, agents 
which inhibit both lipoxygenase and cyclooxygenase are 
available, and in the present of such agents changes inj^a+^ i 
would be expected to be due entirely to the initiating agonist. 
Hence in the fifth study of this section I examined the effect 
of cyclooxygenase inhibition, cyclooxygenase/lipoxygenase
inhibition and also the effect of 12-HETE, one of the
lipoxygenase metabolites which may act as a negative feedback 
inhibitor, on PAF-induced changes injca+^i.
Finally if the cytosolic free calcium concentration regulates 
or mediates the platelet functional response then the 
concentration response curve for|ca+-^ i should correlate with 
the concentration response curve for some functional response. 
To investigate this I monitored|^^cJ-5HT release (a marker 
for dense body secretion) in parallel with changes in|ca+^ i 
induced by PAF, thrombin and ADP.
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Figure 17. Agonist-induced elevation in cytosolic free Ca4-i- ( 
I C^a-w] i ). Agonists , at the concentrations indicated, were added 
to Quin2-labelled platelets suspended in a medium of external free 
Ca-H- = 1 mM. Changes in [Ca4-Q i were calculated from tiie observed
changes in dye fluorescence. Results shown are the cumulative data 
from 3 - 9  experiments using platelets from different donors.
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7.1. THE EFFECT OF PLATELET AGONISTS ON CYTOSOLIC FREE
CALCIUM ( [Cm-^ i ) .
The aim of this study was to examine the effects of PAF,
thrombin, U44069, LPA, vasopressin (VP), ADP, 5HT and
adrenaline on platelet j^a+-^ i.
i in resting platelets was 90 + 3 nM (means + 5E; n =
46). With the exception of adrenaline all agonists induced a
concentration dependent elevation in|^a+-^ i (fig^l7). Threshold 
values and mean E.C.^q values (+^  S.E.) for agonist
induced elevation of|ca+-^i were as follows:- thrombin : 0.5 nM
& 5 + 2 nM; PAF : 5 nM & 50 + 18 nM; U44069 : 10 nM & 80
+ 23 nM; LPA : 100 nM & 700 + 300 nM; VP : 10 nM & 100 +
40 nM; ADP : 100 nM & 500 + 100 nM; 5HT : 300 nM & 700 +
200 nM, respectively.
Thus the rank order of potency was thrombin > PAF > U44069 >
vasopressin > ADP LPA > 5HT »  adr.
However the various agonists did not all elevate|ca+-^ i to the
same extent: PAF, thrombin, U44069, LPA and vasopressin
produced a maximum elevation of around 400 - 700 nM above basal
whereas ADP and 5HT were less efficacious.
7.2. SOURCES OF CALCIUM
Having established that interaction with a receptor for most
agonists presumably on the platelet plasma membrane, results in 
an elevation in |^Ca+4^ i, the potential source of|ca+-^ i was 
examined.
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Figure 18. The effect of external Ca++ on agonist-induced 
elevations of [Ca++J i in platelets. Agonists at the
concentrations indicated were added to quinZ loaded platelets
suspended in normal medium (external free Ca-H- = 1 mM) or in 
medium containing 3 mM EGTA (external free Ca-H- = 0 mM).
Changes in jjCa-nJ i were calculated from the observed changes in 
dye fluorescence. Results are typical fluorescence records for 
each individual agonist and mean values from replicate 
experiments performed using platelets from diffèrent donors.
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Figure 19. [^Ca+-^ 1 orlgiaating from mobilization 
and influx. Quin-2 loaded platelets were 
stimulated with PAF. Fluorescence was monitored
with time and shows the response recorded
initially without adjusting|Ca++jo to ImM (right; 
mobilization) and the effect of restoring [Ca-H^ o 
to ImM (influx) after platelet activation. The 
normal response induced by PAF in the presence of 
^a++^ o = ImM is shown on the left. Changes in [ca+-0 
i were calculated from observed changes in dye 
fluorescence. Results are .from a single 
observation and are representative of at least 4 
similar experiments using platelets from different 
donors.
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Agonist-induced elevations in jjca++Jiwere monitored in the 
presence and absence of EGTA (3 mM) to chelate extracellular 
Ca++. In the presence of EGTA, where|^Ca+-^ o (extracellular free 
Ca-H-) = 0 (nominally zero), any changes in|^a+-^i presumably
are due to mobilization of intracellular Ca-H-. When|ca-H^ o = 0, 
PAE, thrombin, U44069, LPA and ADP induced a
concentration-dependent elevation inj^Ca+-^ i (see also
fig. 22). The observed elevation in j^ Ca-f-^  i evoked by these 
agonists was approximately 20 % of the response recorded when
r- —% iS )
I Ca-H- o = 1  mM.^In contrast 5HT and vasopressin did not elevate 
la-H- i in the absence of extracellular Ca-H-.
An alternative approach to determine the possible source of 
Ca-H- i may be adopted. When Quin2 labelled platelets are
r.
suspended in buffer containing no added Ca-H- or EGTA (to 
facilitate the manipulation of |ca-i-^  o) addition of an agonist
evokes an elevation in|^a-i-^ i which rapidly reaches a peak then 
returns to the resting level. If j^ Ca-i-J o is then adjusted to 1 
mM a second elevation in Ca-H- i is observed. The initial 
in [c "elevation | Ca-H-J i can be attributed to mobilization of
intracellular Ca-H- and the second to an influx of extracellular 
Ca-H-. Using platelets suspended in nominally Ca-H- free medium,
PAF induced an elevation injca-nji (fig. 19), whenj^a-i-^o was
adjusted to 1 mM immediately following the peak of the initial
response, a futher elevation in j^a-H^ i was observed. The
initial elevation inj^a-nj i accounted for approximately 20 %  o f  
the total response observed.
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Figure 20. The effect of membrane
depolarization on [CaM^ 1 and agonist—Induced 
changes ln[cal-f] 1. Quin-2 loaded platelets were 
suspended in medium ccntainingFlu o = 4mM (normal 
environment) and o = 112mM to depolarize the
membrane. In the latter situation osmolarity was 
maintained by adjusting Na+. Fluorescence was 
recorded immediately after depolarization and 
after the addition of thrombin, UA4069 or ADP. 
Changes in [ca-nQ i were calculated from observed 
changes in dye fluorescence. Results are taken 
from a single observation and are representative 
of 3 similar experiments using platelets from 
different donors.
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Figure 21, The effect of BAY K8644 on agonist-induced changes
of i. BAY K8644 or vehicle in controls was preincubated
for 2 minutes before the addition of thrombin or ADP at the 
concentrations indicated. Changes in [^ Ca-i-Q i were calculated 
from the observed changes in dye fluorescence. Results are 
taken from a single experiment and are representative of 3 
similar experiments using platelets from different donors.
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7.3. THE EFFECTS OF MEMBRANE DEPOLARIZATION AND THE Ce++ 
AGONIST BAY K8644 ON RESTINGjcan-^i AND AGONIST INDUCED 
i.
This study sought to establish the type of Ca-H- channel present 
in the human platelet plasma membrane. VOC's may be selectively 
operated by the Ca++-agonist BAY K8644 or by depolarization of 
the membrane. The effect of membrane depolarization onj^a-i-^i 
was examined by suspending Quin2 loaded platelets in a medium 
containing kJ  o  (extracellular K concentration) = 4 mM (normal 
environment) and |^K^ o = 112 mM, which induces a considerable
depolarization of the membrane.
Resting j^Ca-H-J i was unaltered by depolarization and no
potentiation of the elevation in|^a-H-Ji induced by thrombin, 
U44069 and ADP was observed (fig. 20)
BAY K8644 had no effect on resting^Ca++ji (fig. 21). Since the 
action of the dihydropyrldines are enhanced by membrane
depolarization one would predict that increased jca+-^ i, evoked 
by agonists (thrombin & ADP) which allegedly produce membrane 
depolarization, would be potentiated in the presence of BAY 
K8644. Elevation of j^Ca-H-^ i induced by low or high
concentrations of thrombin or ADP was unaffected by BAY K8644
(fig. 21).
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Figure 22. The effect of flurbiprofen and BVT755C on
PAF-induced changes in {ce#-^ i . Flurbiprofen (100 uM) (A A )
or BW775C (100 jjM) (A---A) or vehicle in controls ( ■ ----• )
was preincubated with quin2 loaded platelets for 3 minutes. 
Thereafter PAF, at the concentrations indicated on the 
abscissa, was added and the changes in fluorescence recorded, 
from which changes in Qca-wQ i were calculated. The ordinate 
shows the response recorded as a % of the maximum response 
measured in the absence of drugs. The results are the mean 
values ^  S.E. from three experiments using platelets from 
different donors.
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Figure 23. The effect of increasing concentrations of BW755C 
on elevations of[Ca++]i induced by submaximal concentrations of 
PAF, U44069 or thrombin. BW755C (or vehicle in controls) at 
the concentrations indicated was preincubated with quin2 
labelled platelets. Agonists were added "and changes in 
fluorescence recorded from which changes in [Ca-#-^ i were 
calculated. The results are from a single experiment and are 
representative of 3 - 4 experiments using platelets from
different donors.
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Figure 24. The effect of 12-HETE on PAF-induced changes in 
jCart-i-^  i. 12-HETE or vehicle (ethanol) in controls was 
preincubated with quin2 loaded platelets for 2 minutes. PAF at 
the concentrations indicated was added and the changes in 
fluorescence recorded. The results are taken from a single 
experiment and are typical of 3 similar experiments conducted 
using platelets from différend donors.
116
7.4. THE EFFECT OF CYCLGGXYGENASE INHIBITION, 
CYCLGGXYGENASE/LIPGXYGENASE INHIBITION AND OF 12-HETE ON 
PAF-INDUCED CHANGES IN CYTOSOLIC FREE CALCIUM.
To determine the effect of cyclooxygenase (CO) or 
cyclooxygenase/lipoxygenase (LG) inhibition inhibition on
PAF-induced changes in |^a++J i. Concentration response curves
for changes in ^Ca++^ i induced by PAP were constructed in the 
presence and absence of flurbiprofen, a competitive CO
inhibitor, and BW755C, a CO/LO inhibitor.
Flurbiprofen at concentrations (100 jjM) which inhibited
aggregation induced by arachidonic acid had no effect on
PAF-induced changes in Ca++J i. In contrast BW755C (100 jjM)- .
inhibited PAF-induced elev tions in|ca-t-^i. (fig. 22). However 
BW755C produced a concentration-dependent inhibition of 
PAF-induced elevation in j^a-w-^ i, and at high concentrations 
abolished the response. Responses evoked by agonists other than 
PAF, eg thrombin and U44069 were similarly affected (fig. 23), 
suggesting that the inhibitory effect of BW755C is 
non-specific.
Figure 24 shows that elevation of|ca4^ i induced by low or high 
concentrations of PAF was unaffected by pretreating the cells 
with 12-HETE when compared to the vehicle control. In parallel 
experiments using washed platelets PAF-induced primary 
aggregation was also unaffected by prepreatment with 12-HETE 
(data not shown).
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Figure 25. Agonrêt-ij^uced changes in[Caht-yi monitored when 
[jCo+-i-J o = 1 mM or[ça++jo = O^mM. Platelets were simultaneously 
labelled with quio2 and[ c]“5HT. [Ca-M-] o was restored to 1
mM free or 0 mM by the addition of EGTA (3 mM). Thrombin, PAF
or ADR, at the concentrations indicated on the abscissa, were
added and fluorescence changes recorded. Reactions were
terminated immediately after the maximum change in fluorescence 
the addition of 1 vol. EGTA/imipramine and the released
5HT measured. Agonist-induced changes in[ca+^ i when 
[Ca-M-] o = 1 -.or 0 mM are shown in figure 25 whilst the
corresponding [ CJ-5HT release is shown in figure 26.
Results are the mean values + S.E. from 3 - 4  experiments.
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Figure 26. Agonist-induced[^^(^5HT release monitored when 
[Ca++1 o = 1 mM or fCa^ -ij o = 0 mM. Protocol is described in
figure 25. ^
117
7.5. CORRELATION BETWEEN IccH-f I i AND PLATELET FUNCTIONAL
RESPONSE.
Calcium is required as an essential cofactor in many 
biochemical reactions underlying platelet functional responses. 
A generalized elevation in |^a++J i might satisfy these 
requirements. However agonists induce a
concentration-dependent elevation in ^Ca++J i, supporting the 
hypothesis that this ion truely mediates cellular response. 
This being so, it should be possible to establish a direct 
correlation between |^ Ca-f-^  i and some functional response.
PAF, thrombin and ADP evoke a concentration-dependent elevation
in I^ Ca-H-J i (fig. 25 a). When 14c "5HT release was monitored
in parallel, as a measure of functional response, all three
Fia 1_agonists induced a concentration-dependent release oft C h 
5HT (fig. 26 a). However, although PAF and thrombin evoked a
similar maximum elevation in |jCa-H-^  i, maximum 5 |-|y
release induced by thrombin (88 + 6 % ) was significantly
greater than that induced by PAF (68 + 5 %). ADP, which does
not elevate [ca4-^ i to the same extent as PAF or thrombin 
induced a maximun |l4cJ.5HT release of 43 ^  10 % (means +
S.E. from 3 - 4 experiments conducted in duplicate). Moreover
the elevation in |^ Ca-t-+ i produced by 2 jjM ADP ( 200 nM) was
similar to that produced by 50 mU/ml thrombin and 50 nM PAF yet
release induced by ADP was 10 %  compared with 
33 %  and 60 %  for PAF and thrombin respectively.
When extracellular calcium is chelated using EGTA, the
elevation in |^a+4^ i induced by PAF thrombin and ADP was
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inhibited by 80 %  (fig. 25 b). Under these conditions , .when
compared to controls where^Ca++jo = 1 mM, the maximumj^^Q^-
5HT release induced by PAF (17 ^  5 %) was inhibited by 75
% f  and that induced by ADP ( 6  ±  2 %) was inhibited by 85 
%, however, although the concentration response curve for
thrombin was displaced to the right the maximum release induced 
by thrombin ( 65 %) was only inhibited by 25 % (fig. 26 b).
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CONCLUSION
The hypothesis that |^Ca++J i may act as a stimulus-response
coupling agent was initially drawn from analogy with other
secretory systems (Rubin, 1979). The discovery of the 
protein actomyosin in platelets (Bettex-Galland &. Luscher 
1961) reinforced this hypothesis since a regulatory role for 
Ca-H- was well established in stimulus-contraction coupling in
skeletal, cardiac and smooth muscle (Taylor & Godt, 1976;
Fleckenstein, 197 ),Breeman, 1973). Experiments using the Ca++ 
ionophore A23187 indirectly inferred a central role for|pa+-^ i
in stimulus-response coupling in platelets and suggested that
platelets could utilize both intracellular and extracellular
calcium. Studies designed to measure the uptake of 45Ca++ are
complicated, both technically and in the interpretation of 
results. For example Owen et al. (1980) found that 
adrenaline but not ADP induced a concentration-dependent uptake 
of 4^Ca-H- which correlated with aggregation. Massini &
Luscher (1976) also observed uptake of 4^Ca-H- in response 
to thrombin stimulation, but unlike Owen and colleagues they
attributed this to an exchange reaction occurring concomitantly 
with the release reaction and could be prevented by inhibitors 
of the release reaction. Results using the Ca-H- indicator dye 
chlortetracycline (CTC) also suggest a positive relationship 
between |^Ca-H^ i and platelet activation. However, as noted in 
the section 3, there is some ambiguity over the intepretation 
of CTC results
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The Quin-2 system recorded a ^Ca+-^ i in resting platelets of 
around 10 ^ nM: a value in good accord with resting values 
quoted for other cell types (eg. smooth muscle) recorded by 
conventional methods (Breeman, 1973) and that recorded in 
platelets using null-point determination (Pudon et al, 
1984). With the exception of adrenaline, which was inactive, 
all agonists induced a concentration-dependent elevation of 
j^a++J i. Moreover ADP and 5HT, considered to be weak platelet 
agonists, were incapable of elevating^Ca++ji to the same extent 
as the powerful agonists such as thrombin or PAF. Such results 
tentatively suggest that Ca++ may indeed act as the second 
messenger that mediates the cellular responses initiated by 
occupancy of receptors for thrombin, PAF, U44069, LPA, 
vasopressin, ADP and 5HT on the platelet.
The anomalous result obtained using adrenaline clearly 
complicates this hypothesis however as discussed in section 
3.3., a reduction in the intraplatelet level of cAMP may also 
serve as a transduction process leading to activation of 
platelets. This may be the mechanism by which adrenaline acts, 
since adrenaline has been reported to lower an elevated 
platelet cAMP level (Salzman, 1974). Although inhibition of 
adenylate cyclase as a mechanism for platelet activation is 
currently the subject of much controversy, alpha-2 
adrenoceptors must initiate platelet activation by mechanisms 
unrelated to changes in j^Ca-H^ i (at least as monitored using 
Quin2).
A number of workers (Massini & Luscher, 1974; Feinman et al..
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1974; White et al., 1974) have reported that the 
Ca++-ionophore A23187 can induce platelet activation not only 
when I^ Ca-H-J o = 1 mM but also when extracellular Ca++ has been
chelated, implying that these cells can utilize Ca-M- of both 
external and internal origin. Le Breton et al., (1982) have
suggested that the origin of |^a4-^ i may in fact depend on the 
agonist. These workers reported that both ADP and 
interestingly, adrenaline caused a decrease in CTC
fluorescence, indicating an increase in|ca-i-^i. The decrease in 
CTC fluorescence induced by ADP but not by adrenaline was shown 
to be sensitive to D^O. In parallel studies adrenaline but 
not ADP increased the uptake of These results were
interpreted as indicating that adrenaline activated platelets 
by causing an influx of extracellular Ca-H- whereas ADP promoted 
mobilization of intracellular Ca-H- only (Le Breton et al.
1982).
In this study, when the possible sources of j^ Ca-»-^  i were
examined using platelets suspended in medium ofjca-t-^o = 0 mM,
PAF, thrombin and ADP evoked a concentration-dependent
elevation in|jca-t-^  i which accounted for 20 %  of the response 
recorded when |^Ca-H^ o = 1  mM. These results suggest that, for 
these agonists; elevation of jj^ a-t-^  i is composed of two 
components: the principle component being an influx of
extracellular Ca++, and the minor component consisting of 
mobilization of intracellular Ca++ (^ 20 % of the total
signal). Whether the normal response is composed of both
components (ie. influx and mobilization) remains to be proven.
Vasopressin and 5HT, in contrast, only appear to be capable of
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inducing Ca-M- influx.
Since neither membrane depolarization nor the Ca-M— agonist BAY 
K8644 altered resting j^ Ca-M-J i or potentiated agonist-induced 
elevation of |^ Ca-M-J i, the inward Ca++ current produced by the 
agonists examined appears to be carried through receptor
operated calcium channels.
As inhibition of cyclooxygenase had no effect on PAF-induced 
changes in j^ Ca-f-^  i it must be concluded that PGG^, PGH^
& TXA^ do not mediate PAF-induced dense body secretion by
Ca-H-^i. Although BW755C inhibited agonist-induced
Ca-M^ i this effect occured at high concentrations
increasing 
changes in
and was apparently non-specific. Moreover although low 
concentrations of U44069 are reported to induce arachidonic 
acid release, the free acid is not metabolised by LO or CO 
(Siess et al-, 1985). This being so then the inhibitory 
effect of BW755C cannot be mediated through inhibition of 
cyclooxygenase or lipoxygenase. ’
Although a concentration dependent elevation inj^a-t-^ i has been 
established for the agonists examined, this does not prove a 
causal relationship between |^Ca-M-^ i and functional response. 
Therefore in the last study of this section an attempt was made 
to correlate j^a-t-^ i with secretion of dense body constituents 
by examining the concentration response relationships for both 
events.
With any individual agonist a direct correlation was observed 
between |^a-k^ i and platelet functional response (at least when
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j^Ca-H^ 0  = 1 mM). However for the same |^Ca-M^ i induced by
different agonists (PAF, thrombin or ADP) the functional
response did not correlate with | C^a-f-^i. In the absence of
extracellular Ca-H- |^a-i-^ i induced by thrombin, PAF or ADP is
inhibited by 80 % ,  Therefore one might predict that if the
cytosolic free calcium concentration mediates the functional 
response then it (ie. functional response) would also be 
inhibited by 80 %. Indeed for PAF and ADP this was the case but 
only a small inhibition was observed with thrombin.
^Ca-Ht^ i is clearly an important determinant of secretion of 
dense body constituents, at least for PAF and ADP. However 
equally apparent from these results is that platelet functional 
responses induced by thrombin do not correlate well with 
i, suggesting the involvement of other intracellular mediators 
(eg. 1,2-diacylglycerol; Nishizuka 1984) see section 4.
8. PHARMACOLOGICAL MANIPULATION OF THE CYTOSOLIC FREE CALCIUM
CONCENTRATION: CALCIUM CHANNEL BLOCKERS
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Figure 27. Classes of calcla channel blocker 
proposed by Glossman et. al (1982) from studies 
usingHjnlmodipine.
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The results gleaned from section 7 have established that most 
agonists induce a concentration-dependent elevation in|ca+^i. 
In this section I examined the effects of drugs known to modify 
the availability of |ca-H^ i on platelet functional response. The 
major component of |^ Ca+4^  i is an influx of extracellular Ca++
through a receptor operated Ca-H— channel in the platelet
plasma membrane. Calcium antagonists or calcium channel
blockers are drugs that block the inward calcium current
through VOC's and ROC’s (Cauvin et. al., 1983). Recently on 
the basis of radioligand binding studies, using 
I^H^nimodipine Glossman at. al. (1982) have proposed 
three classes of calcium antagonist/calcium channel blocker
(fig 27) : class 1 includes the 1,4 dihydropyridines,
flunarizine and fendiline while the phenylalkylamines represent 
the principle agents in class II, and the benzothiazepines 
represents class III. In the first study I examined the effect 
of nicardipine (class I), verapamil (class II) and 
diltiazem (class III) on platelet aggregation induced by 
various agonists.
The terminology used for these drugs (ie. calcium
antagonist/calcium channel blocker) has created much confusion 
and arguement. Fleckenstein (1971) introduced the term 
calcium-antagonist to describe the action of those drugs that 
specifically inhibit Ca-H— dependent exitation-response
coupling. Other synonyms include Ca-H— blockers, slow channel 
blockers, slow channel antagonists and calcium entry blockers.
In isolated heart cells Tsien (Lee et al, 1983) has 
demonstrated that the three classes (1,4 dihydropyridines;
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phenylalkylamines; benzothiazepines) of calcium
antagonist/calcium channel blocker block both the inward and 
outward ion currents in these cells, implying true channel 
blockade. Moreover he also shows that elevation of the
extracellular calcium concentration can overcome the blockade 
by these drugs: an effect in accordance with Ca-H— antagonism.
Clearly, therefore, both calcium channel blocker or calcium
antagonist may be appropriate terms. Strict interpretation of 
Ca-H— antagonism implies an action at the site of the calcium 
receptor. However calcium channel blocker is also a rather 
ambiguous term in that it implies physical obstruction of the 
channel as the mechanism of action of these agents. Glossman 
at al., (1982) using Guinea pig brain membranes has shown 
that the 1,4 dihydropyridines bind to the outer mouth of the 
putative calcium channel whereas the phenylalkylamines bind to 
the inner mouth of the channel. Therefore it is likely that
these two classes prevent the inward calcium current by
different mechanisms. Since the primary interest of this study 
is the pharmacological effect of these agents, that is 
preventing an inward calcium current, this action is more 
appropriately described by calcium channel blockade rather than 
calcium antagonism hence the former term has been applied 
throughout these studies.
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Figure 28. Inhibition of human platelet primary 
aggregation by class I, class II and class III 
calcium channel blockers. Increasing
concentrations of nicardipine (class I), verapamil 
(class II) and diltiazem (class III) were 
incubated with aspirin treated PRP for 2 min. at 
37 *c before the addition of agonists at 
concentrations which induce submaximal primary 
aggregation, normally 40 - 70% of the maximum
response. Results are expressed as percentage 
inhibition of the control response (ie. vehicle in 
place of CCB) and are the mean values from 6 - 8  
experiments.
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Figure 29.• Inhibition of platelet aggregation
by methoxyverapami 1. Experiments were performed 
as described for fig. (28) Results are the mean 
values SE from 6 experiments.
Calcium 
inel Blocker
1Ç.Q Value (pM) Versus Agonist.
PAF (n) UAA069 (n) LPA (n ) ADP (n)
:ardi pi ne 
Class I )
rapamil 
Class II )
1tiazem 
Class III )
100±20 (8) 
*** 25±3 (11)
*** 5±1 (10)
94±16 (5) 900±50 (A) 240±30 (6)
120120 (4) 100120 (6) 185126 (8)
*** 1213 (6) 100117 (10) 133113 (10)
*** P 0*001 : Variance Ratio Test - PAF V U44069, PAF V LPA or PAF V ADP.
Table 3. The effect of calcium channel blockers on platelet 
aggregation. Concentration response curves for inhibition, by 
verapamil, nicardipine and diltiazem, of submaximum aggregation 
resposes induced by PAF, U44G69, ADP and LPA were performed 
essentially as described for figure 28. The results show the 
mean K  values S.E. (concentration of C.C.B. which 
inhibited the agonist response by , 50%) calculated from the 
I^g value from 5 - 8  individual curves.
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8.1. THE EFFECT OF CLASS I, CLASS II AND CLASS III CALCIUM 
CHANNEL BLOCKERS ON HUMAN PLATELET AGGREGATION.
Using PRP from aspirin treated donors, to obviate the 
involvement of endogenous platelet mediators, concentration 
response curves for inhibition, by nicardipine (class l), 
verapamil (class 11) and diltiazem (class 111), of submaximum
aggregation (usually 40 % - 70 % of the maximum response)
induced by PAF, ADP, U44069 and LPA (fig. 28 ) were
constructed. From these curves l^g values (the 
concentration that produced 50 % inhibition of the control
value) were estimated (table 3).
8.2. IS THE SELECTIVE INHIBITION OF PAF-INDUCED PLATELET 
AGGREGATION RESTRICTED TO THE PHENYLALKYLAMINES?
Verapamil appears to be a selective inhibitor of aggregation
induced by PAF. To establish whether this effect is common to 
the class 11 calcium channel blockers (CCBS) 1 examined the 
effect of methoxyverapamil (D600) on submaximal aggregation 
induced by PAF, vasopressin, ADP and LPA (fig. 29) and also the 
effect of other class 1 CCBS on aggregation induced by PAF. 
Methoxyverapamil was a more potent inhibitor of aggregation 
induced by PAF (l^^ = 12.5 ±  2.5 jjM; n = 10) than
verapamil ( l<^ g = 25 + 3 jjM) and was approximately ten
fold less potent against aggregation induced by vasopressin 
(l^g = 110 + 21 jjM; n = 4), ADP (igg = 180 + 23 jjM;
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aggregation. Concentration response curves for inhibition, by 
verapamil, nicardipine and diltiazem, of submaximum aggregation 
resposes induced by PAF, U44069, ADP and LPA were performed 
essentially as described for figure 28. The results show the 
mean l<k_ values S.E. (concentration of C.C.B. which 
inhibited the agonist response by , 50%) calculated from the 
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CHANNEL BLOCKERS ON HUMAN PLATELET AGGREGATION.
Using PRP from aspirin treated donors, to obviate the 
involvement of endogenous platelet mediators, concentration 
response curves for inhibition, by nicardipine (class l), 
verapamil (class 11) and diltiazem (class 111), of submaximum 
aggregation (usually 40 % - 70 % of the maximum response)
induced by PAF, ADP, U44069 and LPA (fig. 28 ) were
constructed. From these curves l^g values (the 
concentration that produced 50 % inhibition of the control
value) were estimated (table 3).
8.2. IS THE SELECTIVE INHIBITION OF PAF-INDUCED PLATELET 
AGGREGATION RESTRICTED TO THE PHENYLALKYLAMINES?
Verapamil appears to be a selective inhibitor of aggregation 
induced by PAF. To establish whether this effect is common to 
the class 11 calcium channel blockers (CCBS) 1 examined the 
effect of methoxyverapamil (D600) on submaximal aggregation 
induced by PAF, vasopressin, ADP and LPA (fig. 29) and also the 
effect of other class 1 CCBS on aggregation induced by PAF. 
Methoxyverapamil was a more potent inhibitor of aggregation 
induced by PAF (1^^ = 12.5 ±  2.5 jjM; n = 10) than
verapamil ( l(^ g = 25 3 jjM) and was approximately ten
fold less potent against aggregation induced by vasopressin 
(l^g = 110 + 21 jjM; n = 4), ADP ( l^g = 180 + 23 jjM;
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Figure 30. The effect of vërapaull and
diltiazem on Q%a+^ 1 Induced by PAF and U44069.
Increasing concentrations of verapamil or
diltiazem were incubated with Quin-2 loaded
platelets, from aspirin treated donors, for 2 rain, 
at 37*c before addition of PAF or UAA069 at
concentrations which induced submaximal
fluorescence responses. The results were performed 
using platelets from a single donor and are 
typical of the results obtained from A similar
experiments.
1 2 7
y>M .
n = 4) and LPA = 130 + 3G|; n = 8) (means + SE)
which were inhibited to a similar extent.
Flunarizine = 700 jjM), cinarizine > 300 jüM)
and bepridil ( =  250 jjM), class 1 CCBS, only inhibited 
PAF-induced aggregation at high concentrations.
8.3. THE EFFECT OF VERAPAMIL AND DILTIAZEM ON ELEVATION OF
[ca+^ i INDUCED BY PAF AND Ü44069.
Verapamil and diltiazem inhibit PAF-induced aggregation. Only 
verapamil is selective for PAF, whereas diltiazem inhibits 
aggregation induced by both PAF and U44069. Accordingly if the 
inhibitory action of of these drugs is purely due to blockade
of a receptor operated calcium channel then a similar pattern
should be observed for inhibition of |j]a-H^  i.
The effect of verapamil and diltiazem was examined on similar 
submaximal elevations inj^a-f-^ i induced by PAF and U44069 (fig. 
30). Both drugs produced a concentration-dependent inhibition
of Q]a++J i induced by PAF. In contrast j^Ca+-  ^i induced by 
U44069 was inhibited by diltiazem only.
8.4. THE EFFECTS OF VERAPAMIL ON CALCIUM MOBILIZATION AND
CALCIUM INFLUX INDUCED BY PAF.
The selectivity of verapamil which was observed with
aggregation induced by PAF, also extends to the elevation in 
cytosolic free calcium induced by PAF. If the CCBS act by 
preventing the inward Ca-M- current, an action equivalent to
Inhibition of PAF-induced elevation in platelet j
by verapamil: effect of [Ca^+lg
100 -
% Inhibition 
of control OmM
= ImM
50 -
100
[Verapamil] uM
Figure 31- Inhibition of PAF-induced elevations in^e*-^ i by 
verapamil both when {Ca+-0 o = 1 mM and when|Ca+^g= 0 mM.
Verapamil at the concentrations indicated on the abscissa were 
incubated with qiun2 labelled platelets + EGTA (3 mM). The 
changes in fluorescence induced by submaximum concentrations of 
PAF were recorded and [Ca-H^ i calculated from the observed 
changes in fluorescence. The results are from one experiment 
and are typical of 4 similar experiments using platelets from 
different donors.
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extracellular Ca++ deprivation, then one might expect a 
residual component of the agonist response (ie. 20 %),
originating from intracellular locations, to be insensitive to 
these agents.
Verapamil (and diltiazem) apparently abolish total [ca+-^ i 
implying that these agents not only prevent influx but also 
prevent mobilization of intracellular Ca++. I therefore 
examined the effect of verapamil against total j^a+^ i signal 
(ie the response measured when |^Ca+^o = 1 mM) and against 
l^a-H^ i that arises only from mobilization (ie. in the presence 
of EGTA) induced by a submaximal concentration of PAF.
The concentration response curves for inhibition of total |^a+^ 
i and |^Ca+^ i due to mobilization, by verapamil, were virtually 
superimposable (fig. 31).
With Quin2-labelled platelets suspended in the normal buffer 
but with no added Ca++ and in the absence of EGTA, to 
facilitate the manipulation of|ca+^ o, PAF evoked an elevation 
in i which rapidly reached a peak then returned to resting
levels. If j^a-f-Q o was subsequently readjusted to 1 mM then a 
second elevation in |^a++^ i was observed (see fig. 19). As
discussed in section 7.2. the initial response was attributed 
to mobilization of intracellular Ca++ and the latter to influx 
of extracellular Ca++.
This system appeared to offer a mechanism whereby the influx 
component could be isolated from the component due to
mobilization and hence presented the opportunity to examine the 
effect of verapamil on each component individually.
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Figure 32. The effect of verapamil on
PAF—Induced Ca++ Influx and mobilization.
Experiments were performed essentially as 
described for previous figs (figure 19) I
(a) The normal fluorescence response to a 
submaximal concentration of PAF (left) and right 
the effect of 25jjM verapamil on j^Caf-Q i.
(b) The change inCca-»-+] i induced by PAF when^Ca-*-^
o = OmM (mobilization) and the effect on|"Ca+^ i of 
restoring [Ca+^ o to ImM after activation Cinflux).
(c) The effect of verapamil on PAF-induced Ca++
mobilization.
(d) The effect of verapamil on PAF-induced Ca++
Influx.
Results are representative of at least 3 other 
experiments using platelets from different donors.
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Figure (32) demonstrates that verapamil inhibits both influx 
and mobilization.
All three classes of calcium antagonist inhibit primary
aggregation induced by the agonists examined. Nicardipine
exhibited the least inhibitory activity. This correlates well
with the lack of binding sites for the 1,4 dihydropyridines on 
platelets (Glossman, et. al., 1982). In addition this would 
also exlain the inactivity of the dihydropyridine (DHP) Ca++ 
agonist BAY K8644. In contrast verapamil potently and 
selectively inhibits aggregation induced by PAF. Diltiazem
potently inhibits aggregation induced by PAF and U44069 
apparently indicating that the calcium channel associated with 
the PAF receptor is sensitive to class II and class III calcium 
antagonists whereas the calcium channel associated with the 
U44069 receptor is sensitive to class III only. Indeed the 
identical inhibitory pattern observed when j^Ca-wQ i was 
monitored instead of aggregation would appear to support 
calcium channel blockade as the mechanism underlying the 
inhibitory action of these drugs.
However verapamil and diltiazem abolish ^Ca++ji completely. As 
initial studies established that |^Ca++J i was composed of an 
influx of extracellular calcium ( 80 % )  and mobilization of
intracellular calcium ( 20 %), the predicted result would be a
maximum inhibition of |^Ca+-^ i of 80 %.
One of two conclusions may be derived from this data.
a) As verapamil and diltiazem appear to block both influx and
mobilization they are not acting purely by channel blockade.
1 3 0
b) If both drugs are acting by blockade of ROC's then is j^Ca+-0 
i recorded in the presence of 3 mM EGTA truely mobilization of 
intracellular calcium or could it still represent influx of 
|^a+-^ o .
The effective buffering range of EGTA for ionic calcium occurs 
in the low micromolar concentration range and becomes 
progressively less effective towards nanomolar concentrations. 
In addition the inaccuracy of pH meters (used to pH buffers) 
and calcium contamination from buffer reagents makes an 
accurate assessment of the free|^a+^ o in the presence of EGTA 
particularly difficult.
Consider three possible free j^a++Jo concentrations in the 
presence of EGTA.
a.ljca-f-^  o = 10 nM
With a membrane potential (Vm) of - 60 mV (MacIntyre & Rink, 
1982) and assuming a resting|ca+-^ i of 100 nM. The calcium 
equilibrium potential (Eca)
Eca = 38 log 10 
100
= - 58 mV.
according to the Nernst equation. Since Vm = Eca the electrical
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potential driving inward calcium current would balance the 
outward movement of calcium down its concentration gradient. 
Hence under these conditions no net movement of calcium would 
occur, consequently |^a++j i could only be due to mobilization 
of intracellular calcium.
b.If jca-H^ o = 50 nM
then Eca = 58 log 50 
100
= - 17 mV.
Accordingly, since Vm > Eca the electrical potential driving 
inward calcium current would be larger (- 43 mV) than the 
concentration gradient opposing it. Consequently, in this 
situation, the net movement of calcium would be from the 
extracellular environment to the cytosol. |^Ca+^ i recorded in 
this environment could therefore originate from an influx of 
extracellular calcium rather than mobilization of intracellular 
calcium.
Under these conditions the cytosolic calcium concentration 
would have to elevated to around 500 nM before Eca = - 58 mV 
and therefore balance Vm. Hence in theory an extracellular Ca++ 
concentration of 50 nM could elevate the cytosolic calcium 
concentration to 500 nM.
1 3 2
Although |^a+^o (in the presence of EGTA) cannot be measured 
accurately a computer programme (compiled by Dr. D, Miller; 
Dept, of Physiology, university of Glasgow) which, knowing 
the calcium binding constants of the buffer reagents and which 
accounts for the error due to pH and contamination, predicts 
that the free calcium concentration of this system would be
0.6nM. Assuming this value to be an accurate reflection of the 
real situation then the elevation inj^a+-^ i recorded in the 
presence of EGTA could not be due to influx of extracellular 
calcium.
c. Withj^a+^ o = 0.6 nM
Eca = 58 log 0.6 
100
= - 128 mV, Vm < Eca hence an electrical potential of (+ 66
mV) would augment the movement' of calcium down its 
concentration gradient. Therefore a net efflux would exist, and 
|^a++J i recorded in this environment would be smaller than than 
the true value.
Clearly the exact knowledge of the free calcium concentration 
would be required to achieve an accurate and true 
interpretation of the data. From the predicted free calcium 
concentration it would appear that j^Ca+-^i, in the presence of 
EGTA , is a genuine mobilization of intracellular calcium, 
although its true value may be greater than that recorded. It 
follows therefore that the mechanism of action of verapamil
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Figure 33, The effect of D 575 on PAF-induced 
|ca++] 1 and primary aggregation. Experiments 
were performed as described for figure 30 
Results are from single experiments and are 
representative of 4 similar experiments.
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(and diltiazem) cannot be due purely to calcium channel 
blockade. Furthermore if j^ Ca-»-^  i recorded in the presence of
EGTA is smaller than the true value, because of a net loss of
calcium from the cytosol to the external environment, calcium 
channel blockade, which abolishes ion movements in both
directions across the plasma membrane (Tsien 1984), should 
increase j^Ca-H^ i rather than inhibit.
Finally as the site of action of the phenylalkylamines, as 
calcium channel blockers, is allegedly at the inner mouth of 
the calcium channel, the quaternary derivative of verapamil
(D575), which is only effective when injected into the cell 
(Glossman, et. al., 1982) would therefore provide a useful 
tool to distinguish between calcium channel blockade and
non-calcium channel blocking effects. Inhibition obtained with 
this analogue (added to the suspension medium) could not be due 
to channel blockade. Fig. 34 shows that D575 inhibited changes 
in cytosolic free calcium induced by PAF in a manner similar to 
verapamil.
8.5. COULD OTHER PHARMACOLOGICAL ACTIONS OF VERAPAMIL ACCOUNT 
FOR THE SELECTIVE INHIBITION OF PAF-INDUCED PLATELET
ACTIVATION?
The phenylalkylamines are known to act as alpha-adrenoceptor 
antagonists (Fairhurst et. al., 1980), as sodium channel 
blockers (Frelin et. al., 1982), as inhibitors of cAMP 
phosphodiesterase (Epstein et. al., 1982), and as local 
anaesthetics (Hay & Wadsworth, 1982). Could such actions
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Figure 34- Effects of sodium channel blockers 
and alpha—adrenoceptor antagonists on primary 
aggregation Induced by subma Imal concentrations
of PAF and ADF- Experiments were performed 
essentially as described for CCBs fig. 30| Results 
are the mean values + SE from 3 - 4  experiments 
using platelets from different donors-
value ((iM) versus agonist:
Drug m M Ml M
Phentolamine 190 ± 50 (4) >  200 (3)
Yohimbine >  200 (3) >  200 (3)
Tetrodotoxin 280 i  60 (4) 115 Î  25 (3)
Amiloride 220 1 40 (3 ) 185 t 25 (3)
Table 4. The effect of sodium channel blockers and
alpha-adrenoceptor antagonists on PAF- and ADR-induced platelet 
aggregation. Experiments were performed essentially as 
described for the calcium antagonists in table 3. The results 
are the mean values +_ S.E. frdm the observations (n) 
indicated.
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account for the selective inhibition of PAF-induced platelet 
aggregation and elevation of|ca+-^ i?
Verapamil (300uM) had no effect on platelet cAMP levels when 
assayed using PRP (9.4 _+ Ipmol/lO^ cells compared to
control 8.0 4: 0.4 pmol/ 10^ cells; means _+ SE from 
three experiments) indicating that phosphodiesterase inhibition 
cannot explain the selective inhibition of PAF-induced platelet 
activation. Moreover an elevation in cAMP levels leads to a 
non-specific inhibition of platelet reactivity. A similar 
argument (ie non-specific inhibition ) applies to its local 
anaesthetic activity.
To exclude the possibility that selectivity may be due to 
antagonism of alpha-adrenoceptors or sodium channel blockade 
the inhibitory effect of verapamil was compared to that evoked 
by specific alpha adrenoceptor antagonists and sodium channel 
blockers.
Concentration response curves for .inhibition by tetrodotoxin 
and amiloride (sodium channel blockers) and phentolamine and 
yohimbine (alpha-adrenoceptor antagonists), of aggregation 
induced by PAF and ADP were constructed (fig. 34) and from 
these a table of 1^^ values estimated (table 4).
Yohimbine had little effect on aggregation induced by ADP or 
PAF, producing less than 20 %  inhibition even at the highest 
concentrations. Amiloride, phentolamine and tetrodotoxin 
inhibited PAF- and ADP-induced aggregation in a concentration 
dependent manner but only at high concentrations. Hence these 
results exclude alpha adrenoceptor antagonism or sodium channel 
blockade as the mechanism of action of verapamil on PAF-induced
[52p] phosphatldate c.p.m. x lO'^/mg protein
o
_i_
Verapamil (50^M) 
Saline
PAF 
(lOOnM)X +Verapaml 1 (20;jM) 
+Verapaml 1 (50/iM)
PAF
(30nM) ■••Verapamil (20/jM) 
Verapamil (SOjjM)
Figure 35- The effect of verapamil on PAF-induced
Phosphatidic acid formation- Verapamil at the concentrations 
indicated were incubated with aliquots (400 |j1) of|_ fj-
labelled platelets for 2 minutes. PAF 30 nM or 100 nM was added 
to initiate PI hydrolysis. The reactions were terminated 5 
minutes later by transferring the platelet sample into 2 ml of 
chloroform/methanol/HCL and platelet lipids extracted and 
separated as described in experimental procedure. Results are 
the mean values from 3 experiments conducted in duplicate.
100 1
PAF (6nM) 
PAF (60nM)_  8 0 -  
o
c
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H-
O
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IZc
20-
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Figure 36. The effect of agonist concentration on inhibition, 
by verapamil, of PAF-induced elevations of[Ca+-^ i. Verapamil, 
at the concentrations indicated on the abscissa, was 
preincubated with quin2 loaded platelets for 2minutes. PAF (6 
nM or 60 nm) was added to initiate platelet activation. The 
changes in fluorescence was recorded from which the changes in 
[Ca++j i were calculated. The results arethe mean values + S.E. 
from 3 experiments and are expressed as percentage inhibition 
of the control response.
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platelet activation.
8.6. THE EFFECT OF VERAPAMIL ON INOSITOL PHOSPHOLIPID 
HYDROLYSIS.
The hydrolysis of the inositol phospholipids has been suggested 
to be the mechanism by which agonists elicit an elevation in 
cytocolic free calcium. As that includes both influx and 
mobilization (see section 4.3.) then its inhibition (inhibition 
of inositol phospholipid hydrolysis) by verapamil would account 
for the observation that this agent abolished both influx and 
mobilization. Figure 35 shows that, like aggregation and 
[^Ca+^ i induced by PAF,^^^^^ PA formation (a monitor for PI 
hydrolysis) is also inhibited by verapamil.
Against 100 nM PAF, 20 jjM and 50 jjM verapamil inhibited the 
agonist response by 38 + 13 % and 55 ^  10 % (means + 5D 
from three experiments) respectively. Against 30 nM PAF 20 jjM 
and 50 jjM verapamil inhibited the agonist response by 46 _+ 21 
% and 60 + 30 % (means ±  SD from three experiments) 
respectivly.
As all agonist which induce an elevation in cytosolic free 
calcium induce inositol phospholipid hydrolysis its inhibition 
by verapamil would evoke a non-specific inhibitory response. 
Therefore the action of verapamil must occur at a point 
proceeding this event. It was noted (fig. 36) that the 
concentration response curve for inhibition of cytosolic free 
calcium could be displaced to the right by increasing the 
concentration of PAF, indicating a competitive interaction
5000f
1000-
?100-
A'
10-
A
A
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—I—
50 ~ m 1000 5000
[ L i g a n d ]  nM^
were
Figure 37. ^ PAF binding to rabbit platelets.
Aliquotes of plasma free suspensions of rabbit^platelets \ 
incubated with 1-0-alkyl-l'-2' [ H^Z-acetyl
glycerophosphocholine (New England Nuclear) in the presence and 
absence of excess unlabelled PAF. Icubations were terminated by 
rapid centrifugation. After the supernatant was asp&rated the 
platelet pellet was digested with hyamine hydroxide and the 
radioactivity in each aliquote measured by liquid scintilation 
counting. The results show the concentration of free ligand
bound (ordinate) in the presence ( • “— • )  and absence (A à
) of excess PAF versus the concentration of ligand added 
(abscissa). The results from one experiment were typical of 5 
similar experiments.
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between PAF and verapa il. Hence the posibility exists that 
verapamil may be acting as a PAF receptor antagonist. Several 
attempts to show a specific binding site for PAF were 
unsuccessful in that no high affinity (saturable) binding site 
was detected. A typical binding curve is shown in figure 37. 
However other workers : Valone, et. al. (1984); Chessney, et. 
al. (1983) and Wade, et. al. (1984) have been able to 
demonstrate a high affinity binding site of Kd = 37 nM; 0.7 nM 
and 0.18 nM respectively. The latter group have reported that 
verapamil displaced ^ ^H^PAF binding with an of 30
nM. The reason why my attempts to demonstrate specific binding 
sites for PAF were unsuccessful is unclear. However, more 
recently it has been shown that the radioligand used in this 
study for some unknown reason fails to bind to PAF receptors 
(Kloprogge & Akkerman 1983)
Hence the data presented in this section suggests that the 
inhibition of PAF-induced platelet activation by the 
phenylalkylamines (and diltiazem) is not mediated by blockade 
of a specific calcium channel. Rather receptor antagonism may 
be the mechanism underlying the specific inhibition of 
PAF-induced events
9. PHARMACOLOGICAL MANIPULATION OF THE CYTOSOLIC FREE CALCIUM 
CONCENTRATION: CYCLIC NUCLEOTIDES
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In platelets, adenylate cyclase stimulants and exogenous cAMP 
analogues inhibit aggregation and the release reaction induced 
by all known agonists (Salzman et. al., 1972; Haslam, 
1975). Similarly, aggregation and secretion induced by
collagen, adrenaline, ADP, arachidonic acid, A23187 and 
thrombin are inhibited by guanylate cyclase stimulants and by 
exogenous cGMP analogues (Nishikawa et. al., 1982). It 
would seem likely, therefore, that these nucleotides act by 
inhibiting a mechanism common to all excitatory agonists. As 
several studies have shown the ability of cAMP to enhance Ca++ 
sequestration, not only in platelets, but also in microsomal 
fractions of various smooth muscle preparations (Anderson & 
Nilsson, 1972), it has been proposed that the inhibitory 
action of cAMP may be due to reducing the availability of|ca-+~]
i. In addition, besides promoting Ca++ sequestration, cAMP also
may impair the processes (mobilization and influx) that promote 
elevation of j^ a-t-] i
In vascular smooth muscle Schultz et. al. (1977) have
proposed that the relaxation associated with elevated cGMP
levels in this tissue is due to the redistribution of|pa-»-^i. 
In support of this view Zsotér et. al. (1977) have shown
that cGMP enhances ^^Ca++ efflux in certain types of smooth 
muscle.
Cyclic AMP- and cGMP-dependent protein kinases have been shown 
to phosphorylate the same proteins, although to varying
extents, in platelets (Haslam et. al., 1980) and in other 
tissues: for example rabbit skeletal muscle glycogen synthetase
and phosphorylase b kinase, and rat pyruvate kinase and
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fructose 1,6, diphosphatase (Lincoln & Corbin, 1977). In 
most cases cAMP kinase appears to be the more efficient 
catalyst.
Although circumstantial, the evidence tentatively suggests that 
cAMP and cGMP may exert their inhibitory action by the same 
mechanism, possibly suppression of |ca+^ i availability. Hence 
in this study I examined the effects of cAMP and cGMP on 
platelet |^Ca+4^ i and attempted to correlate the inhibitory 
action of various agents that mimic or elevate cAMP or cGMP on 
platelet functional response (aggregation) and on j^a-H^ i 
induced by PAF.
Finally, it was noted that the rate of^a+-^ i restoration 
following agonist stimulation was directly proportional to 
agonist concentration (fig. 38). Such an observation could be 
explained by the phenomenon of homologous receptor 
desensitization or perhaps by the generation of some endogenous 
mediator that promotes calcium sequestration and/or calcium 
extrusion.
Potential endogenous regulators may include cAMP and cGMP. 
Formation of cAMP by platelets in response to stimulatory 
agonists has not been reported, therefore it is unlikely that 
this nucleotide would subserve such a regulatory mechanism. 
However in certain smooth muscle systems, a rise in the 
intracellular concentration of cGMP has been reported following 
the initial contractile event. Since this nucleotide promotes 
relaxation, allegedly through redistribution of[ca+^ i, it has
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been proposed that cGMP might function in a negative feedback
mechanism limiting cellular response. (Schultz, 197^). That
a similar mechanism might operate in platelets has been
suggested by Haslam (1980). In support of such a role,
though not a universal observation, some workers have reported
that an elevation in intraplatelet cGMP levels follows
stimulation (Haslam & McClenaghan, 1974). Moreover platelet
stimulation is also followed by an enhanced efflux of
^^Ca++ (Massini & Luscher, 1974 ). Guanylate cyclase
stimulants include unsaturated fatty acid peroxides (Hidaka &
Asano, 1977), which in platelets, can be formed from 
flutiD
arachidonic^metabolism following stimulation.
Therefore it is conceivable that following platelet activation 
a late rise in the intracellular level of cGMP is responsible 
for restoring the cell to its former unactivated state. A 
possible sequence of events, following receptor occupation,
could be:-
(1) an agonist mediated elevation in|^a+-^ i.
(2) platelet functional responses.
(3) mobilization of arachidonic acid and its metabolism via 
cyclooxygenase (CO) and lipoxygenase (LO).
The metabolism of arachidonic acid via LG is known to lag 
behind that of CO (Samuelsson, et. al., 1976)
(4) the formation of hydroperoxy-metabolites of arachidonic 
acid, which simulate guanylate cyclase, could represent one 
mechanism underlying a delayed rise in cGMP.
I therefore examined the effect of cGMP and cAMP on|ca+^ i
restoration and measured the platelet concentrations of these
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nucleotides after stimulation by PAF, thrombin and U44069 to 
determine whether they could form part of a negative feedback 
mechanism in these cells.
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Figure 39. The effect of PGI^, PGD^, NaNP, 8Br cAMP 
and 8Br cGMP on a). primary aggregation induced by submaximum 
concentrations of PAF and b). elevations in[Ce+^ i induced by 
submaximum concentrations of PAF- PGI_, PGD. or NaNP 
was preincubated for 2 minutes and BBr cAMP and 8Br cGMP for 5
minutes with PRP, for aggregation studies, or in plasma free
medium with quin2 loaded, for j^a+-^ i studies. PAF was added to 
initiate aggregation or changes in{ca-H^i. and the responses 
recorded as described before. The results are the mean values
+ S.E. from 4 experiments and are expressed as %  inhibition
of the control response.
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Figure AO. The effect of PGI^, PGO« and NaNP on total 
platelet cAMP and cGMP condBntration. PGIg, PGD2  and 
NaNP were added to a plasma free suspension of platelets at 
37®C for 2 minutes (unstirred). Reactions were terminated and 
nucleotides extracted by the addition of ethanol (1 vol.). The 
cyclic nucleotide content in the organic phase was then 
determined by radioimmunoassay as described in section 5.6. 
Results are the mean values + S.E from 4 - 8  experiments.
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9.1. INHIBITION OF PLATELET FUNCTIONAL RESPONSE BY CYCLIC 
NUCLEOTIDES: CORRELATION WITH INHIBITION OF [^Ca4H-Ji.
The inhibitory effect of PGI^, PGD^ (which stimulate 
adenylate cyclase), sodium nitroprusside (NaNP) (which 
stimulates guanylate cyclase), 8 -bromo-cyclic AMP and 
8 -bromo-cyclic GMP on submaximal primary aggregation induced by 
PAF is shown in figure 39 a. PGI^ (l^g = 1 + 0 . 5  
nM), PCD, (Igg = 10+ 0.2 nM), NaNP (igg = 4.8 +
1 juM), 8 -bromo-cGMP (l^g = 350 ±  30 jjM) and 8 -bromo-cAMP 
(l^g > 1 mM ) produced a concentration-dependent inhibition
of PAF-induced aggregation.
r 1 4)Ti
The elevation in[Ca++Ji, from 90 +_ 3^resting to 250 +50 nM
induced by a submaximal concentration of PAF (80 nM) was
inhibited in a concentration dependent manner (fig. 3 ^ b) by
PGI2  (I%g = 2.07 + 0.05 nM) > PGD^ (l^g = 6 . 0
_+ 2 nM), > NaNP (l^^ = 220 ±  40 nM) > 8 -bromo-cGMP
(I^g = 140 +  40 jjM) > 8 -bromo-cAMP (l^g > ImM) (means
jk SE of 4 experiments).
To investigate a possible causal relationship between 
inhibition of |^Ca++J i, and platelet cAMP or cGMP, platelet 
concentrations of these nucleotides were measured over the 
active concentration ranges of PGI^, PGD2  and NaNP 
(fig. ^ 9 ). In the presence of a phosphodiesterase inhibitor 
(IBMX, lOOuM) resting platelet cAMP and cGMP were 1 2 + 1  pmol 
and 315 ±  20 fmol/10® cells respectively (means ±  SE of 
4 - 8  experiments). PGI2  and PGD2  evoked a
concentration-dependent elevation in both cAMP and cGMP.
1A2
PGI2  (1 nM) and PGD^ (10 nM) (the nearest concentration 
to the values measured for inhibition of |j a^+4^  i)
produced an elevation in cAMP of 2.5- and Cf 3.5- fold 
respectively. In contrast NaNP (100 nM) stimulated the 
formation of cGMP only { C : 3 fold).
This study has shown that agents which elevate cAMP or cGMP 
inhibit aggregation and |ca-H^ i induced by PAF. Furthermore the 
rank order of potency of agents that inhibit aggregation was 
identical to that for inhibition of |ca-H^ i suggesting that 
the suppression of |^a-H^ i availability could be the mechanism 
underlying the action of these nucleotides.
The potency of NaNP and 8Br cGMP as inhibitors of |ca+4^ i 
clearly differs from their potencies for inhibition of 
aggregation. Platelet aggregation was monitored using PRP 
whereas |^Ca++J| i was measured using washed platelets. Hence, 
although unlikely binding to plasma proteins may account for
the observed difference in potency of NaNP and 8Br cGMP in the
two systems.
Interestingly PGI^ end PGD^ elevate both cAMP and cGMP.
Similar findings were observed by Bruckdopfer et. al. 
(1984). The findings with NaNP which inhibits elevation of 
|^ Ca+-^  i at concentrations that promote synthesis of cGMP but not 
cAMP, and the effects of 8Br cGMP clearly indicate that cGMP 
can regulate agonist-induced elevation of [ca+-^ i. Could the
elevation in cGMP explain the inhibitory action of PGI2  or
PGD2   ^ PGI2  (10 nM) and PGD2  (100 nM) virtually 
abolish elevation of j^a+^i, yet the rise in cGMP is similar
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to that produced by lOOnM NaNP. The inhibition produced by 
lOOnM NaNP (ie. increased cGMP only) is less than 50 %  o f  the 
control response. Clearly, while cGMP may contribute to the 
inhibition , the major effect must be due primarily to cAMP.
It could be argued that if cAMP and cGMP were metabolized by 
the same phosphodiesterase then incomplete inhibition of this 
enzyme could account for the elevation in cGMP produced by 
PGI2  and PGD^. For example if the metabolizing capacity 
of the phosphodiesterase were reduced (by IBMX) to a point 
where the elevated level of cAMP (induced by PGI2  and 
PGD2 ) was competing with cGMP (formed by basal turnover) 
then an elevation in the latter nucleotide would occur. 
Assuming competition between these two nucleotides for a 
limited metabolic capacity of the phosphodiesterase then 
changes in cGMP should occur in parallel with changes in cAMP. 
Clearly the results show this not to be so, moreover a specific 
cGMP phosphodiesterase has been identified in platelets 
(Asano &  Hidaka, 1977).
A similar argument may be applied to the suggestion that high 
concentrations of cAMP may cross react with the cGMP antibody. 
Again if this were the situation the apparent elevation in cGMP 
would have to parallel any elevation in cAMP.
From these results it must be concluded that the elevation in 
cGMP induced by PGI2  and PGD2  is independent of their 
ability to stimulate adenylate cyclase.
One might expect that agents which inhibit agonist-induced 
elevations in jca+-tj i also promote sequestration or extrusion of 
Ce++. Again the potential endogenous regulators would include
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Figure 41. The effect of adenylate or quanylate cyclase 
stimulants on the rate of restoration of jCan-?] i following an 
agonist-induced elevation. PGI^ or NaNP at the
concentrations indicated were added at the peak of the 
elevation of [Ca++j| i induced by PAF. The results are from a 
single observartion but are typical of at least 4 observations 
using platelets from different donors.
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cAMP and cGMP. Indeed addition of adenylate cyclase or
guanylate cyclase stimulants accelerate the restoration of
agonist-induced changes in ^a+-^ i (fig 41). To assess the
potential role of cAMP and cGMP, as mediators of|ca-h^i
restoration, the levels of these nucleotides were monitored, in 
the presence of a phosphodiesterase inhibitor, following
stimulation by a supramaximal concentration of PAF (500nM).
When compared to controls (unstimulated cells) no significant
elevation in cAMP or cGMP was detected for up to 5 min. of 
agonist addition; by which time returned to normal
values. Similar results were obtained with thrombin and U44069 
(data not shown).
9.2. IS THE INHIBITORY ACTION OF cAMP AND cGMP MEDIATED BY 
THEIR ABILITY TO SUPPRESS THE AVAILABILITY OF C/TOSOLIC FREE
CALCIUM ?
The results of this study show that pretreating the cells with 
adenylate or guanylate cyclase stimulants can prevent changes 
in[ca-i-^ i.
Does the available evidence suggest that these nucleotides 
mediate their inhibitory effect by suppressing the availability 
of [ca+-^ i.
In theory two mechanisms exist by which these agents might 
suppress agonist-induced elevations in[ca-H^ i. They could act 
by inhibiting the mechanism responsible for increasing the 
cytosolic calcium concentration (ie. the mechanism that 
regulates Ca++ influx and/or mobilization from intracellular
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sites). As inositol phospholipid metabolism is currently 
believed to be the mechanism responsible for Ca++ "gating", 
then its inhibition would clearly be an essential target for 
these nucleotides. Indeed both adenylate and guanylate cyclase 
stimulants have been shown to inhibit agonist-induced PI
hydrolysis (Takai et al. 1981; MacIntyre et al 1985).
In permeabilized platelets Knight & Scrutton (1984) have 
shown that can be released in a concentration
dependent manner by increasing the concentration of 
extracellular calcium (in this system small ions, including 
Ca++, in the buffer medium can equilibrate with the cytosol). 
Both thrombin and BAG displace the concentration response curve 
for Ca-H- to the left (presumably by activating protein kinase C 
- the Ca-H-- independent mechanism for platelet activation: 
section . Cyclic AMP was able to suppress the effects of
thrombin but had little effect on the enhancement evoked by
BAG. As BAG mimics diacylglycerol, the endogenous activator of 
PKC formed by agonist-induced hydrolysis of PI, these results 
indicate that the target for cAMP must proceed
activation of PKC but must prevent agonist-induced formation of 
DAG. DAG formation results from the action of a PLC enzyme on 
the inositol phospholipids therefore the most likely target for 
cAMP would be the inhibition of this enzyme.
In permeabilized cells cGMP enhances the effect of thrombin. 
This is in contradiction to its effect in intact cells. Haslam 
has also noted this anomaly, but suggests that this is due to 
the metabolic conversion of cGMP to GTP or other guanine 
nucleotides, which enhance agonist-induced 5HT release
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(Haslam & Davidson, 1984) Clearly the non-metabolizable 8 
Br-cGMP should resolve this problem.
It is possible therefore, that cAMP and cGMP, via their 
respective kinases, suppresses the agonist-induced elevation in 
cytosolic free calcium by preventing agonist-induced PI 
hydrolysis. However, as both nucleotides suppress the cellular 
response to adrenaline; an agonist which does not evoke PI 
hydrolysis or changes in cytosolic calcium, then these 
nucleotides must also be capable of evoking an inhibitory 
response which does not involve Ca++ metabolism.
A second mechanism by which these nucleotides could prevent 
agonist-induced elevations in cytosolic free calcium could be 
to stimulate calcium sequestration and extrusion, such that, 
even with continued influx or mobilization the cytosolic Ca++ 
concentration remains low. In this study both adenylate and 
guanylate cyclase stimulants accelerate the restoration of 
agonist-induced elevations in|ca-i-^i. In early studies cAMP was 
shown to accelerate the ATP-depehdent uptake of Ca-H- by 
platelet membrane fractions (Kaser-Glanzman et al-, 1971). 
Cyclic AMP phosphorylates four proteins in platelets with 
molecular weights of 50, 36, 24 & 22 Kdaltons (Kd). The 24 Kd 
peptide is associated with a membrane fraction, capable of Ca-H- 
uptake (Haslam, 1980). Recent studies have isolated the 
platelet Ca-H- "pump". It is interesting to note from these 
studies that, even though stimulatory agonists are not reported 
to elevate the cytosolic concentration of cAMP, the principle 
regulator of this "pump" is a cAMP dependent-kinase. The 
intensity of phosphorylation of the 24 Kd peptide parallels the
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rate of Ca++ uptake (Levy-Toledano et al., 1985). One would 
expect that if this "pump" is involved in Ca++ homeostasis then 
its principle regulator, cAMP, would also be involved in Ca++ 
sequestration.
Guanylate cyclase stimulants selectively phosphorylate a 49 Kd 
peptide and also the 50 Kd peptide to the same extent as cAMP. 
However the role of these proteins is unknown. Guanylate 
cyclase stimulants also phosphorylate the 24 Kd peptide but to 
a much smaller extent than cAMP. Hence cAMP appears to be 
capable of promoting Ca++ "pump" activity in platelets, though 
a similar role for cGMP is less clear.
Finally, the Ca++-induced 5HT release in permeabilized
platelets is unaffected by cAMP. In this system Ca++
extrusion/sequestration would not be expected to alter the 
cytosolic Ca++ concentration as both external and internal Ca-H- 
are in equilibrium. This however suggests that normally, in 
intact cells where cAMP inhibits 5HT release, 
extrusion/sequestration of Ca-H- must play an important role in 
the inhibitory response evoked by this nucleotide.
GENERAL DISCUSSION.
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PAF AND LPA: putative lipid mediators of platelet
activation.
Both PAF and LPA are produced by activated platelets. Exogenous 
PAF and LPA can induce platelet activation though dense body 
release evoked by these lipids is mediated by the endoperoxides 
or thromboxane A^. PAF- or LPA-induced release of alpha 
granule or lysosomal constituents has not been examined but may 
also require the formation of these icosanoids as 
intetmediaries.
Although PAF is generated by activated platelets its 
contribution to agonist-induced platelet activation (ie. as an 
endogenous mediator propagating platelet activation) is 
unclear. PAF formed during platelet activation was originally 
hypothesiScO as mediating the ADP/TXA^ independent pathway 
of platelet activation induced by thrombin. To date a specific 
receptor antagonist of PAF has not been available, uch an agent 
would cletrly be a valuable tool to determine the importance of 
PAF in platelet reactivity. The results of the present study 
suggest that analogs of the phenylalkylamines may fulfil such a 
role.
One approach which has been used to demonstrate the importance 
of endogenous mediators in an agonist-induced response has been 
to make use of the phenomenon of homologus desensitization - 
that is platelets pre-exposure to an agonist are desensitized 
to subsequent challenge by the same agonist. In such a study 
(Wal et al.,(1985). reported that platelets desensitized to
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PAF aggregate normally to high concentrations thrombin, in the 
presence of aspirin and ADP scavengers, but are less 
responsive to low concentrations of thrombin.
A second approach to elucidate the importance this lipid has 
been to inhibit the enzymes involved in the formation of PAF. 
These experiments have yielded essentially the same results as 
the desensitization experiments. That is a reduced sensitivity 
of the platelet to low concentrations of thrombin but no 
significant effect with high concentrations of thrombin 
(Touqui et al., 1984).
Therefore PAF may have some role in propagation the response to 
low concentrations of thrombin, as do cyclooxygenase 
metabolites of arachidonic acid and released ADP. From these 
results it would appear that PAF does not contribute 
significantly to mediating the ADP/TXA^ independent 
platelet response induced by high concentrations of thrombin. 
It remains a posibility that PAF may be important in mediating 
the responses of other platelet agonists.
The function of PAF generated by activated platelets, if not
propagation of the platelet response, is therefore unclear. In
whole animal experiments PAF produces hypotension and
<3L
bronchoconstriction thus platelet derived PAF may have^more 
important role in mediating inflammatory and allergic responses 
rather than as a mediator of the haemostatic response.
Although relatively high concentrations of LPA are required to 
induce platelet activation it has been demonstrated that under 
specific conditions low concentrations (2 - 20 jjM) are capable
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of inducing activation (Benton et al., 1982). Again the 
role of LPA generated during platelet activation remains to be 
fully assessed. In a recent study McCrea et al. (1985) have 
shown that quinacrine inhibits thrombin-induced aggregation, 
serotonin secretion, formation of LPA, arachidonic acid release 
and phosphorylation of the 40/47 Kd substrate of protein kinase 
C. It was suggested that quinacrine inhibited both PLC and 
PLA2  to produce this effect. In the same study it was found 
that the addition of LPA (2.5 - 22 jjM) reversed the quinacrine 
block of thrombin-induced aggregation, protein phosphorylation 
and secretion of serotonin without overcoming thrombin-induced 
arachidonic acid release. It was concluded from these results 
that endogenous LPA mediates part of the response induced by 
thrombin. Interestingly, and in contrast to the results of the
present study, LPA was able to evoke serotonin release in the
absence of arachidonic acid metabolism.
Again the lack of a specific receptor antagonist for LPA
severely handicaps the study of this lipid in the role of
platelet activation. Like PAF, platelets pre-exposed to LPA 
exhibit the phenomenon of homologous desensitization. Therefore 
perhaps the application of this technique, in a manner similar 
to that used in the PAF studies, may throw some light on the 
role of endogenous LPA. Platelets desensitized to LPA should 
exhibit a reduced sensitivity to thrombin if LPA is involved in 
propagating the response of this agonist.
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REGULATION OF PLATELET CYTOSOLIC FREE CALCIUM.
The present results show that the extent to which agonists 
elevate cytosolic free calcium in platelets correlates closely 
with the rank order of potency of those agonists, in evoking a 
functional response. Thus the concentration of |^a-n^ i would 
appear to be important in linking receptor occupancy to 
functional response. However agonists can elevate|ca++ji to 
similar extents without displaying the same efficacy when a 
functional response is measured in parallel. Suggesting that 
one, or more, intermediaries, other thanj^a-»-^ i , are involved 
in linking receptor occupancy to functional response. For 
example PAF and thrombin can elevate j^ a-j-^  i to similar extents 
but thrombin is a more potent inducer of serotonin secretion 
than PAF. Thrombin is a more effective inducer of PI hydrolysis 
than PAF (MacIntyre et al., 1985). The generation of 
diacylglycerol (a Ca++ independent intermediary, section 3 & 4) 
would be greater for thrombin than PAF, and this may account 
for the ability of thrombin to evoke a greater dense body 
release. The elevation of j^ Ca-t-+J i apparently originates 
principally from an influx of extracellular Ca++ presumably 
through "channels" in the plasma membrane, which are 
insensitive to changes in the transmembrane potential and the
n
organic calcium channel blockers. Platelets are also capable of 
mobilizing intracellular Ca-H-.
The biochemical events underlying Ca++ influx or mobilization 
are unclear though the generation of IP3 by agonist-induced 
hydrolysis of PI presents a plausible mechanism by which
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mobilization may be evoked.
Membrane glycoprotein complex Ilb/lIIa which serves as the 
fibrinogen receptor (section 2) and is also the site for high 
affinity Ca-H- binding may be involved in the Ca++ influx. 
Normal platelets have 45000 Ilb/llla sites per cell. 
Thrombasthénie platelets have less than 10 %  of this number. In 
a recent study Brass (1985) has compared the ability of 
normal platelets and thrombasthénie platelets to exchange Ca++. 
It was found that thrombasthénie platelets had a much reduced 
ability to exchange Ca-H-. Moreover normal platelets exposed to 
agents that dissociate the Ilb/lIIa complex also display a 
reduced Ca++ exchange. The deficiency in the exchange of Ca++ 
was predominantly in the Ca-H- influx component rather than Ca++ 
efflux. Hence the glycoprotein complex Ilb/IIIa may comprise 
or be assosiated with the Ca-H- channel.
iIn the present study the maximum elevation in | C^a4-y  was 
slightly less than 1 jjM. Since the principle contribution to 
changes of |^ Ca-H^  i is a passive influx of |^a-H^ o then opening a 
Ca-H- channel in the plasma membrane, in the presence of an 
extracellular Ca-H- concentration of 1 mM could elevate|^ a-f-^  i 
to greater than 1 mM, infact to 10 mM given a membrane 
potential of - 58 mV.
Therefore there must exist a mechanism which limits the extent 
of Ca-H- influx. In molluscan neurons Tillotson (1984) has 
demonstrated that inactivation of the Ca-H- conductance is 
dependent on the entry of the Ca++ ion itself. Hence the influx 
of Ca++ may be responsible for closing the gating mechanism.
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The platelet clearly posesses efficient Ca++ homeostatic 
mechanisms. One would expect that were influx of Ca++ to be the 
principle source of elevated |^Ca++1 i, then although 
sequestration of Ca++, by the DIS or by mitochondria, may 
account for short term Ca++ homeostasis, long term homeostasis 
would require extrusion of Ca++.
Interestingly in a study designed to determine the subcellular 
distribution of the platelet Ca++/Mg ATPase the location of 
this Ca++ pump was predominantly in the vesicle membrane rather 
than in the plasma membrane. The biochemical events underlying 
the Ca-H- homeostatic mechanisms are unclear. The most potent
activator of the Ca++ pump is cAMP however agonists do not
apparently elevate the level of this nucleotide.
The role of cyclic CMP, as an activator of the Ca++ pump, has
not yet been examined. However cGMP is known to promote the
phosphorylation of the 23 Kd protein associated with activation 
of the Ca-H- pump. Agonists have been reported to elevate cGMP 
though this has not been a universal finding and was not
observed in this study. Platelet agonists are known to induce 
the formation of unsaturated fatty acid peroxides, as a 
relatively late event following receptor occupancy. It remains 
a tantilising prospect that such entities are potent activators
of guanylate cyclase, and by eliciting the formation of cGMP
could play a role in the termination of cellular
responsiveness.
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